
<html lang="en"     class="pb-page"  data-request-id="cceced3e-21a2-4e71-83c6-9dfc28ff0c76"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.6b00955;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-19"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity" /></meta><meta name="dc.Creator" content="Aiman  Abu Ammar" /></meta><meta name="dc.Creator" content="Raji  Raveendran" /></meta><meta name="dc.Creator" content="Dan  Gibson" /></meta><meta name="dc.Creator" content="Taher  Nassar" /></meta><meta name="dc.Creator" content="Simon  Benita" /></meta><meta name="dc.Description" content="Side effects and acquired resistance by cancer cells limit the use of platinum anticancer drugs. Modification of oxaliplatin (OXA) into a lipophilic Pt(IV) complex [Pt(DACH)(OAc)(OPal)(ox)] (1), co..." /></meta><meta name="Description" content="Side effects and acquired resistance by cancer cells limit the use of platinum anticancer drugs. Modification of oxaliplatin (OXA) into a lipophilic Pt(IV) complex [Pt(DACH)(OAc)(OPal)(ox)] (1), co..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 20, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00955" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00955" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00955" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00955" /></link>
        
    
    

<title>A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00955" /></meta><meta property="og:title" content="A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0007.jpeg" /></meta><meta property="og:description" content="Side effects and acquired resistance by cancer cells limit the use of platinum anticancer drugs. Modification of oxaliplatin (OXA) into a lipophilic Pt(IV) complex [Pt(DACH)(OAc)(OPal)(ox)] (1), containing both lipophilic and hydrophilic axial ligands, was applied to improve performance and facilitate incorporation into polymeric nanoparticles. Complex 1 exhibited unique potency against a panel of cancer cells, including cisplatin-resistant tumor cells. [Pt(DACH)(OAc)(OPal)(ox)] incorporated nanoparticles (2) presented a mean diameter of 146 nm with encapsulation yields above 95% as determined by HPLC. Complexes 1 and 2 showed enhanced in vitro cellular Pt accumulation, DNA platination, and antiproliferative effect compared to OXA. Results of an orthotopic intraperitoneal model of metastatic ovarian cancer (SKOV-3) and a xenograft subcutaneous model of colon (HCT-116) tumor in SCID-bg mice showed that the activity of 1 and 2 significantly decreased tumor growth rates compared to control and OXA treatment groups. Consequently, these findings warrant further development toward clinical translation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00955"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00955">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00955&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00955&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00955&amp;href=/doi/10.1021/acs.jmedchem.6b00955" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 9035-9046</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00944" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00981" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aiman++Abu+Ammar">Aiman Abu Ammar</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Raji++Raveendran">Raji Raveendran</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dan++Gibson">Dan Gibson</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Taher++Nassar">Taher Nassar</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Benita">Simon Benita</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol "><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">The Hebrew University of Jerusalem, Institute for Drug Research of the School of Pharmacy, Faculty of Medicine, POB 12065, Jerusalem 9112100, Israel</span></div><div class="corresp-info"><strong>*</strong> S.B. Tel: +97226758668. E-mail: <a href="/cdn-cgi/l/email-protection#6b1802060405092b0e00060f45031e0102450a08450207"><span class="__cf_email__" data-cfemail="1d6e747072737f5d787670793375687774337c7e337471">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>T.N.: Tel: +97226757620. E-mail: <a href="/cdn-cgi/l/email-protection#ff8b9e979a8d91bf9a94929bd1978a9596d19e9cd19693"><span class="__cf_email__" data-cfemail="e99d88818c9b87a98c82848dc7819c8380c7888ac78085">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00955&amp;href=/doi/10.1021%2Facs.jmedchem.6b00955" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 9035–9046</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 7, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 June 2016</li><li><span class="item_label"><b>Published</b> online</span>20 September 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 October 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00955" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00955</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9035%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAiman%2BAbu%2BAmmar%252C%2BRaji%2BRaveendran%252C%2BDan%2BGibson%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D19%26contentID%3Dacs.jmedchem.6b00955%26title%3DA%2BLipophilic%2BPt%2528IV%2529%2BOxaliplatin%2BDerivative%2BEnhances%2BAntitumor%2BActivity%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9046%26publicationDate%3DOctober%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00955"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1797</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">37</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00955" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Aiman&quot;,&quot;last_name&quot;:&quot;Abu Ammar&quot;},{&quot;first_name&quot;:&quot;Raji&quot;,&quot;last_name&quot;:&quot;Raveendran&quot;},{&quot;first_name&quot;:&quot;Dan&quot;,&quot;last_name&quot;:&quot;Gibson&quot;},{&quot;first_name&quot;:&quot;Taher&quot;,&quot;last_name&quot;:&quot;Nassar&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Benita&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;9035-9046&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00955&quot;},&quot;abstract&quot;:&quot;Side effects and acquired resistance by cancer cells limit the use of platinum anticancer drugs. Modification of oxaliplatin (OXA) into a lipophilic Pt(IV) complex [Pt(DACH)(OAc)(OPal)(ox)] (1), containing both lipophilic and hydrophilic axial ligands, was applied to improve performance and facilitate incorporation into polymeric nanoparticles. Complex 1 exhibited unique potency against a panel of cancer cells, including cisplatin-resistant tumor cells. [Pt(DACH)(OAc)(OPal)(ox)] incorporated nanoparticles (2) presented a mean diameter of 146 nm with encapsulation yields above 95% as determined by HPLC. Complexes 1 and 2 showed enhanced in vitro cellular Pt accumulation, DNA platination, and antiproliferative effect compared to OXA. Results of an orthotopic intraperitoneal model of metastatic ovarian cancer (SKOV-3) and a xenograft subcutaneous model of colon (HCT-116) tumor in SCID-bg mice showed that the activity of 1 and 2 significantly decreased tumor growth rates compared to control and OXA treatment grou&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00955&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00955" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00955&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00955" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00955&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00955" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00955&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00955&amp;href=/doi/10.1021/acs.jmedchem.6b00955" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00955" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00955" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00955%26sid%3Dliteratum%253Aachs%26pmid%3D27603506%26genre%3Darticle%26aulast%3DAbu%2BAmmar%26date%3D2016%26atitle%3DA%2BLipophilic%2BPt%2528IV%2529%2BOxaliplatin%2BDerivative%2BEnhances%2BAntitumor%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D19%26spage%3D9035%26epage%3D9046%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292098" title="Platinum">Platinum</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/jmcmar.2016.59.issue-19/20161013/jmcmar.2016.59.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Side effects and acquired resistance by cancer cells limit the use of platinum anticancer drugs. Modification of oxaliplatin (OXA) into a lipophilic Pt(IV) complex [Pt(DACH)(OAc)(OPal)(ox)] (<b>1</b>), containing both lipophilic and hydrophilic axial ligands, was applied to improve performance and facilitate incorporation into polymeric nanoparticles. Complex <b>1</b> exhibited unique potency against a panel of cancer cells, including cisplatin-resistant tumor cells. [Pt(DACH)(OAc)(OPal)(ox)] incorporated nanoparticles (<b>2</b>) presented a mean diameter of 146 nm with encapsulation yields above 95% as determined by HPLC. Complexes <b>1</b> and <b>2</b> showed enhanced <i>in vitro</i> cellular Pt accumulation, DNA platination, and antiproliferative effect compared to OXA. Results of an orthotopic intraperitoneal model of metastatic ovarian cancer (SKOV-3) and a xenograft subcutaneous model of colon (HCT-116) tumor in SCID-bg mice showed that the activity of <b>1</b> and <b>2</b> significantly decreased tumor growth rates compared to control and OXA treatment groups. Consequently, these findings warrant further development toward clinical translation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88274" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88274" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer is considered to be one of the main causes of death in the world. While chemotherapy continues to be the mainstay treatment for cancer, it is closely linked with considerable mortality and morbidity rates especially due to nonspecific damage to normal cells.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The clinical success of cisplatin has played an instrumental role in the development of Pt anticancer compounds. With the purpose of searching for safer and more effective Pt-based compounds, numerous efforts have been made in the past decades. However, only a few of these complexes have entered clinical trials. Two of these, carboplatin and oxaliplatin (OXA) have been approved by the FDA and are currently being used worldwide for malignant tumor chemotherapy.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">OXA is a diaminocyclohexane (DACH) derivative of cisplatin; however, the spectrum of activity of OXA differs from cisplatin and includes several lines of colon, ovarian, and lung cancer, as well as cell lines that are resistant to Pt therapy. OXA was the first Pt-based drug approved for use against metastatic colorectal cancer in combination with fluorouracil and leucovorin. OXA interferes with DNA replication and transcription systems through nuclear DNA adduct formation. Despite its better tolerability compared to other Pt compounds, OXA is also associated with side effects such as neurotoxicity, hematologic and gastrointestinal tract toxicities, neutropenia, nausea, and vomiting that limit the range of usable doses.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Hence, novel Pt complexes displaying increased antitumor activity and reduced cross-resistance are still being sought.</div><div class="NLM_p">Pt(IV) complexes are a new generation of Pt-based drugs, possessing markedly different properties from those of Pt(II) compounds. The kinetic inertness prevents the conversion to off-target biological substances before the Pt complex can reach the nuclear DNA. Furthermore, the two additional ligands can be utilized and tuned to adjust the chemical properties and facilitate the incorporation of Pt compounds into nanoparticles. These features can potentially improve both the efficacy and tolerability profile of Pt complexes.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The strategy for the preparation of Pt(IV) complexes involves oxidative addition of the square planar Pt(II) complexes, usually with hydrogen peroxide, to yield axial hydroxide ligands, which can be carboxylated or carbamated with the aim of introducing versatile axial ligands.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5-7)</a> The reduction to Pt(II) is a paramount demand for binding to the targeted biological sites. Thus, the reduction potential of the Pt(IV) complexes as well as the redox status of the tumor environment have a strong impact on the activity of Pt(IV) anticancer drugs.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Pt(IV) drugs are generally regarded as prodrugs due to the disparity in reactivity prior to and following reduction.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Solubility and lipophilicity have a crucial role in designing new Pt(IV) compounds. Numerous studies have shown a good correlation between lipophilicity and cytotoxicity.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a> Even though it has a critical role in enhancing the cytotoxic activity of the prodrug, lipophilicity is not the main factor that determines the overall activity. Moreover, high lipophilicity usually leads to low water solubility, making the drug formulation in an aqueous solution difficult. The low aqueous solubility has been always considered a stumbling block to the development and clinical use of anticancer compounds, due to the intravenous (iv) infusion route of their administration. Poorly water-soluble anticancer drugs need to be formulated in cosolvents or surfactant solutions to enhance their solubility, but many of these solutiuons, which have been used for solubilization of such drugs, are responsible for the severe side effects. The classic examples for these formulations are the marketed taxane products, paclitaxel and docetaxel, which have had a profound effect in a wide variety of malignancies. In the case of paclitaxel, a polyoxyl-35 castor oil surfactant vehicle is used in the commercial formulation. Its presence triggers severe hypersensitive reactions in patients, and it has been reported that 30–40% of the patients receiving paclitaxel suffer from abnormal lipoprotein patterns, aggregation of erythrocytes, severe hypersensitive reactions and peripheral neuropathy.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> Similarly, ethanol and polysorbate 80, used for docetaxel solubilization, also lead to adverse effects.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> Thus, there is a clear need to compromise between lipophilicity and solubility. Well-designed drug delivery systems are essential if we wish to continue to clinical practice.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Nanoparticles (NPs) are particulate dispersions or solid particles possessing dimensions of 1–1000 nm, with the capability to transport and deliver medicinal substances to selected targets within biological systems.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> A large number of nanotherapeutics have been designed and evaluated over the years, relying on liposomes, polymers, micelles, NPs, and antibodies as carrier materials.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Due to their miniscule and colloidal nature, polymer-based NPs are considered an ideal transport vehicle for drugs and other therapeutic agents because the agent can be encapsulated within or conjugated onto the NP’s surface.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Several methods for polymeric NP preparation have been developed. Among them, the nanoprecipitation technique, also known as the solvent displacement method, exhibits manifest advantages, essentially because it is a one-step process and easy to perform at room temperature.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Owing to their size, NPs preferentially target solid tumors rather than healthy tissues by exploiting vasculature inadequacy.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> One of the clinically successful candidates was the albumin-based formulation of paclitaxel NPs. It was developed with the aim of overcoming the very low solubility of paclitaxel, to form nab-paclitaxel NPs with a mean particle size of 130 nm. The resulting marketed paclitaxel nanoparticulate formulation is water-dispersible and was first approved by the FDA in 2005 for the treatment of metastatic breast cancer.</div><div class="NLM_p">This study presents the development and characterization of a drug delivery system loaded with a potent Pt(IV) prodrug of OXA, [Pt(DACH)(OAc)(OPal)(ox)] (<b>1</b>; <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), as well as handling properties of NPs before and after freeze-drying and storage. The cytotoxicity, Pt accumulation, and DNA platination of <b>2</b> was evaluated <i>in vitro</i> in comparison to <b>1</b> and OXA. Furthermore, two <i>in vivo</i> studies were conducted in SCID-bg mice including an orthotopic intraperitoneal (ip) model of metastatic ovarian cancer and a subcutaneous xenograft model of colon cancer.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Structure of OXA and Lipophilic Pt(IV) Compound <b>1</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2 Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60403" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60403" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1 <i>In Vitro</i> Cytotoxic Activity</h3><div class="NLM_p">The antiproliferative activities of <b>1</b> and OXA were tested in PC-3 and PC-3-luc (human prostate cancer), BxPC-3 (human pancreatic cancer), OVCAR-8 and SKOV-3 (human ovarian cancer), and CT-26-luc (murine colorectal cancer) cell lines by the MTT assay. The cells were treated continuously over 120 h. The 50% growth inhibitory concentration (IC<sub>50</sub>) values were calculated and summarized in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Complex <b>1</b> showed a unique potency against different cancer cell lines, with higher cytotoxicity than OXA.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values of OXA and <b>1</b> in Various Cancer Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center" char=".">OXA</th><th class="colsep0 rowsep0" align="center" char="."><b>1</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC-3</td><td class="colsep0 rowsep0" align="char" char=".">9.2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char=".">0.35 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC-3-luc</td><td class="colsep0 rowsep0" align="char" char=".">27.7 ± 9.1</td><td class="colsep0 rowsep0" align="char" char=".">0.46 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BxPC-3</td><td class="colsep0 rowsep0" align="char" char=".">3.4 ± 0.9</td><td class="colsep0 rowsep0" align="char" char=".">0.35 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">OVCAR-8</td><td class="colsep0 rowsep0" align="char" char=".">9.4 ± 4.4</td><td class="colsep0 rowsep0" align="char" char=".">0.46 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SKOV-3</td><td class="colsep0 rowsep0" align="char" char=".">58.3 ± 6.3</td><td class="colsep0 rowsep0" align="char" char=".">0.54 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CT-26-luc</td><td class="colsep0 rowsep0" align="char" char=".">5.6 ± 0.6</td><td class="colsep0 rowsep0" align="char" char=".">0.62 ± 0.24</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Values are means ± SD obtained from three independent experiments.</p></div></div></div><div class="NLM_p">The activity of OXA and <b>1</b> against a pair of cisplatin-sensitive and -resistant ovarian cancer cell lines, A2780 and A2780-cisR, was determined as a function of the concentration. The resistance of A2780-cisR to cisplatin is achieved by reducing the uptake, improving DNA repair, and increasing glutathione levels.</div><div class="NLM_p last">The resistance factor (RF) is defined as the ratio of IC<sub>50</sub> value in the resistant cell line to that in the parent cell line. The RF values of cisplatin, OXA, and <b>1</b> were 15.53, 5.21, and 0.93, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_001.pdf" class="ext-link">Table S1</a>). The results show that <b>1</b> has the lowest RF values, which indicates that <b>1</b> can overcome acquired resistance to cisplatin and exhibit efficient activity against the A2780-cisR line and probably against other cancer cell lines that are typically resistant to Pt therapy.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2 Preparation and Characterization of <b>2</b></h3><div class="NLM_p">The preparation of <b>2</b> was carried out using the well-established solvent interfacial deposition method resulting in the formation of spherical NPs (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). The mean diameter of <b>2</b> was about 146 nm with polydispersity index (PDI) of 0.1, and the ζ potential value of <b>2</b> was approximately −49 mV. Furthermore, optimal encapsulation yields were achieved (>95% as determined by HPLC) and incorporation into the NPs ranged from 21.5% to 22.7% w/w. However, because NPs are unstable within aqueous mediums, their clinical use in delivery systems is significantly limited. Freeze-drying is a reliable method to maintain long-term stability for a wide range of biological products such as proteins, peptides or drug-loaded NPs or liposomes.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Therefore, after drug encapsulation, formulation <b>2</b> was freeze-dried using five cryo- and lyoprotectants: sucrose, (+)-trehalose, <span class="smallcaps smallerCapital">d</span>-(−)-mannitol, hydroxypropyl-β-cyclodextrin (HPβCD), and xylitol at different concentrations. Among these, lyophilization of <b>2</b> using sucrose (5% w/v) resulted in physically stable NPs. The lyophilized formulation of <b>2</b> was stable following incubation at 4 °C over a period of 4 weeks and following incubation at −20 °C over a period of 16 weeks (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_001.pdf" class="ext-link">Figure S3</a>). Considering possible clinical issues, the procedures established to freeze-dry <b>2</b> appear to be appropriate for the successful development of drug-loaded nanoparticulate formulations intended for parenteral administration. Each batch of <b>2</b> was tested in triplicate, and the results were similar indicating a good reproducibility of the manufacturing process of the nanoparticles and control of the experimental parameters.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Morphological evaluation of <b>2</b>: (A) SEM secondary electron image. (B) SEM backscattered electron image. (C,D) TEM micrographs of uranyl acetate negatively stained NPs at different areas of the grid, scale bar = 200 nm. (E,F) Two and three-dimensional AFM images of NPs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Once <b>1</b> was successfully encapsulated into NPs, the cytotoxic activity was evaluated in SKOV-3 ovarian cancer cells. The results showed that the cytotoxic activity of <b>1</b> and <b>2</b> were more pronounced than the toxic activity of OXA, as depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_001.pdf" class="ext-link">Figure S1 and Table S2</a>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.3 Cellular Uptake, DNA Platination, and Intracellular Localization</h3><div class="NLM_p">To examine the cellular accumulation of platinum of OXA, <b>1</b>, and <b>2</b> in cancer cells, the total Pt content was measured by ICP-MS in SKOV-3 cells following their 24 h exposure to the compounds at a concentration of 35 μM. The data, normalized to the total cellular protein, are presented in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A. Moreover, the platination of DNA was assessed. Analysis of the extent of DNA platination measured after 24 h exposure of SKOV-3 cells to 25 μg/mL of OXA (62.5 μM), <b>1</b>, and <b>2</b> (35 μM), indicated higher levels of DNA platination for <b>1</b> and <b>2</b> in comparison to OXA (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B). Further cellular uptake studies were carried out to measure the distribution of Pt species in different subcellular fractions. SKOV-3 cells were treated with 35 μM of OXA, <b>1</b>, and <b>2</b> for 24 h, and the cells were fractionated into four compartments: membrane, cytosol, nucleus, and cytoskeleton. The Pt levels in each compartment were measured by ICP-MS. The results are presented in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Platinum accumulation in whole cells following incubation with 35 μM of OXA, <b>1</b>, and <b>2</b> following a 24 h exposure to SKOV-3 cells as measured by ICP-MS. Values are the means ± SD obtained from three independent experiments. Statistical analysis revealed that the observed difference in platinum accumulation values was significant (<i>p</i> < 0.01, one-way ANOVA). (B) The extent of DNA platination following 24 h exposure to SKOV-3 cells as measured by ICP-MS. Values are mean ± SD obtained from seven independent experiments. Statistical analysis revealed that the observed difference in DNA platination values was significant (<i>p</i> < 0.01, one-way ANOVA). (C) Cellular distribution of Pt compounds in different fractions. The amount of Pt per 5.0 × 10<sup>4</sup> cells in cell membrane, cytosol, nucleus, and cytoskeleton fractions. Cells were exposed to 35 μM of Pt compounds for 24 h. Values are means ± SD. Nuclear fraction described by the manufacturer as follows: total nucleus soluble proteins, including the nuclear membrane proteins. Cytosol fraction: total cellular soluble proteins from cytoplasm. Membrane/particulate: total cellular membrane proteins including cellular organelles and organelle membrane proteins (excluding the nuclear membrane proteins). Cytoskeletal fraction: total cellular insoluble proteins, genomic DNA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.4 Cellular Uptake of NPs in SKOV-3 Cells by CLSM</h3><div class="NLM_p">Localization and cellular uptake of the NPs were evaluated 15 min following incubation (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A) and was most evident after 6 h (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). The nucleus was stained with DAPI (blue) whereas the NPs, fluorescently labeled using PE lissamine rhodamine B (red), were easily visualized within the cytoplasm. Indeed, increased cytoplasmic accumulation of NPs was observed as a function of dilution (1:100 versus 1:200) and time with a more pronounced perinuclear and nuclear localization pattern (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Intracellular uptake of NPs visualized by CLSM. (A) Intracellular uptake of PE lissamine rhodamine B-loaded NPs (red) by SKOV-3 cells was evaluated following 0–60 min incubation with two formulation dilutions, 1:100 and 1:200; nuclei were stained with DAPI (blue). (B) <i>Z</i>-stack confocal imaging of SKOV-3 cells incubated with PE lissamine rhodamine B-loaded NPs (red) for 6 h (dilution 1:100).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.5 <i>In Vivo</i> Evaluation of <b>1</b> and <b>2</b> for the Treatment of Solid Tumors</h3><div class="NLM_p">For <i>in vivo</i> evaluation of <b>1</b>, <b>2</b>, and OXA, the mice were divided into three treatment groups including solution of <b>1</b> in polyoxyl-35 castor oil/ethanol diluted by 10 in water for injection, free OXA, control (polyoxyl-35 castor oil/ethanol diluted by 10 in water for injection), and <b>2</b>. In fact, when diluted in 90% water for injection, solution of <b>1</b> in polyoxyl-35 castor oil/ethanol produces micelles of approximately 13 nm diameter, indicating that the administered solution could behave like a transparent tiny suspension of micelle-type nanocarrier, with potential accumulation ability at reticuloendothelial system (RES) organs and tumor tissue (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_001.pdf" class="ext-link">Figure S2</a>). A pharmacological evaluation was performed to verify the therapeutic superiority of <b>1</b> and <b>2</b> compared to OXA using a CCCD camera to detect the luminescence emitted from the tumor following luciferin ip administration. The tumor bioluminescence evaluation (at longitudinal view) of the tumor within the same groups of animals exhibits both sensitive and quantitative measurement of tumor response <i>in vivo.</i></div><div class="NLM_p">Metastatic ovarian tumors were induced by luciferase transfected SKOV3-luc-D3 cells injected into the peritoneal cavity of SCID-bg mice. Tumor development and progression was validated by bioluminescent imaging. Tumor signals from the images were quantified using LivingImage software, version 4.3.1, and luminescence group averages were plotted over time. Thirty days following cell injection, treatments were injected into the tail vein once a week over 4 weeks. It can be clearly seen from <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A,D that <b>1</b> and <b>2</b> were significantly more efficient in ovarian tumor growth inhibition in comparison to OXA and the control. Although the tumor was not completely eradicated, <b>1</b> and <b>2</b> reached the tumor more efficiently than the OXA, and the subsequent therapeutic effect was significantly greater. Ventral images of a representative mouse from each group taken on weeks 4, 7, 9, and 10 following tumor inoculation are presented in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>D. Importantly, no signs of systemic toxicities [weight loss (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B), weakness, pain, or discomfort] and no local reactions at the injection site were observed following <b>1</b> and <b>2</b> administration.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Efficacy study. (A) Longitudinal detection and quantification of SKOV3-luc-D3 ovarian tumor growth in live mice by the bioluminescent luciferase imaging assay using a CCCD camera. Tumor size is designated by the total luminescence intensity of the dorsal and ventral images, expressed in radiance units (photons/(s·cm<sup>2</sup>·sr)). Arrows indicate the treatment schedules on the 30th, 37th, 45th, and 52nd day. Results are presented as mean ± SE. Statistical analysis revealed that the observed differences at days 62 and 72 were significant (<i>p</i> < 0.01, one-way ANOVA). Post hoc analysis showed that there are significant differences between the control group and <b>1</b> and <b>2</b> treatment groups [<i>p</i> < 0.01, Dunnett test (2-sided)]. (B) Body weight follow-up beginning from tumor inoculation (day 0) through the study period. Changes were recorded as a percentage of the initial body weight observed on the day of tumor cells injection (100% at day 0). Results are presented as mean ± SD. (C) Kaplan–Meier survival curve from day of tumor cell injection until death. Death was recorded once animals fulfilled predetermined euthanasia criteria. ****<i>p</i> < 0.0001. The study was terminated on the 93rd day. (D) Representative ventral images of mice taken on weeks 4, 7, 9, and 10 following tumor inoculation are given.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We were interested in evaluating the effect of larger tolerated doses of <b>1</b> than with OXA based on molar calculations. The molar equivalence dose of OXA (5 mg/kg) for <b>1</b> is 9 mg/kg while the dose injected was 15 mg/kg. However, the results of a small pilot study where 15 mg/kg of <b>1</b> was compared to 9 mg/kg equivalent to the dose injected of OXA of 5 mg/kg, showed no significant difference in tumor growth inhibition and therefore it was decided to proceed with only 9 mg/kg of <b>1</b> either in free solution or in NPs for the other cancer models.</div><div class="NLM_p">Animals treated with <b>1</b> and <b>2</b> exhibited the longest survival rate compared to OXA and control groups (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C). On the 73rd day, 100% of mice in the <b>2</b> group were still alive, whereas all mice in the control and OXA groups had died, and 75% survival proportions were recorded for the <b>1</b> group. The mean survival time in the <b>1</b> and <b>2</b> groups, as analyzed by the Kaplan–Meier statistics, was 88 and 84 days, respectively, whereas for OXA and the control the mean survivals were 70 and 71 days, respectively. Survival differences were statistically significant.</div><div class="NLM_p">We next monitored the effect of <b>1</b>, <b>2</b>, and OXA on tumor growth over time in a mouse xenograft model of colon cancer by noninvasive <i>in vivo</i> luminescence imaging. Mice were subcutaneously injected with HCT 116-luc2 cells, which stably express firefly luciferase, and treatment was administered once every fourth day by iv injection (tail) as described previously. There was an increase in tumor growth in the groups of the control and OXA. However, in the groups of <b>1</b> and <b>2</b> at an equivalent concentration to OXA, tumor growth was significantly impaired with a decrease in tumor volume compared to the control (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). In contrast to the other animal studies, the animals in the treated groups initially lost weight but recovered and even increased in weight with time (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Efficacy study. (A) Longitudinal detection and quantification of HCT 116–luc2 colon tumor growth in live mice by the bioluminescent luciferase imaging assay using a CCCD camera. Tumor size is designated by the luminescence intensity of the dorsal images, expressed in radiance units (photons/(s·cm<sup>2</sup>·sr)). Results are presented as mean ± SE. Statistical analysis revealed that the observed differences in radiance values on the 33rd day were significant (<i>p</i> < 0.01, one-way ANOVA). Post hoc analysis showed significant differences between <b>1</b>, <b>2</b>, and control on the 33rd day [<i>p</i> < 0.01, Dunnett test (2-sided)], whereas there was no significant difference between OXA and control. (B) Body weight follow-up beginning from tumor inoculation (day 0) through the study period. Changes were recorded as a percentage of the initial body weight observed on the day of tumor cell injection (100% at day 0). Results are presented as mean ± SD. (C) Kaplan–Meier survival curve from tumor cell injection day until death. Death was recorded once animals fulfilled predetermined euthanasia criteria. ****<i>p</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Animals treated with <b>2</b> exhibited the longest survival rate compared to other treatment groups (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). On the 63rd day, 50% of mice in the <b>2</b> treatment group were still alive, whereas all mice in the <b>1</b>, control, and OXA groups had died. The mean survival time in the <b>2</b> treatment group, as analyzed by Kaplan–Meier statistics, was 69 days, whereas for <b>1</b>, OXA, and control the mean survivals were 55, 55, and 47 days, respectively. Survival differences were statistically significant, even when <b>2</b> treated mice were only compared to <b>1</b> treated mice, reinforcing the added value provided by the nanodelivery system (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">3 Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33872" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33872" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pt-based complexes are widely used in the treatment of various solid tumors, although exhibiting serious side-effects. Furthermore, it is well-known from the literature that the therapeutic outcome of Pt-based chemotherapy can be impaired by acquired resistance, which is one of the major limitations of Pt anticancer chemotherapy. The present study aimed to develop and characterize a drug delivery system loaded with a novel potent Pt(IV) prodrug of OXA for improved treatment of solid tumors.</div><div class="NLM_p">Because of the drawbacks of Pt(II) drugs, there is an incentive to synthesize lipophilic Pt(IV) complexes in an attempt to improve efficacy and overcome resistance as already reported by other authors, while trying to enhance the lipophilicity of cisplatin<a onclick="showRef(event, 'ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28">(25-28)</a> and OXA.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29-31)</a> Due to their octahedral coordination geometry, platinum(IV) complexes are preferred over their platinum(II) counterparts. The presence of two additional ligands facilitates their ability to detect and attach to specified targets. In contrast to previous approaches, in which symmetric Pt(IV) compounds were designed with the aim of tuning lipophilicity,<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32-34)</a> in the present study efforts concentrated on enhancing the lipophilicity of OXA using a different approach based on combining adversative ligands, by means of aqueous solubility and lipophilicity on the same Pt(IV) scaffold resulting in an asymmetric compound, namely, <b>1</b>.</div><div class="NLM_p">The antiproliferative activities of OXA and <b>1</b> were assessed in several cancer cell lines, as depicted in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. The cytotoxicity of <b>1</b> was substantially greater (more than 2 orders of magnitude) than that of OXA in both Pt sensitive and resistant cell lines, perhaps as a result of its enhanced accumulation because of its lipophilic character, as shown previously with other Pt compounds.<a onclick="showRef(event, 'ref29 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref29 ref35 ref36 ref37">(29, 35-37)</a></div><div class="NLM_p">Formulation <b>2</b> formed using the interfacial deposition method in the presence of lipoid E80 and OCA. PLGA was selected for this study because of its biocompatibility, biodegradability, and FDA approval for biomedical applications.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The formed particles typically displayed a remarkable loading rate in contrast to other nanoparticulate formulations where low loading rates (less than 6% w/w) of the active ingredients were obtained, confirming the adequate optimization of the actual formulation. Fatemeh et al. reported preparation of cisplatin and carboplatin-loaded polybutylcyanoacrylate NPs with loading percentages of 4% and 6%, respectively.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Indeed, the low drug loading is common for Pt NPs and can be attributed to their physicochemical characteristics.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a></div><div class="NLM_p">It should be emphasized that in contrast to other studies<a onclick="showRef(event, 'ref2 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref2 ref42 ref43">(2, 42, 43)</a> where the incorporation of Pt-based agents within NPs enhanced their cytotoxic activity owing to improved internalization, in the present case, <b>1</b> displayed similar activity to <b>2</b>. This is apparently due to its lipophilic character and intrinsic properties of the free active molecule allowing for significant penetration within the cytosol as shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> where the amounts of <b>1</b> in the various cellular fractions were much higher than the amount of <b>2</b>, with the exception of the cytoskeletal fraction where the amount was not significantly different. A plausible explanation for why these differences in concentrations in the various cellular fractions are not reflected in the cytotoxic activity should be attributed to the gradual release of <b>1</b> from NPs over a prolonged period of time into the target nucleus and cytoskeletal fraction compensating for the smaller concentration, which remains active. Moreover, an alternative explanation cannot be excluded, that is, the formation of free <b>1</b> molecules assembling into large micelles following the preparation of <b>1</b> solution and dilution by cell culture media. Nevertheless, it is still worth continuing the development of <b>2</b> because the presence of two additional ligands in <b>1</b> modified the chemical properties compared with the parent drug (OXA), making it more lipophilic and difficult to formulate in an aqueous solution.</div><div class="NLM_p">Delivery of a lipophilic drug to its target has always been a challenge and a subject of active research. The reduced solubility of drug molecules may hinder their ability to cross the physiological aqueous environments encompassing a cell and to penetrate the cell membrane. Furthermore, complications such as embolisms and local toxicity are likely to occur if the lipophilic or hydrophobic molecules tend to precipitate once injected iv at the site of administration.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Thus, such compounds need to be formulated in surfactant solutions to enhance the solubility and prevent potential precipitation. However, it is known from literature that surfactant agents such as polyoxyl-35 castor oil and polysorbate 80, widely used in the marketed cytotoxic products, can cause many adverse effects including pain, inflammation, neutropenia, hypersensitivity, and even anaphylactic shock.<a onclick="showRef(event, 'ref12 ref15 ref17'); return false;" href="javascript:void(0);" class="ref ref12 ref15 ref17">(12, 15, 17)</a> Therefore, in the present case and in order to avoid the adverse effects normally elicited by these excipients as well as future complications, it was decided to formulate the novel compound in PLGA NPs. This is a promising approach to overcome the poor water solubility of a lipophilic drug, by encapsulation in a NP-based carrier. Additionally, in the present study it was anticipated that the incorporation of <b>1</b> in NPs would not enhance the cytotoxic activity by accumulation of drug-loaded NPs in the cancer cells via endocytosis, as already reported in other studies,<a onclick="showRef(event, 'ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47">(45-47)</a> because it was assumed that like other lipophilic prodrugs under dilution of the parent drug, it would form micellar nanocarriers per se.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Nevertheless, cellular internalization of NPs into cancer cells was observed within minutes and gradually increased (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><div class="NLM_p">Pt(II) complexes are kinetically labile, and one advantage of Pt(IV) prodrugs is their relatively greater kinetic inertness.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> This reduced reactivity is expected to translate into prolonged circulation time <i>in vivo</i>, because of the protection of the Pt(II) pharmacophore from deactivation by biological nucleophiles. Once the complex enters the reducing environment of the cancer cell, it should reduce, forming the active Pt(II) agent.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> We propose that incorporation of <b>1</b> into NPs further protects it from reduction by physically preventing interaction between reducing agents and the encapsulated <b>1</b>. It was recently reported that encapsulation of the Pt(IV) anticancer compound mitaplatin prolonged retention of Pt in the bloodstream more than unencapsulated mitaplatin. Moreover, while both mitaplatin alone and mitaplatin-loaded NPs displayed the same long-term tumor growth inhibition in mice carrying MDA-MB-468 triple-negative breast cancer xenografts, the nanodelivery of the Pt agent significantly shifted the biodistribution of Pt in treated animals away from accumulation in the kidneys, a traditional site of Pt-induced toxicity.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><div class="NLM_p">In the present study, an <i>in vivo</i> experiment was conducted in which SKOV-3-luc cells were inoculated in SCID-bg mice. Due to the lack of an anatomical barrier between the ovaries and the peritoneal cavity, metastatic resistance of patients with ovarian cancer is severely reduced, and cancer cells are able to escape from the ovaries and form tumor nodules on the peritoneal surface.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> To closely mimic the disease, we established an ip disease model by injecting SKOV-3 cells intraperitoneally and evaluating the efficacy of <b>1</b>, <b>2</b>, and OXA accordingly. The antitumor activity of <b>1</b> and <b>2</b> indicated significantly decreased tumor growth compared to the control and OXA treatment groups (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).</div><div class="NLM_p">The similar antitumor activity exhibited by <b>1</b> and <b>2</b> irrespective of the animal cancer model might be due to micelle formation resulting from dilution of <b>1</b> in polyoxyl-35 castor oil/ethanol solution in 90% water for injection, suggesting that the administered solution is in fact a micellar solution displaying an enhanced permeability and retention (EPR) effect (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_001.pdf" class="ext-link">Figure S2</a>). Additionally, <i>in vivo</i> findings reinforce <i>in vitro</i> results obtained for the tested cell lines (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> and <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), in which IC<sub>50</sub> values of <b>1</b> and <b>2</b> were lower than those of OXA and respective Pt accumulation values were significantly greater than OXA elicited values.</div><div class="NLM_p">Moreover, animals treated with <b>1</b> and <b>2</b> exhibited the longest survival rate compared to OXA and control groups in animal models. In ovarian cancer model, on the 73rd day, 100% of mice in <b>2</b> treatment group were still alive, whereas all mice in the control and OXA groups had died, and 75% survival proportions were recorded for <b>1</b> treatment group (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C). Moreover, on the 63rd day in the subcutaneous model of colon cancer (HCT-116) in SCID-bg mice, 50% of mice in the <b>2</b> treatment group were still alive, whereas all mice in the <b>1</b>, control, and OXA groups had died (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). These findings reinforce the advantage of the <b>1</b> molecule per se and <b>2</b> over OXA in the treatment of ovarian and colon cancer. Tumor development and progression were also validated by bioluminescent imaging. The results revealed that <b>1</b> and <b>2</b> were equally and significantly more efficient in tumor growth inhibition compared to OXA and the control (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). It should be emphasized that <b>2</b> exhibited a remarkable survival advantage over other groups in the colon cancer animal model since the final surviving mouse lived for 90 days, whereas all the mice in the other groups survived up to 63 days, indicating the added value of <b>2</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). The findings of this study support the improved treatment hypothesis and substantially enhanced tumor growth inhibition elicited by <b>1</b> and <b>2</b> over OXA, although no complete tumor eradication was achieved. This could be attributed to several factors, one being that the cancer cells applied in the <i>in vivo</i> experiments are of human origin, yielding very aggressive tumor models with a rapid growth rate, which is unlikely to be seen in the clinic. Indeed, while the efficacy of the novel complex as a single-agent therapy was demonstrated, combination therapy is the mainstay treatment of cancer in clinical practice, particularly for advanced stages of the disease. Moreover, the results of this study are encouraging and reveal considerable potential for further development of this formulation.</div><div class="NLM_p last">So far, only a few reports of nano-delivery systems of OXA have been reported.<a onclick="showRef(event, 'ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref54 ref55">(52-55)</a> Among them, to the best of our knowledge, there are no reports describing the asymmetric Pt(IV) prodrug of OXA incorporated into PLGA nanospheres.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">4 Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62813" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62813" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Pt drugs are still among the most essential drugs in chemotherapy, but their lack of cancer-cell selectivity leads to toxicity issues. Here we report a novel Pt(IV) prodrug of OXA, namely, <b>1</b>, containing both lipophilic and hydrophilic axial ligands, with increased efficiency in killing cancer cells. The overall results indicate that <b>1</b> and <b>2</b> lead to significant tumor growth inhibition in comparison to OXA and were effective in both orthotopic and xenograft tumor models. Moreover, complex <b>1</b> was incorporated in PLGA NP delivery vehicles with the aim of mitigating the high systematic toxicity and severe side effects associated with Pt drugs. Such a NP treatment could become an attractive candidate for further investigation as a chemotherapeutic treatment for solid tumors.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">5 Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80837" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80837" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">5.1 Materials</h3><div class="NLM_p last">Oxaliplatin was acquired from AK Scientific, Inc. (Union City, CA, US); cisplatin, palmitic acid, polyoxyl-35 castor oil (CremophorEL), and thiazolyl blue tetrazolium bromide were purchased from Sigma-Aldrich (Jerusalem, Israel). Lipoid E80 was acquired from Lipoid GmbH (Ludwigshafen, Germany). PLGA (MW 50 kDa, Resomer RG 504 H) was purchased from Boehringer Ingelheim GmbH (Ingelheim, Germany). Oleyl cysteineamide (OCA) was synthesized as published previously.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Solutol HS 15 was donated by BASF (Ludwigshafen, Germany). Firefly D-luciferin, potassium salt, was obtained from Regis Technologies, Morton Grove, IL, USA. All organic solvents were HPLC grade and purchased from J.T Baker (Deventer, Holland). The PC-3, BxPC-3, OVCAR-8, and SKOV-3 cell lines were purchased from American Type Culture Collection (ATCC), Rockville, MD, USA. PC-3-luc, SKOV3-luc-D3, and HCT 116-luc2 were purchased from Caliper Life Sciences (Hopkinton, MA, USA). CT-26-luc cell line was kindly supplied by Dr. Gilad Bachrach from Hebrew University. A2780 and A2780-cisR cells line were kindly supplied by Prof. B. Keppler from University of Vienna. Most of the cells were purchased during the last three years, and normally when received, they were thawed, subcultured according to the manufacturer protocol to the appropriate passage, and stored as aliquots in liquid nitrogen. Every two months, the cells were tested for mycoplasma contamination according to the manufacturer protocol. All tissue culture products were from Biological Industries Ltd. (Beit Ha Emek, Israel). Luciferase transfected cell lines were obtained from Caliper Life Sciences (Hopkinton, MA). Pt concentrations were determined by an Agilent 7500ce inductively coupled plasma mass spectroscopy (ICP-MS). Tumor signals from the images of <i>in vivo</i> studies were quantified using LivingImage software version 4.3.1.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">5.2 Instrumentation</h3><div class="NLM_p last">All NMR data were collected on a Bruker AVANCE IIITM HD 500 MHz spectrometer using a 500 MHz SmartProbe. <sup>195</sup>Pt NMR data were collected at 107.47 MHz using sw = 217391.3 Hz, aq = 0.002 s, and rd = 0.001 s. The data were processed using MestreNova with a 300 Hz line broadening and backward linear prediction. <sup>1</sup>H spectra were recorded with standard parameters. Analytical HPLC analysis was performed on a standard Dionex UPLC system equipped with a Kinetex 5 μ XB-C18 100A New Column 250 mm × 4.6 mm with detection at 220 nm. Preparative purification was carried out on a Dionex semi- preparative HPLC using Phenomenex Luna 10 μ C18 100A 250 mm × 21.20 mm column at 220 nm. Platinum concentrations were determined by an Agilent 7500ce inductively coupled plasma mass spectroscopy (ICP-MS). The mean diameter and the ζ potential of the NPs were characterized using Malvern’s Zetasizer (Nano series, Nanos-ZS, UK) at 25 °C using water as diluent. Morphological evaluation was performed on carbon-coated Cu grids (300-mesh), using an electron microscope (CM12 TEM, Philips) at 100 kV, after negative staining using 2% uranyl acetate. Cellular uptake evaluation of NPs was done by Zeiss LSM 710 spectral confocal laser scanning microscope (CLSM). MS analysis was performed with a TSQ Quantum Access Max mass spectrometer with a heated electrospray ionization (H-ESI) interface (Thermo Scientific, San Jose, CA, USA).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">5.3 Synthesis and Characterization of <b>1</b></h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">5.3.1 Synthesis of [Pt(DACH)(OAc)(OH)(ox)]</h4><div class="NLM_p last">OXA (1.5 g, 3.8 mmol) was taken in 100 mL of acetic acid, and 50 μL of 30% H<sub>2</sub>O<sub>2</sub> was added. The reaction mixture was stirred at room temperature for 4–5 h, and the reaction was monitored by <sup>195</sup>Pt NMR. Excess acetic acid was removed by vacuum evaporation, and the resulting white solid was washed with diethyl ether and acetone and dried under vacuum. The product was further purified by preparative HPLC (5% ACN/95% H<sub>2</sub>O as mobile phase), <i>R</i><sub>T</sub> = 7.6 min. Yield: 1.456 g, 80.94%. <sup>195</sup>Pt NMR (in acetic acid), δ (ppm) = +1389. <sup>1</sup>H NMR (D<sub>2</sub>O) δ = 1.02–1.17 (b, 2H), 1.32–1.54 (b, 4H), 1.89 (s, 3H), 2.06–2.18 (b, 2H), 2.66–2.75 (b, 2H).</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">5.3.2 Synthesis of Palmitic Anhydride</h4><div class="NLM_p last">Palmitic acid (500 mg, 1.95 mmol) was dissolved in 20 mL of dichloromethane and <i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide (0.5 equiv, 201.2 mg, 0.975 mmol) was added. The reaction mixture was stirred at room temperature for 12 h. Progress of the reaction was monitored by TLC with ethyl acetate as the mobile phase. <i>N</i>,<i>N</i>′-Dicyclohexylurea that formed was filtered off from the reaction mixture, and excess dichloromethane was removed by evaporation. The white solid obtained after the removal of dichloromethane was redissolved in a small amount of dichloromethane, and the <i>N</i>,<i>N</i>′-dicyclohexylurea that precipitated was filtered off again. This step was repeated four times to remove <i>N</i>,<i>N</i>′-dicyclohexylurea completely. Palmitic anhydride was characterized by<sup>1</sup>H NMR. Yield: 858 mg 89%. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ = 0.8–0.9 (t, 6H), 1.16–1.36 (m, 48H), 1.56–1.69 (q, 4H), 2.30–2.46 (t, 4H).</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">5.3.3 Synthesis of <b>1</b></h4><div class="NLM_p last">[Pt(DACH)(OAc)(OH)(ox)] (1 g, 2.1 mmol) was dissolved in 5 mL of DMF, and palmitic anhydride (1.57g. 3.17 mmol) was added. The reaction mixture was stirred at 40 °C overnight and monitored by <sup>195</sup>Pt NMR. Unreacted anhydride (precipitated upon cooling) was filtered off from the reaction mixture, and DMF was removed by vacuum evaporation yielding a light-yellow solid. In order to purify the compound, 1 mL of methanol was added to the solid obtained after the evaporation of DMF, and the mixture was shaken well. The insoluble white precipitate was collected by centrifugation and washed twice with small portions of methanol and dried in vacuum. The compound obtained was characterized by <sup>195</sup>Pt NMR and <sup>1</sup>H NMR. Yield: 1.156 g, 76.97%, <sup>195</sup>Pt NMR (DMF) δ = 1589. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ = 0.79–0.87 (t, 3H), 1.13–1.27 (b, 24H), 1.30–1.54 (b, 5H), 1.93 (s, 3H), 2.02–2.15 (m, 2H), 2.17–2.28 (m, 2H), 2.76–2.94 (b, 2H), 8.20–8.6 (b, 4H). <i>m</i>/<i>z</i> (calculated) = 711.75, <i>m</i>/<i>z</i> (found) = 712.19. The calculated elemental analysis for <b>1</b> is C, 43.87; H, 6.80; N, 3.94. The actual analysis of the prepared material was C, 43.69; H, 6.61; N, 3.89. HPLC chromatogram of <b>1</b> (100% acetonitrile), <i>R</i><sub>T</sub> = 3.6 min. According to these findings, the purity of <b>1</b> is higher than 98%. The purity of <b>1</b> was further confirmed by the HPLC method previously described in the <a class="ref internalNav" href="#sec5_2" aria-label="Instrumentation">Instrumentation</a> section following injection of high concentrations (200 μg/mL). The purity was higher than 95% based on the various peaks areas detected in the chromatogram.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">5.4 Cell Lines and Cell Incubation Conditions</h3><div class="NLM_p">All cell culture media and all the cell lines were tested and authenticated from any mycoplasma contamination. A mycoplasma contamination test was done prior to the use of cells by a polymerase chain reaction (PCR) method (EZ-PCR Mycoplasma kit, Biological Industries, Israel). The <i>in vitro</i> experiments were performed in human cell lines of prostate cancer (PC-3 and PC-3-luc), pancreatic cancer (BxPC-3), ovarian cancer (SKOV-3, A2780, A2780-cisR, and OVCAR-8) and in murine colorectal cancer CT-26-luc cells. BxPC-3 and OVCAR-8 cells were grown in RPMI medium supplemented with 10% fetal bovine serum (Gibco), 1% <span class="smallcaps smallerCapital">l</span>-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 0.13% w/w gentamycin. PC-3 and PC-3-luc cells were cultured in DMEM plus 10% fetal bovine serum, 1% <span class="smallcaps smallerCapital">l</span>-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 1% pyrovate. SKOV-3 cells were cultured in McCoy’s 5A medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. A2780 and A2780-cisR cells were grown in RPMI medium supplemented with 10% fetal bovine serum, 1% <span class="smallcaps smallerCapital">l</span>-glutamine, and 0.1% w/w gentamycin, and the acquired resistance in A2780-cisR cell line was maintained by supplementing the medium with 1 μM cisplatin every second passage. CT-26-luc cells were grown in RPMI supplemented with 10% fetal bovine serum, 1% <span class="smallcaps smallerCapital">l</span>-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 100 μg/mL neomycin. SKOV3-luc-D3 and HCT 116-luc2 cells were cultured in McCoy’s 5A medium supplemented with 10% heat inactivated fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin.</div><div class="NLM_p last">The cell lines were maintained at 37 °C under a moist atmosphere containing 5% CO<sub>2</sub> and 95% air. All cell culture products were obtained from Biological Industries (Beit Ha Emek, Israel).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">5.5 Preparation and Characterization of <b>2</b></h3><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">5.5.1 Preparation of <b>2</b></h4><div class="NLM_p">Formulation <b>2</b> was prepared using the solvent deposition method.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Briefly, 7 mg of <b>1</b>, 14 mg of PLGA 50 kDa, 7 mg of lipoid E80, and 1.5 mg of oleyl cysteineamide (OCA) were dissolved in 4 mL of ethanol/acetone (1:20) mixture. The organic phase was added to 2.5 mL of aqueous solution containing 0.1% w/v Solutol HS 15. The suspension was stirred at 900 rpm over 15 min and then concentrated by solvent evaporation to a final volume of 2.5 mL, followed by centrifugation for 10 min at 4400 rpm.</div><div class="NLM_p last">The resulting drug-loaded NPs consisted of spherical nanomatrices of PLGA, lipoid E-80, and OCA embedding <b>1</b>, dispersed in 0.1% of Solutol HS15; solution was entitled <b>2</b>.</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">5.5.2 Content Determination of <b>1</b> in NPs</h4><div class="NLM_p last">To determine the amount of drug loaded in the NPs, formulation <b>2</b> was dissolved in acetonitrile, and the drug concentration was determined using analytical Dionex HPLC system equipped with a Kinetex 5u XB-C18 100A column 250 mm × 4.6 mm. Compound <b>1</b> was detected at a wavelength of 220 nm. Acetonitrile 100% was used as a mobile phase, and the flow rate was 1 mL/min.</div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">5.5.3 Physicochemical and Morphological Characterization</h4><div class="NLM_p last">The particle size distribution and ζ potential of <b>2</b> were characterized by dynamic light scattering (DLS, Malvern Zetasizer Nano ZS, UK). Morphological and size evaluation of <b>2</b> was carried out using XHR SEM (model Magellan 400L, FEI, Germany). The samples were fixed on a SEM-stub using double-sided adhesive tape and then made electrically conductive following standard coating by gold sputtering (Pilaron E5100) under vacuum. Morphological evaluation of the NPs was performed on carbon-coated Cu grids (300-mesh), using an electron microscope (CM12 TEM, Philips) at 100 kV, after negative staining using 2% uranyl acetate. A diluted suspension of <b>2</b> (1:1 × 10<sup>6</sup>) in water (HPLC grade, Baker) was placed onto the surface of cover glass (Marienfeld cover glass, 100, 22 mm × 22 mm). Samples were left to dry. The morphology and surface states were investigated using scanning probe microscope Dimension 3100, Nanoscope V (Veeco, CA, USA).</div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">5.5.4 Lyophilization of <b>2</b></h4><div class="NLM_p last">Finally, to ensure the prolonged physical stability of the NPs, five types of sugars were evaluated as cryo- and lyoprotectants for the freeze-drying process of <b>2</b>: sucrose, (+)-trehalose, <span class="smallcaps smallerCapital">d</span>-(−)-mannitol, xylitol, and hydroxypropyl-β-cyclodextrin (HPβCD). The NP suspension was freeze-dried using an Epsilon 2-6d Martin Christ lyophilizer (Gef., Germany) to obtain a dry powder.</div></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">5.6 <i>In Vitro</i> Cytotoxicity Assay</h3><div class="NLM_p last">Cytotoxicity was determined by the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) assay as described previously.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> In brief, cells were seeded in a sterile 24-well plate and incubated in the presence of the drug for 120 h at 37 °C, 5% CO<sub>2</sub>. In the first 24 h, the cells were allowed to settle and resume exponential growth. Then, cells were incubated for 120 h with treatments dispersed in full growth medium at different drug concentrations (0–50 μg/mL). Cells were extensively washed with HBSS and incubated with MTT solution (0.5 mg/mL) in HBSS, 2, 37 °C. Following another washing step, the dye was solubilized with DMSO, and the absorbance was determined at 540 nm.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">5.7 Determination of Platinum Accumulation in Whole Cell</h3><div class="NLM_p last">SKOV-3 cells were seeded in triplicate 24-well plates (50 × 10<sup>3</sup> cells/well), allowed to reach 80–90% confluence, and treated with OXA, <b>1</b>, and <b>2</b> at concentrations of 35 μM for 24 h at 37 °C. Following incubation, the drug-containing medium was removed, and cells were rinsed twice with cold PBS. The cells were harvested and centrifuged into a pellet. Concentrated nitric acid (1 mL) was added to cell pellets and incubated at 70 °C on a hot plate until the samples dried. The samples were dissolved in 0.1% SDS and 1% nitric acid and analyzed for Pt content by ICP-MS. Protein concentration analysis was conducted by BCA assay. Briefly, the cells were incubated in the same mentioned conditions and concentrations. Following incubation, the drug-containing medium was removed, and each well was rinsed twice with cold PBS and trypsinized, and the cells were centrifuged into a pellet (4400 rpm, 5 min). The pellet was rinsed one more time with PBS, and NaOH (0.1 N) was added. After the samples were diluted using water, they were incubated at 70 °C for 1 h, and the absorbance was measured at 562 nm. The protein concentration of the sample was calculated according to the BSA standard curve.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">5.8 Determination of Platinum Content Binding to DNA (DNA Platination)</h3><div class="NLM_p">SKOV-3 cells were seeded in triplicate 24-well plates (50 × 10<sup>3</sup> cell/well), allowed to reach 80–90% confluence, and treated with OXA, <b>1</b>, and <b>2</b> at concentrations of 25 μg/mL for 24 h at 37 °C. Following incubation, the drug-containing medium was removed, and cells were rinsed twice with cold PBS. The cells were harvested and centrifuged into a pellet (4400 rpm, 5 min). Genomic DNA was isolated using Qiagen DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA) as per the manufacturer’s instructions. The quantity of DNA was determined by Uvikon XS spectrophotometer (Secomam, France) from the absorption at 260 nm. Triplicate runs were performed to determine the content of Pt in DNA.</div><div class="NLM_p last">Upon determination of the DNA concentration, the remaining solution was overnight wet ashed in 1% nitric acid at 70 °C and analyzed for Pt content by ICP-MS. DNA platination was expressed as ng of Pt/μg of DNA.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">5.9 Cellular Distribution into Different Subcellular Compartments</h3><div class="NLM_p last">SKOV-3 cells were seeded in triplicate 24-well plates at a density of 5.0 × 10<sup>4</sup> cells/well and allowed to reach 80–90% confluence, then treated with the compounds (35 μM) for 24 h. Following incubation, the drug-containing medium was removed, and cells were rinsed twice with cold PBS. Cellular distribution into the different cell fractions (cytosol, nucleus, membrane/particulate, and cytoskeleton) was performed using a Fraction PREP cell fractionation kit from BioVision (Mountain View, CA), as per the manufacturer’s instructions. Final Pt content was determined by inductively coupled plasma mass spectroscopy (ICP-MS).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">5.10 Cellular Uptake Evaluation of NPs by Confocal Laser Scanning Microscopy (CLSM)</h3><div class="NLM_p last">NPs were prepared as described earlier, with the addition of 200 μg of Egg Liss Rhod PE into the organic phase. SKOV-3 cells were seeded in full growth medium on μ-Slide 8 well (ibidi GmbH, Germany) (50 000 cells/0.2 mL/well). Cells were grown for 24 h until subconfluence and washed with PBS (37 °C, 2 mM MgCl<sub>2</sub>). Cells were incubated with the formulations at 37 °C in serum-free medium over 0, 15, 30, and 60 min, then washed extensively using PBS with MgCl<sub>2</sub> and fixed with 4% formaldehyde in PBS for 15 min at room temperature (0.2 mL/well). Cells were washed again, and nucleus stained using 4′,6-diamidino-2-phenylindole (DAPI), 10 μg/mL in PBS, for 5 min (0.2 mL/well), washed with PBS, and then mounted with 20 μL of fresh DABCO solution in glycerol and visualized by CLSM.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">5.11 <i>In Vivo</i> Evaluation of <b>1</b> and <b>2</b> for the Treatment of Solid Tumors</h3><div class="NLM_p">Strict animal care procedures set forth by The Authority for Biological and Biomedical Models of the Hebrew University of Jerusalem based on guidelines from the NIH guide for the Care and Use of Laboratory Animals were followed (approval no. MD-13-13707-5).</div><div id="sec5_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">5.11.1 Bioluminescent Imaging and Efficacy Determination in an Orthotopic Intraperitoneal Model of Metastatic Ovarian Cancer in SCID-bg Mice</h4><div class="NLM_p last">Mice used were severe combined immunodeficiency female (SCID)-bg, 5–6 weeks old (Harlan, Jerusalem, Israel). Luciferase transfected SKOV3-luc-D3 cells (2 × 10<sup>6</sup> cells in 100 μL of PBS) were injected directly into ip cavity of mice. For tumor validation and tumor growth follow up, bioluminescent imaging was performed every 7 days using a CCCD camera (IVIS, Caliper Life Sciences, Xenogen Corporation) as previously described.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Firefly D-luciferin was injected intraperitoneally, and mice were anesthetized using 3% isoflurane. Animals were placed onto black paper in the IVIS imaging box and imaged dorsally and ventrally. Total luminescence (dorsal and ventral) was recorded in radiance units (photons/(s·cm<sup>2</sup>·sr)). Thirty days following cell injection and validation of tumor inoculation, mice were divided into four groups with equal average radiance values (<i>n</i> = 10–12). The following four formulations were tested: control (polyoxyl-35 castor oil/ethanol diluted by 10 in water for injection), free OXA at a dose of 5 mg/kg, <b>1</b> in polyoxyl-35 castor oil/ethanol diluted by 10 in water for injection (15 mg/kg), and <b>2</b> (15 mg/kg). Treatments were injected into the tail vein once a week for 4 weeks.</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32">5.11.2 Bioluminescent Imaging and Efficacy Determination in a Subcutaneous Xenograft Model of Colon Cancer in SCID-bg Mice</h4><div class="NLM_p">Mice used were severe combined immunodeficiency male (SCID)-bg, 5–6 weeks old (Harlan, Jerusalem, Israel). Luciferase transfected HCT 116-luc2 cells (1 × 10<sup>6</sup> cells in 100 μL of PBS) were subcutaneously injected in the dorsal flank of mice. For tumor validation and tumor growth follow up, bioluminescent imaging was performed every 7 days using a CCCD camera (IVIS, Caliper Life Sciences, Xenogen Corporation). Firefly D-luciferin was injected intraperitoneally and mice were anesthetized with 3% isoflurane. Animals were placed onto black paper in the IVIS imaging box and imaged dorsally. Luminescence was recorded in radiance units (photons/(s·cm<sup>2</sup>·sr)). One day following tumor inoculation, mice were randomly divided into the treatment groups (<i>n</i> = 9–10). The same four formulations were tested: control (polyoxyl-35 castor oil/ethanol diluted by 10 in water for injection), free OXA at a dose of 5 mg/kg, <b>1</b> in polyoxyl-35 castor oil/ethanol diluted by 10 in water for injection (9 mg/kg), and <b>2</b> (9 mg/kg). Treatments were injected into the tail vein once every fourth day, four treatments in total.</div><div class="NLM_p last">In the two animal studies, mice were euthanized according to strict predetermined criteria set by the Ethical Committee of the Animals’ Authority.</div></div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">5.12 Statistical Analysis</h3><div class="NLM_p last">Statistical analysis was performed with IBM SPSS Statistics Software version 22. One-way ANOVA was used to determine the difference between treatments, followed by the Tukey or Dunnett (2-sided) test. Statistical analysis of Kaplan–Meier statistics was performed using GraphPad Prism software version 6.07. Differences were considered significant if <i>p</i> < 0.05.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00955">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00955" class="ext-link">10.1021/acs.jmedchem.6b00955</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">IC<sub>50</sub> (μM) and resistant factor values for OXA and <b>1</b> against A2780 and A2780-cisR cell lines,  IC<sub>50</sub> values of OXA, <b>1</b>, and <b>2</b> in cancer cell lines used in the efficacy animal studies, DLS particle size distribution of <b>1</b> NPs spontaneously formed following dilution of <b>1</b> solution in DMSO by DDW at the same concentration as used for the cell culture experiments, the freeze-drying parameters and characterization of lyophilized NPs after various time periods, and the <sup>1</sup>H and <sup>195</sup>Pt NMR spectra, HPLC chromatograms, and ESI-MS spectra of complex <b>1</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular strings for OXA, <b>1</b>, and <b>2</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_001.pdf">jm6b00955_si_001.pdf (1.34 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_002.csv">jm6b00955_si_002.csv (0.23 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00955" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65308" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65308" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Benita</span> - <span class="hlFld-Affiliation affiliation">The Hebrew University of
Jerusalem, Institute for Drug Research of
the School of Pharmacy, Faculty of Medicine, POB 12065, Jerusalem 9112100, Israel</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fe8d979391909cbe9b95939ad0968b9497d09f9dd09792"><span class="__cf_email__" data-cfemail="7f0c161210111d3f1a14121b51170a1516511e1c511613">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aiman Abu Ammar</span> - <span class="hlFld-Affiliation affiliation">The Hebrew University of
Jerusalem, Institute for Drug Research of
the School of Pharmacy, Faculty of Medicine, POB 12065, Jerusalem 9112100, Israel</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raji Raveendran</span> - <span class="hlFld-Affiliation affiliation">The Hebrew University of
Jerusalem, Institute for Drug Research of
the School of Pharmacy, Faculty of Medicine, POB 12065, Jerusalem 9112100, Israel</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dan Gibson</span> - <span class="hlFld-Affiliation affiliation">The Hebrew University of
Jerusalem, Institute for Drug Research of
the School of Pharmacy, Faculty of Medicine, POB 12065, Jerusalem 9112100, Israel</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taher Nassar</span> - <span class="hlFld-Affiliation affiliation">The Hebrew University of
Jerusalem, Institute for Drug Research of
the School of Pharmacy, Faculty of Medicine, POB 12065, Jerusalem 9112100, Israel</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4034212825322e00252b2d246e28352a296e21236e292c"><span class="__cf_email__" data-cfemail="a1d5c0c9c4d3cfe1c4caccc58fc9d4cbc88fc0c28fc8cd">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>T.N and S.B. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e1620-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48474" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48474" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors gratefully acknowledge Prof. Reuven Reich for providing excellent technical assistance in orthotopic intraperitoneal model of metastatic ovarian cancer and Ofir Tirosh for long hours and hard work on the ICP-MS. D.G. thanks the Israel Science Foundation (Grant 1611/14) for partial support.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i37" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i37"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i38" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i38"> Abbreviations</h2><tr><td class="NLM_term">CLSM</td><td class="NLM_def"><p class="first last">confocal laser scanning microscopy</p></td></tr><tr><td class="NLM_term">DDW</td><td class="NLM_def"><p class="first last">double-distilled water</p></td></tr><tr><td class="NLM_term">DLS</td><td class="NLM_def"><p class="first last">dynamic light scattering</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">50% growth inhibitory concentration</p></td></tr><tr><td class="NLM_term">ICP-MS</td><td class="NLM_def"><p class="first last">inductively coupled plasma mass spectroscopy</p></td></tr><tr><td class="NLM_term">OCA</td><td class="NLM_def"><p class="first last">oleyl cysteineamide</p></td></tr><tr><td class="NLM_term">OXA</td><td class="NLM_def"><p class="first last">oxaliplatin</p></td></tr><tr><td class="NLM_term">PDI</td><td class="NLM_def"><p class="first last">polydispersity index</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">SE</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">TEM</td><td class="NLM_def"><p class="first last">transmission electron microscopy</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74266" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74266" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 55 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Akbarzadeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikaeili, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarghami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barkhordari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davaran, S.</span><span> </span><span class="NLM_article-title">Preparation and in vitro evaluation of doxorubicin-loaded Fe(3)O(4) magnetic nanoparticles modified with biocompatible copolymers</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.2147/IJN.S24326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.2147%2FIJN.S24326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22334781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFaktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=511-526&author=A.+Akbarzadehauthor=H.+Mikaeiliauthor=N.+Zarghamiauthor=R.+Mohammadauthor=A.+Barkhordariauthor=S.+Davaran&title=Preparation+and+in+vitro+evaluation+of+doxorubicin-loaded+Fe%283%29O%284%29+magnetic+nanoparticles+modified+with+biocompatible+copolymers&doi=10.2147%2FIJN.S24326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers</span></div><div class="casAuthors">Akbarzadeh, Abolfazl; Mikaeili, Haleh; Zarghami, Nosratollah; Mohammad, Rahmati; Barkhordari, Amin; Davaran, Soodabeh</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">511-526</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Superparamagnetic iron oxide nanoparticles are attractive materials that have been widely used in medicine for drug delivery, diagnostic imaging, and therapeutic applications.  In our study, superparamagnetic iron oxide nanoparticles and the anticancer drug, doxorubicin hydrochloride, were encapsulated into poly (, -lactic-co-glycolic acid) poly (ethylene glycol) (PLGA-PEG) nanoparticles for local treatment.  The magnetic properties conferred by superparamagnetic iron oxide nanoparticles could help to maintain the nanoparticles in the joint with an external magnet.  Methods: A series of PLGA:PEG triblock copolymers were synthesized by ring-opening polymn. of , -lactide and glycolide with different mol. wts. of polyethylene glycol (PEG2000, PEG3000, and PEG4000) as an initiator.  The bulk properties of these copolymers were characterized using 1H NMR spectroscopy, gel permeation chromatog., Fourier transform IR spectroscopy, and differential scanning calorimetry.  In addn., the resulting particles were characterized by x-ray powder diffraction, SEM, and vibrating sample magnetometry.  Results: The doxorubicin encapsulation amt. was reduced for PLGA:PEG2000 and PLGA:PEG3000 triblock copolymers, but increased to a great extent for PLGA:PEG4000 triblock copolymer.  This is due to the increased water uptake capacity of the blended triblock copolymer, which encapsulated more doxorubicin mols. into a swollen copolymer matrix.  The drug encapsulation efficiency achieved for Fe3O4 magnetic nanoparticles modified with PLGA:PEG2000, PLGA:PEG3000, and PLGA:PEG4000 copolymers was 69.5%, 73%, and 78%, resp., and the release kinetics were controlled.  The in vitro cytotoxicity test showed that the Fe3O4-PLGA:PEG4000 magnetic nanoparticles had no cytotoxicity and were biocompatible.  Conclusion: There is potential for use of these nanoparticles for biomedical application.  Future work includes in vivo investigation of the targeting capability and effectiveness of these nanoparticles in the treatment of lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3e9SazMqoY7Vg90H21EOLACvtfcHk0ljlADvedUk4hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFaktr0%253D&md5=a530d4c7524e94d8c750bd5b112504d3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2147%2FIJN.S24326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S24326%26sid%3Dliteratum%253Aachs%26aulast%3DAkbarzadeh%26aufirst%3DA.%26aulast%3DMikaeili%26aufirst%3DH.%26aulast%3DZarghami%26aufirst%3DN.%26aulast%3DMohammad%26aufirst%3DR.%26aulast%3DBarkhordari%26aufirst%3DA.%26aulast%3DDavaran%26aufirst%3DS.%26atitle%3DPreparation%2520and%2520in%2520vitro%2520evaluation%2520of%2520doxorubicin-loaded%2520Fe%25283%2529O%25284%2529%2520magnetic%2520nanoparticles%2520modified%2520with%2520biocompatible%2520copolymers%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2012%26volume%3D7%26spage%3D511%26epage%3D526%26doi%3D10.2147%2FIJN.S24326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Oberoi, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukolova, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabanov, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronich, T. K.</span><span> </span><span class="NLM_article-title">Nanocarriers for delivery of platinum anticancer drugs</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1667</span><span class="NLM_x">–</span> <span class="NLM_lpage">1685</span><span class="refDoi"> DOI: 10.1016/j.addr.2013.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.addr.2013.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=24113520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWmurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1667-1685&author=H.+S.+Oberoiauthor=N.+V.+Nukolovaauthor=A.+V.+Kabanovauthor=T.+K.+Bronich&title=Nanocarriers+for+delivery+of+platinum+anticancer+drugs&doi=10.1016%2Fj.addr.2013.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarriers for delivery of platinum anticancer drugs</span></div><div class="casAuthors">Oberoi, Hardeep S.; Nukolova, Natalia V.; Kabanov, Alexander V.; Bronich, Tatiana K.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">1667-1685</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clin. use esp. for management of tumors of the ovary, testes, and the head and neck.  However, several dose limiting toxicities assocd. with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life.  These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy.  Nanocarrier-based delivery of platinum compds. is one such area of intense research effort beginning to provide encouraging preclin. and clin. results and may allow the development of the next generation of platinum chemotherapy.  This review highlights current understanding on the pharmacol. and limitations of platinum compds. in clin. use, and provides a comprehensive anal. of various platinum-polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9t-JIgD2CMrVg90H21EOLACvtfcHk0ljlADvedUk4hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWmurbO&md5=25ea0f4f9f5f2712c294c8f37bb541ce</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2013.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2013.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DOberoi%26aufirst%3DH.%2BS.%26aulast%3DNukolova%26aufirst%3DN.%2BV.%26aulast%3DKabanov%26aufirst%3DA.%2BV.%26aulast%3DBronich%26aufirst%3DT.%2BK.%26atitle%3DNanocarriers%2520for%2520delivery%2520of%2520platinum%2520anticancer%2520drugs%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1667%26epage%3D1685%26doi%3D10.1016%2Fj.addr.2013.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Kelland, L.</span><span> </span><span class="NLM_article-title">The resurgence of platinum-based cancer chemotherapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">584</span><span class="refDoi"> DOI: 10.1038/nrc2167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1038%2Fnrc2167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=17625587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=573-584&author=L.+Kelland&title=The+resurgence+of+platinum-based+cancer+chemotherapy&doi=10.1038%2Fnrc2167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of platinum-based cancer chemotherapy</span></div><div class="casAuthors">Kelland, Lloyd</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-584</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The accidental discovery of the anticancer properties of cisplatin and its clin. introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.  Although carboplatin - a second-generation analog that is safer but shows a similar spectrum of activity to cisplatin - was introduced in the 1980s, the pace of further improvements slowed for many years.  However, in the past several years interest in platinum drugs has increased.  Key developments include the elucidation of mechanisms of tumor resistance to these drugs, the introduction of new platinum-based agents (oxaliplatin, satraplatin and picoplatin), and clin. combination studies using platinum drugs with resistance modulators or new molecularly targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTEI4HRCjxQrVg90H21EOLACvtfcHk0lga6CpM7jj7dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D&md5=9d55f600a83a19d7836a2524de20efbf</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2167%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%26atitle%3DThe%2520resurgence%2520of%2520platinum-based%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D573%26epage%3D584%26doi%3D10.1038%2Fnrc2167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">Basis for design and development of platinum(IV) anticancer complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">3403</span><span class="NLM_x">–</span> <span class="NLM_lpage">3411</span><span class="refDoi"> DOI: 10.1021/jm070280u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070280u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvFKqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3403-3411&author=M.+D.+Hallauthor=H.+R.+Mellorauthor=R.+Callaghanauthor=T.+W.+Hambley&title=Basis+for+design+and+development+of+platinum%28IV%29+anticancer+complexes&doi=10.1021%2Fjm070280u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Basis for Design and Development of Platinum(IV) Anticancer Complexes</span></div><div class="casAuthors">Hall, Matthew D.; Mellor, Howard R.; Callaghan, Richard; Hambley, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3403-3411</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Recent advances in design and development of anticancer Platinum(IV) Complexes are discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrST9_M1CnGgbVg90H21EOLACvtfcHk0lga6CpM7jj7dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvFKqsLg%253D&md5=aaccf47b20d49d299f871846824cb61e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm070280u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070280u%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DMellor%26aufirst%3DH.%2BR.%26aulast%3DCallaghan%26aufirst%3DR.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DBasis%2520for%2520design%2520and%2520development%2520of%2520platinum%2528IV%2529%2520anticancer%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3403%26epage%3D3411%26doi%3D10.1021%2Fjm070280u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Reithofer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bytzek, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valiahdi, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowol, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartinger, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakupec, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span> </span><span class="NLM_article-title">Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes</span> <span class="citation_source-journal">J. Inorg. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/j.jinorgbio.2010.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.jinorgbio.2010.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=21134601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFahsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=46-51&author=M.+R.+Reithoferauthor=A.+K.+Bytzekauthor=S.+M.+Valiahdiauthor=C.+R.+Kowolauthor=M.+Groesslauthor=C.+G.+Hartingerauthor=M.+A.+Jakupecauthor=M.+Galanskiauthor=B.+K.+Keppler&title=Tuning+of+lipophilicity+and+cytotoxic+potency+by+structural+variation+of+anticancer+platinum%28IV%29+complexes&doi=10.1016%2Fj.jinorgbio.2010.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes</span></div><div class="casAuthors">Reithofer, Michael R.; Bytzek, Anna K.; Valiahdi, Seied M.; Kowol, Christian R.; Groessl, Michael; Hartinger, Christian G.; Jakupec, Michael A.; Galanski, Markus; Keppler, Bernhard K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-51</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) compds. with IC50 values ranging between 142 μM and 18 nM was investigated with respect to their lipophilicity (by the shake flask method as well as microemulsion electrokinetic chromatog.), redn. potential, as well as their cellular accumulation in cancer cells in vitro.  In general, the antiproliferative properties of the complexes correlated with their lipophilicity as well as their accumulation, whereas differences in antiproliferative potency could not be explained by redn. potentials since they do not vary significantly within the investigated series of compds.  Only minor effects for complexes featuring polar end groups were detected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbNpB_Ezgos7Vg90H21EOLACvtfcHk0liwWFl1bcvFlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFahsrrI&md5=e3f3e1d4fc69d5f051b39ef9b7b255c7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2010.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2010.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DReithofer%26aufirst%3DM.%2BR.%26aulast%3DBytzek%26aufirst%3DA.%2BK.%26aulast%3DValiahdi%26aufirst%3DS.%2BM.%26aulast%3DKowol%26aufirst%3DC.%2BR.%26aulast%3DGroessl%26aufirst%3DM.%26aulast%3DHartinger%26aufirst%3DC.%2BG.%26aulast%3DJakupec%26aufirst%3DM.%2BA.%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26atitle%3DTuning%2520of%2520lipophilicity%2520and%2520cytotoxic%2520potency%2520by%2520structural%2520variation%2520of%2520anticancer%2520platinum%2528IV%2529%2520complexes%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2011%26volume%3D105%26spage%3D46%26epage%3D51%26doi%3D10.1016%2Fj.jinorgbio.2010.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Giandomenico, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murrer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollano, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rheinheimer, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyer, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossard, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J. D.</span><span> </span><span class="NLM_article-title">Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entr.acte.ee into orally active platinum(IV) antitumor agents</span> <span class="citation_source-journal">Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1021/ic00109a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic00109a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1995&pages=1015-1021&author=C.+M.+Giandomenicoauthor=M.+J.+Abramsauthor=B.+A.+Murrerauthor=J.+F.+Vollanoauthor=M.+I.+Rheinheimerauthor=S.+B.+Wyerauthor=G.+E.+Bossardauthor=J.+D.+Higgins&title=Carboxylation+of+kinetically+inert+platinum%28IV%29+hydroxy+complexes.+An+entr.acte.ee+into+orally+active+platinum%28IV%29+antitumor+agents&doi=10.1021%2Fic00109a004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fic00109a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic00109a004%26sid%3Dliteratum%253Aachs%26aulast%3DGiandomenico%26aufirst%3DC.%2BM.%26aulast%3DAbrams%26aufirst%3DM.%2BJ.%26aulast%3DMurrer%26aufirst%3DB.%2BA.%26aulast%3DVollano%26aufirst%3DJ.%2BF.%26aulast%3DRheinheimer%26aufirst%3DM.%2BI.%26aulast%3DWyer%26aufirst%3DS.%2BB.%26aulast%3DBossard%26aufirst%3DG.%2BE.%26aulast%3DHiggins%26aufirst%3DJ.%2BD.%26atitle%3DCarboxylation%2520of%2520kinetically%2520inert%2520platinum%2528IV%2529%2520hydroxy%2520complexes.%2520An%2520entr.acte.ee%2520into%2520orally%2520active%2520platinum%2528IV%2529%2520antitumor%2520agents%26jtitle%3DInorg.%2520Chem.%26date%3D1995%26volume%3D34%26spage%3D1015%26epage%3D1021%26doi%3D10.1021%2Fic00109a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Galanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span> </span><span class="NLM_article-title">Carboxylation of dihydroxoplatinum(IV) complexes via a new synthetic pathway</span> <span class="citation_source-journal">Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1709</span><span class="NLM_x">–</span> <span class="NLM_lpage">1711</span><span class="refDoi"> DOI: 10.1021/ic9509490</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic9509490" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1996&pages=1709-1711&author=M.+Galanskiauthor=B.+K.+Keppler&title=Carboxylation+of+dihydroxoplatinum%28IV%29+complexes+via+a+new+synthetic+pathway&doi=10.1021%2Fic9509490"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fic9509490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic9509490%26sid%3Dliteratum%253Aachs%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26atitle%3DCarboxylation%2520of%2520dihydroxoplatinum%2528IV%2529%2520complexes%2520via%2520a%2520new%2520synthetic%2520pathway%26jtitle%3DInorg.%2520Chem.%26date%3D1996%26volume%3D35%26spage%3D1709%26epage%3D1711%26doi%3D10.1021%2Fic9509490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Gibson, D.</span><span> </span><span class="NLM_article-title">The mechanism of action of platinum anticancer agents--what do we really know about it?</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">10681</span><span class="NLM_x">–</span> <span class="NLM_lpage">10689</span><span class="refDoi"> DOI: 10.1039/b918871c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1039%2Fb918871c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=10681-10689&author=D.+Gibson&title=The+mechanism+of+action+of+platinum+anticancer+agents%2D%2Dwhat+do+we+really+know+about+it%3F&doi=10.1039%2Fb918871c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1039%2Fb918871c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb918871c%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520platinum%2520anticancer%2520agents--what%2520do%2520we%2520really%2520know%2520about%2520it%253F%26jtitle%3DDalton%2520Trans.%26date%3D2009%26volume%3D48%26spage%3D10681%26epage%3D10689%26doi%3D10.1039%2Fb918871c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Loh, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrap, K. R.</span><span> </span><span class="NLM_article-title">Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1109</span><span class="NLM_x">–</span> <span class="NLM_lpage">1115</span><span class="refDoi"> DOI: 10.1038/bjc.1992.419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1038%2Fbjc.1992.419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1457352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADyaK3sXhtl2gu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1992&pages=1109-1115&author=S.+Y.+Lohauthor=P.+Mistryauthor=L.+R.+Kellandauthor=G.+Abelauthor=K.+R.+Harrap&title=Reduced+drug+accumulation+as+a+major+mechanism+of+acquired+resistance+to+cisplatin+in+a+human+ovarian+carcinoma+cell+line%3A+circumvention+studies+using+novel+platinum+%28II%29+and+%28IV%29+ammine%2Famine+complexes&doi=10.1038%2Fbjc.1992.419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line:  circumvention studies using novel platinum (II) and (IV) ammine/amine complexes</span></div><div class="casAuthors">Loh, S. Y.; Mistry, P.; Kelland, L. R.; Abel, G.; Harrap, K. R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1109-15</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">Acquired resistance to cisplatin (cis-diamminedichloroplatinum (II)) has been generated in vitro in the 41M human ovarian carcinoma cell line, established from a previously untreated patient.  Three cisplatin-resistant variants were selected at approx. 2, 4 and 6-fold resistance (in terms of 50% inhibitory concns.), in order to study the underlying mechanisms of acquired cisplatin resistance.  Compared to the parent line, platinum accumulation following exposure to equimolar concns. of cisplatin was on av. (across the entire concn. range) 2.9, 3.6 and 4.8-fold lower in the 41McsiR2, 41McisR4 and 41 McisR6 cell lines, resp.  Thus the difference in uptake corresponded closely with their resistance factor in the three resistant variants.  Moreover, a significant redn. in platinum accumulation was obsd. as early as 5 min after exposure to cisplatin in the 41M vs 41McisR6 cell lines.  Platinum accumulation was similar in all cell lines following exposure to equitoxic concns. (2 h IC50) of cisplatin.  Enhanced efflux of drug was not obsd. between the 41M and 41McisR6 cells.  In addn., there was no difference in intracellular glutathione (GSH) levels.  Our previous studies have shown no indication of metallothionein involvement and the decrease in cisplatin uptake in the 41McisR6 cells was reflected by a similar redn. in DNA interstrand cross-links (ISC) formation.  These results suggest that the mechanism of acquired resistance to cisplatin in the 41McisR6 cell line may be predominantly due to reduced drug uptake.  The 41McisR6 cells were not found to be cross-resistant to ouabain, a postulated specific inhibitor of sodium-potassium ATPase (Na+,K+-ATPase), suggesting that decreased cisplatin accumulation in these cells is probably not regulated by alterations in their Na+,K+-ATPase levels, and Na+ potential across the plasma membrane.  Cellular accumulation of a novel class of platinum (IV) ammine/cyclohexylamine dicarboxylates, which exhibit enhanced cytotoxicity over cisplatin and completely circumvent resistance to cisplatin in the 41McisR line, was also examd.  The data suggests that increased accumulation of these compds., as a result of their enhanced lipophilicity, could account for the dramatic increase in their potency over cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqmtI4v6PUS7Vg90H21EOLACvtfcHk0liwWFl1bcvFlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtl2gu7Y%253D&md5=61bef5971f3ec0b9dfb116b4bb6e5a3f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1992.419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1992.419%26sid%3Dliteratum%253Aachs%26aulast%3DLoh%26aufirst%3DS.%2BY.%26aulast%3DMistry%26aufirst%3DP.%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DAbel%26aufirst%3DG.%26aulast%3DHarrap%26aufirst%3DK.%2BR.%26atitle%3DReduced%2520drug%2520accumulation%2520as%2520a%2520major%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520cisplatin%2520in%2520a%2520human%2520ovarian%2520carcinoma%2520cell%2520line%253A%2520circumvention%2520studies%2520using%2520novel%2520platinum%2520%2528II%2529%2520and%2520%2528IV%2529%2520ammine%252Famine%2520complexes%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1992%26volume%3D66%26spage%3D1109%26epage%3D1115%26doi%3D10.1038%2Fbjc.1992.419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Moeller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kangarloo, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puscasu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, J. E.</span><span> </span><span class="NLM_article-title">Rational design of platinum chemotherapeutic drugs: hydrophobicity increases cytotoxicity</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4435</span><span class="NLM_x">–</span> <span class="NLM_lpage">4439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=11205284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVejsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=4435-4439&author=N.+Moellerauthor=B.+S.+Kangarlooauthor=I.+Puscasuauthor=C.+Mockauthor=B.+Krebsauthor=J.+E.+Wolff&title=Rational+design+of+platinum+chemotherapeutic+drugs%3A+hydrophobicity+increases+cytotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of platinum chemotherapeutic drugs: hydrophobicity increases cytotoxicity</span></div><div class="casAuthors">Moeller, Niclas; Kangarloo, Bill S.; Puscasu, Ina; Mock, Christian; Krebs, Bernt; Wolff, Johannes E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6B</span>),
    <span class="NLM_cas:pages">4435-4439</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: Malignant glioma are often resistant to cisplatin.  Numerous chem. modifications have been made to overcome this limitation.  Analyzing such novel compds., we previously hypothesized, that hydrophobicity improves the cytotoxicity of NH3 substituted platinum agents.  Materials and Methods: Testing this hypothesis, we synthesized further eight novel platinum agents, substituting the NH3 groups with various pyridyl ring systems.  The cytotoxicity was measured in MTT tests using the cisplatin resistant human U25 1 malignant glioma cell line as a model.  Soly. was measured in water using flameless at. absorption spectroscopy.  Results: Cytotoxicity correlated significantly with low water soly.  The relation of cells surviving 72-h of 1 OuM drug exposure was best described by a logarithmic formula: Surviving cells (% of control) = 6.4+38.4 log (water soly. in mg Pt/L) Adding an oxime group to the arom. substitute decreased cytotoxicity.  Conclusions: These data confirmed that increased hydophobicity increases cytotoxicity in this group.  This might be caused by better cellular penetration, or by shielding of DNA-adducts from repair processes.  The data created a further hypothesis: A pos. mesomeric effect as characteristic for the oxime-group might decrease DNA binding, a neg. mesomeric might improve it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQCdtstlb6zLVg90H21EOLACvtfcHk0liC9Y38QTx4iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVejsLw%253D&md5=03f6935db832d62c6d76cf41a1b78714</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoeller%26aufirst%3DN.%26aulast%3DKangarloo%26aufirst%3DB.%2BS.%26aulast%3DPuscasu%26aufirst%3DI.%26aulast%3DMock%26aufirst%3DC.%26aulast%3DKrebs%26aufirst%3DB.%26aulast%3DWolff%26aufirst%3DJ.%2BE.%26atitle%3DRational%2520design%2520of%2520platinum%2520chemotherapeutic%2520drugs%253A%2520hydrophobicity%2520increases%2520cytotoxicity%26jtitle%3DAnticancer%2520Res.%26date%3D2000%26volume%3D20%26spage%3D4435%26epage%3D4439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Tallen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangopadhyay, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kangarloo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, J. E.</span><span> </span><span class="NLM_article-title">Overcoming cisplatin resistance: design of novel hydrophobic platinum compounds</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">449</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10769694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisl2ntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=445-449&author=G.+Tallenauthor=C.+Mockauthor=S.+B.+Gangopadhyayauthor=B.+Kangarlooauthor=B.+Krebsauthor=J.+E.+Wolff&title=Overcoming+cisplatin+resistance%3A+design+of+novel+hydrophobic+platinum+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming cisplatin resistance: design of novel hydrophobic platinum compounds</span></div><div class="casAuthors">Tallen, G.; Mock, C.; Gangopadhyay, S. B.; Kangarloo, B.; Krebs, B.; Wolff, J. E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1A</span>),
    <span class="NLM_cas:pages">445-449</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">The anticancer activity of cisplatin derives from its ability to crosslink DNA.  Cisplatin-resistance is partially caused by enhanced nucleotide excision repair (NER).  Major 1,2-intrastrand crosslinks can create a hydrophobic notch at the damage site, which can be specifically bound by damage-recognition proteins, thus shielded from NER-activity.  We aimed at preventing resistance by enhancing this mechanism using more hydrophobic platinum compds.  We synthesized three platinum analogs with increased hydrophobic characteristics.  Performing MTT-assays, the efficacy of cisplatin and the novel agents was compared in a fibroblast and eight brain tumor cell lines.  Among the novel compds., the most hydrophobic mol., methylpyridineplatinum, was most cytotoxic (LC50= 5.84 × 10-5M), followed by methylpyrazineplatinum, the second most hydrophobic (LC50=1.79 × 10-4M), and pyridineplatinum (LC50=2.76 × 10-4M).  Overall, cisplatin revealed highest cytotoxicity (LC50=8.77 × 10-6M).  Comparison of the novel compds. supports the hypothesis that increased hydrophobicity contributes to higher antitumor-activity.  Other advantageous characteristics of cisplatin might relate to its remaining highest efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpbybyZKhxQbVg90H21EOLACvtfcHk0liC9Y38QTx4iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisl2ntLs%253D&md5=e1c9432f315e457a823c7dcbf9f15a0f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTallen%26aufirst%3DG.%26aulast%3DMock%26aufirst%3DC.%26aulast%3DGangopadhyay%26aufirst%3DS.%2BB.%26aulast%3DKangarloo%26aufirst%3DB.%26aulast%3DKrebs%26aufirst%3DB.%26aulast%3DWolff%26aufirst%3DJ.%2BE.%26atitle%3DOvercoming%2520cisplatin%2520resistance%253A%2520design%2520of%2520novel%2520hydrophobic%2520platinum%2520compounds%26jtitle%3DAnticancer%2520Res.%26date%3D2000%26volume%3D20%26spage%3D445%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Gelderblom, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nooter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparreboom, A.</span><span> </span><span class="NLM_article-title">Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1590</span><span class="NLM_x">–</span> <span class="NLM_lpage">1598</span><span class="refDoi"> DOI: 10.1016/S0959-8049(01)00171-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2FS0959-8049%2801%2900171-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=11527683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmt1Oqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=1590-1598&author=H.+Gelderblomauthor=J.+Verweijauthor=K.+Nooterauthor=A.+Sparreboom&title=Cremophor+EL%3A+the+drawbacks+and+advantages+of+vehicle+selection+for+drug+formulation&doi=10.1016%2FS0959-8049%2801%2900171-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Cremophor EL the drawbacks and advantages of vehicle selection for drug formulation</span></div><div class="casAuthors">Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1590-1598</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Cremophor EL (CrEL) is a formulation vehicle used for various poorly-water sol. drugs, including the anticancer agent paclitaxel (Taxol).  In contrast to earlier reports, CrEL is not an inert vehicle, but exerts a range of biol. effects, some of which have important clin. implications.  Its use has been assocd. with severe anaphylactoid hypersensitivity reactions, hyperlipidemia, abnormal lipoprotein patterns, aggregation of erythrocytes and peripheral neuropathy.  The pharmacokinetic behavior of CrEL is dose-independent, although its clearance is highly influenced by duration of the infusion.  This is particularly important since CrEL can affect the disposition of various drugs by changing the unbound drug concn. through micellar encapsulation.  In addn., it has been shown that CrEL, as an integral component of paclitaxel chemotherapy, modifies the toxicity profile of certain anticancer agents given concomitantly, by mechanisms other than kinetic interference.  A clear understanding of the biol. and pharmacol. role of CrEL is essential to help oncologists avoid side-effects assocd. with the use of paclitaxel or other agents using this vehicle.  With the present development of various new anticancer agents, it is recommended that alternative formulation approaches should be pursued to allow a better control of the toxicity of the treatment and the pharmacol. interactions related to the use of CrEL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAU0VQq8SHerVg90H21EOLACvtfcHk0liC9Y38QTx4iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmt1Oqtb0%253D&md5=0ec6b45267094be60ab04aefae474985</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2801%2900171-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252801%252900171-X%26sid%3Dliteratum%253Aachs%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DNooter%26aufirst%3DK.%26aulast%3DSparreboom%26aufirst%3DA.%26atitle%3DCremophor%2520EL%253A%2520the%2520drawbacks%2520and%2520advantages%2520of%2520vehicle%2520selection%2520for%2520drug%2520formulation%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26spage%3D1590%26epage%3D1598%26doi%3D10.1016%2FS0959-8049%2801%2900171-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Savjani, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajjar, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savjani, J. K.</span><span> </span><span class="NLM_article-title">Drug solubility: importance and enhancement techniques</span> <span class="citation_source-journal">ISRN Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2012</span><span class="NLM_x">, </span> <span class="NLM_fpage">195727</span><span class="refDoi"> DOI: 10.5402/2012/195727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.5402%2F2012%2F195727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22830056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A280%3ADC%252BC38fpslGjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=195727&author=K.+T.+Savjaniauthor=A.+K.+Gajjarauthor=J.+K.+Savjani&title=Drug+solubility%3A+importance+and+enhancement+techniques&doi=10.5402%2F2012%2F195727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Drug solubility: importance and enhancement techniques</span></div><div class="casAuthors">Savjani Ketan T; Gajjar Anuradha K; Savjani Jignasa K</div><div class="citationInfo"><span class="NLM_cas:title">ISRN pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Solubility, the phenomenon of dissolution of solute in solvent to give a homogenous system, is one of the important parameters to achieve desired concentration of drug in systemic circulation for desired (anticipated) pharmacological response.  Low aqueous solubility is the major problem encountered with formulation development of new chemical entities as well as for the generic development.  More than 40% NCEs (new chemical entities) developed in pharmaceutical industry are practically insoluble in water.  Solubility is a major challenge for formulation scientist.  Any drug to be absorbed must be present in the form of solution at the site of absorption.  Various techniques are used for the enhancement of the solubility of poorly soluble drugs which include physical and chemical modifications of drug and other methods like particle size reduction, crystal engineering, salt formation, solid dispersion, use of surfactant, complexation, and so forth.  Selection of solubility improving method depends on drug property, site of absorption, and required dosage form characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3fbidYXcW67FU0A1HOshhfW6udTcc2ebZ1ivtdFsGvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fpslGjsg%253D%253D&md5=5dce666f4aaa82df009fcc5edeb9ff79</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.5402%2F2012%2F195727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5402%252F2012%252F195727%26sid%3Dliteratum%253Aachs%26aulast%3DSavjani%26aufirst%3DK.%2BT.%26aulast%3DGajjar%26aufirst%3DA.%2BK.%26aulast%3DSavjani%26aufirst%3DJ.%2BK.%26atitle%3DDrug%2520solubility%253A%2520importance%2520and%2520enhancement%2520techniques%26jtitle%3DISRN%2520Pharm.%26date%3D2012%26volume%3D2012%26spage%3D195727%26doi%3D10.5402%2F2012%2F195727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Shin, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alani, A. W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockich, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, G. S.</span><span> </span><span class="NLM_article-title">Multidrug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2009.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.jconrel.2009.04.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2009&pages=294-300&issue=3&author=H.+C.+Shinauthor=A.+W.+G.+Alaniauthor=D.+A.+Raoauthor=N.+C.+Rockichauthor=G.+S.+Kwon&title=Multidrug+loaded+polymeric+micelles+for+simultaneous+delivery+of+poorly+soluble+anticancer+drugs&doi=10.1016%2Fj.jconrel.2009.04.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2009.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2009.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DH.%2BC.%26aulast%3DAlani%26aufirst%3DA.%2BW.%2BG.%26aulast%3DRao%26aufirst%3DD.%2BA.%26aulast%3DRockich%26aufirst%3DN.%2BC.%26aulast%3DKwon%26aufirst%3DG.%2BS.%26atitle%3DMultidrug%2520loaded%2520polymeric%2520micelles%2520for%2520simultaneous%2520delivery%2520of%2520poorly%2520soluble%2520anticancer%2520drugs%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2009%26volume%3D140%26issue%3D3%26spage%3D294%26epage%3D300%26doi%3D10.1016%2Fj.jconrel.2009.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Gradishar, W. J.</span><span> </span><span class="NLM_article-title">Albumin-bound paclitaxel: a next-generation taxane</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1041</span><span class="NLM_x">–</span> <span class="NLM_lpage">1053</span><span class="refDoi"> DOI: 10.1517/14656566.7.8.1041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1517%2F14656566.7.8.1041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=16722814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVOgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=1041-1053&author=W.+J.+Gradishar&title=Albumin-bound+paclitaxel%3A+a+next-generation+taxane&doi=10.1517%2F14656566.7.8.1041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin-bound paclitaxel: a next-generation taxane</span></div><div class="casAuthors">Gradishar, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1041-1053</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Taxanes are std. treatment for metastatic breast cancer; however, the solvents used as vehicles in these formulations cause severe toxicities.  The FDA recently approved a solvent-free formulation of paclitaxel for the treatment of metastatic breast cancer that utilizes 130-nm albumin-bound (nab) technol. (Abraxane nab-paclitaxel) to circumvent the requirement for solvents.  Nab-Paclitaxel utilizes the natural properties of albumin to reversibly bind paclitaxel, transport it across the endothelial cell and conc. it in areas of tumor.  The proposed mechanism of drug delivery involves, in part, glycoprotein 60-mediated endothelial cell transcytosis of paclitaxel-bound albumin and accumulation in the area of tumor by albumin binding to SPARC (secreted protein, acidic and rich in cysteine).  Clin. studies have shown that nab-paclitaxel is significantly more effective than paclitaxel formulated as Cremophor EL (CrEL, Taxol, CrEL-paclitaxel), with almost double the response rate, increased time to disease progression and increased survival in second-line patients.  The absence of CrEL from the formulation is assocd. with decreased neutropenia and rapid improvement of peripheral neuropathy with nab-paclitaxel, compared with CrEL-paclitaxel.  For these reasons, nab-paclitaxel can be administered using higher doses of paclitaxel than that achievable with CrEL-paclitaxel, with shorter infusion duration and without the requirement for corticosteroid and antihistamine premedication to reduce the risk of solvent-mediated hypersensitivity reactions.  Taken together, these studies have demonstrated that nab technol. has increased the therapeutic index of paclitaxel compared with the conventional, solvent-based formulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNKtA35_81WrVg90H21EOLACvtfcHk0lhorNy3RO5mcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVOgsrg%253D&md5=2a150fb09d4675e3ab64b189e84da4bc</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F14656566.7.8.1041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.7.8.1041%26sid%3Dliteratum%253Aachs%26aulast%3DGradishar%26aufirst%3DW.%2BJ.%26atitle%3DAlbumin-bound%2520paclitaxel%253A%2520a%2520next-generation%2520taxane%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2006%26volume%3D7%26spage%3D1041%26epage%3D1053%26doi%3D10.1517%2F14656566.7.8.1041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mei, L.</span><span> </span><span class="NLM_article-title">Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2679</span><span class="NLM_x">–</span> <span class="NLM_lpage">2688</span><span class="refDoi"> DOI: 10.2147/IJN.S25251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.2147%2FIJN.S25251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22114498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1entL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=2679-2688&author=Y.+Maauthor=Y.+Zhengauthor=X.+Zengauthor=L.+Jiangauthor=H.+Chenauthor=R.+Liuauthor=L.+Huangauthor=L.+Mei&title=Novel+docetaxel-loaded+nanoparticles+based+on+PCL-Tween+80+copolymer+for+cancer+treatment&doi=10.2147%2FIJN.S25251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment</span></div><div class="casAuthors">Ma, Yuandong; Zheng, Yi; Zeng, Xiaowei; Jiang, Liqin; Chen, Hongbo; Liu, Ranyi; Huang, Laiqiang; Mei, Lin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2679-2688</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: The formulation of docetaxel available for clin. use (Taxotere) contains a high concn. of polysorbate 80 (Tween 80).  After incorporation of Tween 80 into poly-.vepsiln.-caprolactone (PCL)-Tween 80 copolymer, the relative amt. of Tween 80 should be decreased and the advantages of PCL and Tween 80 should be combined.  Methods: A novel PCL-Tween 80 copolymer was synthesized from .vepsiln.-caprolactone and Tween 80 in the presence of stannous octoate as a catalyst via ring opening polymn.  Two types of nanoparticle formulation were made from com. PCL and a self-synthesized PCL-Tween 80 copolymer using a modified solvent extn./evapn. method.  Results: The nanoparticles were found by field emission SEM to have a spherical shape and be 200 nm in diam.  The copolymers could encapsulate 10% of the drug in the nanoparticles and release 34.9% of the encapsulated drug over 28 days.  PCL-Tween 80 nanoparticles could be internalized into the cells and had higher cellular uptake than the PCL nanoparticles.  The drug-loaded PCL-Tween 80 nanoparticles showed better in vitro cytotoxicity towards C6 cancer cells than com. Taxotere at the same drug concn.  Conclusion: Nanoparticles using PCL-Tween 80 copolymer as drug delivery vehicles may have a promising outcome for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnI_yHBWxx2bVg90H21EOLACvtfcHk0lhorNy3RO5mcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1entL7F&md5=e55202eeaf590bb9ed78df621d505baf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2147%2FIJN.S25251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S25251%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DMei%26aufirst%3DL.%26atitle%3DNovel%2520docetaxel-loaded%2520nanoparticles%2520based%2520on%2520PCL-Tween%252080%2520copolymer%2520for%2520cancer%2520treatment%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2011%26volume%3D6%26spage%3D2679%26epage%3D2688%26doi%3D10.2147%2FIJN.S25251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Ten Tije, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loos, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparreboom, A.</span><span> </span><span class="NLM_article-title">Pharmacological effects of formulation vehicles: implications for cancer chemotherapy</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">685</span><span class="refDoi"> DOI: 10.2165/00003088-200342070-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.2165%2F00003088-200342070-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=12844327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFShsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=665-685&author=A.+J.+Ten+Tijeauthor=J.+Verweijauthor=W.+J.+Loosauthor=A.+Sparreboom&title=Pharmacological+effects+of+formulation+vehicles%3A+implications+for+cancer+chemotherapy&doi=10.2165%2F00003088-200342070-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological effects of formulation vehicles: implications for cancer chemotherapy</span></div><div class="casAuthors">ten Tije, Albert J.; Verweij, Jaap; Loos, Walter J.; Sparreboom, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">665-685</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  The non-ionic surfactants Cremophor EL (CrEL; polyoxyethyleneglycerol triricinoleate 35) and polysorbate 80 (Tween 80; polyoxyethylene-sorbitan-20-monooleate) are widely used as drug formulation vehicles, including for the taxane anticancer agents paclitaxel and docetaxel.  A wealth of recent exptl. data has indicated that both solubilizers are biol. and pharmacol. active compds., and their use as drug formulation vehicles has been implicated in clin. important adverse effects, including acute hypersensitivity reactions and peripheral neuropathy.  CrEL and Tween 80 have also been demonstrated to influence the disposition of solubilized drugs that are administered i.v.  The overall resulting effect is a highly increased systemic drug exposure and a simultaneously decreased clearance, leading to alteration in the pharmacodynamic characteristics of the solubilized drug.  Kinetic expts. revealed that this effect is primarily caused by reduced cellular uptake of the drug from large spherical micellar-like structures with a highly hydrophobic interior, which act as the principal carrier of circulating drug.  Within the central blood compartment, this results in a profound alteration of drug accumulation in erythrocytes, thereby reducing the free drug fraction available for cellular partitioning and influencing drug distribution as well as elimination routes.  The existence of CrEL and Tween 80 in blood as large polar micelles has also raised addnl. complexities in the case of combination chemotherapy regimens with taxanes, such that the disposition of several coadministered drugs, including anthracyclines and epipodophyllotoxins, is significantly altered.  In contrast to the enhancing effects of Tweene 80, addn. of CrEL to the formulation of oral drug prepns. seems to result in significantly diminished drug uptake and reduced circulating concns.  The drawbacks presented by the presence of CrEL or Tween 80 in drug formulations have instigated extensive research to develop alternative delivery forms.  Currently, several strategies are in progress to develop Tween 80- and CrEL-free formulations of docetaxel and paclitaxel, which are based on pharmaceutical (e.g. albumin nanoparticles, emulsions and liposomes), chem. (e.g. polyglutamates, analogs and prodrugs), or biol. (e.g. oral drug administration) strategies.  These continued investigations should eventually lead to more rational and selective chemotherapeutic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpckWw2-u6jK7Vg90H21EOLACvtfcHk0lime9AkSl03kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFShsLo%253D&md5=62887dbfb8d69a5e4bf04032e777aebd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2165%2F00003088-200342070-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200342070-00005%26sid%3Dliteratum%253Aachs%26aulast%3DTen%2BTije%26aufirst%3DA.%2BJ.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DLoos%26aufirst%3DW.%2BJ.%26aulast%3DSparreboom%26aufirst%3DA.%26atitle%3DPharmacological%2520effects%2520of%2520formulation%2520vehicles%253A%2520implications%2520for%2520cancer%2520chemotherapy%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2003%26volume%3D42%26spage%3D665%26epage%3D685%26doi%3D10.2165%2F00003088-200342070-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Gabano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osella, D.</span><span> </span><span class="NLM_article-title">Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">9813</span><span class="NLM_x">–</span> <span class="NLM_lpage">9820</span><span class="refDoi"> DOI: 10.1039/c4dt00911h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1039%2Fc4dt00911h" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=9813-9820&author=E.+Gabanoauthor=M.+Raveraauthor=D.+Osella&title=Pros+and+cons+of+bifunctional+platinum%28IV%29+antitumor+prodrugs%3A+two+are+%28not+always%29+better+than+one&doi=10.1039%2Fc4dt00911h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2Fc4dt00911h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4dt00911h%26sid%3Dliteratum%253Aachs%26aulast%3DGabano%26aufirst%3DE.%26aulast%3DRavera%26aufirst%3DM.%26aulast%3DOsella%26aufirst%3DD.%26atitle%3DPros%2520and%2520cons%2520of%2520bifunctional%2520platinum%2528IV%2529%2520antitumor%2520prodrugs%253A%2520two%2520are%2520%2528not%2520always%2529%2520better%2520than%2520one%26jtitle%3DDalton%2520Trans.%26date%3D2014%26volume%3D43%26spage%3D9813%26epage%3D9820%26doi%3D10.1039%2Fc4dt00911h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O.</span><span> </span><span class="NLM_article-title">Cancer nanomedicine: from targeted delivery to combination therapy</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span><span class="refDoi"> DOI: 10.1016/j.molmed.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.molmed.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=25656384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=223-232&author=X.+Xuauthor=W.+Hoauthor=X.+Zhangauthor=N.+Bertrandauthor=O.+Farokhzad&title=Cancer+nanomedicine%3A+from+targeted+delivery+to+combination+therapy&doi=10.1016%2Fj.molmed.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer nanomedicine: from targeted delivery to combination therapy</span></div><div class="casAuthors">Xu, Xiaoyang; Ho, William; Zhang, Xueqing; Bertrand, Nicolas; Farokhzad, Omid</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The advent of nanomedicine marks an unparalleled opportunity to advance the treatment of various diseases, including cancer.  The unique properties of nanoparticles (NPs), such as large surface-to-vol. ratio, small size, the ability to encapsulate various drugs, and tunable surface chem., give them many advantages over their bulk counterparts.  This includes multivalent surface modification with targeting ligands, efficient navigation of the complex in vivo environment, increased intracellular trafficking, and sustained release of drug payload.  These advantages make NPs a mode of treatment potentially superior to conventional cancer therapies.  This review highlights the most recent developments in cancer treatment using NPs as drug delivery vehicles, including promising opportunities in targeted and combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN0lD-ZXqgVLVg90H21EOLACvtfcHk0lime9AkSl03kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVOhuw%253D%253D&md5=bbb8815e635f43b856dbaeddc7a3f37d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHo%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBertrand%26aufirst%3DN.%26aulast%3DFarokhzad%26aufirst%3DO.%26atitle%3DCancer%2520nanomedicine%253A%2520from%2520targeted%2520delivery%2520to%2520combination%2520therapy%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D223%26epage%3D232%26doi%3D10.1016%2Fj.molmed.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Rizzo, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storm, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiessling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammers, T.</span><span> </span><span class="NLM_article-title">Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications</span> <span class="citation_source-journal">Curr. Opin. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1159</span><span class="NLM_x">–</span> <span class="NLM_lpage">1166</span><span class="refDoi"> DOI: 10.1016/j.copbio.2013.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.copbio.2013.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=23578464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1Shu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1159-1166&author=L.+Y.+Rizzoauthor=B.+Theekauthor=G.+Stormauthor=F.+Kiesslingauthor=T.+Lammers&title=Recent+progress+in+nanomedicine%3A+therapeutic%2C+diagnostic+and+theranostic+applications&doi=10.1016%2Fj.copbio.2013.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications</span></div><div class="casAuthors">Rizzo, Larissa Y.; Theek, Benjamin; Storm, Gert; Kiessling, Fabian; Lammers, Twan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Biotechnology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1159-1166</span>CODEN:
                <span class="NLM_cas:coden">CUOBE3</span>;
        ISSN:<span class="NLM_cas:issn">0958-1669</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In recent years, the use of nanomedicine formulations for therapeutic and diagnostic applications has increased exponentially.  Many different systems and strategies have been developed for drug targeting to pathol. sites, as well as for visualizing and quantifying important (patho-) physiol. processes.  In addn., ever more efforts have been undertaken to combine diagnostic and therapeutic properties within a single nanomedicine formulation.  These so-called nanotheranostics are able to provide valuable information on drug delivery, drug release and drug efficacy, and they are considered to be highly useful for personalizing nanomedicine-based (chemo-) therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSzWX8o4GMZrVg90H21EOLACvtfcHk0lime9AkSl03kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1Shu7w%253D&md5=571653bab00fbe707b6243d3cfe6a7ee</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.copbio.2013.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.copbio.2013.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DRizzo%26aufirst%3DL.%2BY.%26aulast%3DTheek%26aufirst%3DB.%26aulast%3DStorm%26aufirst%3DG.%26aulast%3DKiessling%26aufirst%3DF.%26aulast%3DLammers%26aufirst%3DT.%26atitle%3DRecent%2520progress%2520in%2520nanomedicine%253A%2520therapeutic%252C%2520diagnostic%2520and%2520theranostic%2520applications%26jtitle%3DCurr.%2520Opin.%2520Biotechnol.%26date%3D2013%26volume%3D24%26spage%3D1159%26epage%3D1166%26doi%3D10.1016%2Fj.copbio.2013.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Mahapatro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, D. K.</span><span> </span><span class="NLM_article-title">Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines</span> <span class="citation_source-journal">J. Nanobiotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="refDoi"> DOI: 10.1186/1477-3155-9-55</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1186%2F1477-3155-9-55" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22123084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1Crug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=55&author=A.+Mahapatroauthor=D.+K.+Singh&title=Biodegradable+nanoparticles+are+excellent+vehicle+for+site+directed+in-vivo+delivery+of+drugs+and+vaccines&doi=10.1186%2F1477-3155-9-55"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines</span></div><div class="casAuthors">Mahapatro, Anil; Singh, Dinesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nanobiotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55</span>CODEN:
                <span class="NLM_cas:coden">JNOAAO</span>;
        ISSN:<span class="NLM_cas:issn">1477-3155</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Biodegradable nanoparticles (NPs) are gaining increased attention for their ability to serve as a viable carrier for site specific delivery of vaccines, genes, drugs and other biomols. in the body.  They offer enhanced biocompatibility, superior drug/vaccine encapsulation, and convenient release profiles for a no. of drugs, vaccines and biomols. to be used in a variety of applications in the field of medicine.  In this manuscript, the methods of prepn. of biodegradable NPs, different factors affecting optimal drug encapsulation, factors affecting drug release rates, various surface modifications of nanoparticles to enhance in-vivo circulation, distribution and multimodal functionalities along with the specific applications such as tumor targeting, oral delivery, and delivery of these particles to the central nervous system have been reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpY_XiZnOqnrVg90H21EOLACvtfcHk0lia6lYbocraOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1Crug%253D%253D&md5=46713b2574a145f930a5f7f51aa3e0b8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2F1477-3155-9-55&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1477-3155-9-55%26sid%3Dliteratum%253Aachs%26aulast%3DMahapatro%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DD.%2BK.%26atitle%3DBiodegradable%2520nanoparticles%2520are%2520excellent%2520vehicle%2520for%2520site%2520directed%2520in-vivo%2520delivery%2520of%2520drugs%2520and%2520vaccines%26jtitle%3DJ.%2520Nanobiotechnol.%26date%3D2011%26volume%3D9%26spage%3D55%26doi%3D10.1186%2F1477-3155-9-55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Fessi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devissaguet, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ammoury, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benita, S.</span><span> </span><span class="NLM_article-title">Nanocapsule formation by interfacial polymer deposition following solvent displacement</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">R1</span><span class="NLM_x">–</span> <span class="NLM_lpage">R4</span><span class="refDoi"> DOI: 10.1016/0378-5173(89)90281-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2F0378-5173%2889%2990281-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADyaL1MXmtF2hsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1989&pages=R1-R4&author=H.+Fessiauthor=F.+Puisieuxauthor=J.+P.+Devissaguetauthor=N.+Ammouryauthor=S.+Benita&title=Nanocapsule+formation+by+interfacial+polymer+deposition+following+solvent+displacement&doi=10.1016%2F0378-5173%2889%2990281-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocapsule formation by interfacial polymer deposition following solvent displacement</span></div><div class="casAuthors">Fessi, H.; Puisieux, F.; Devissaguet, J. P.; Ammoury, N.; Benita, S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">R1-R4</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    </div><div class="casAbstract">Indomethacin-loaded nanocapsules were prepd. by deposition of poly(DL-lactide) polymer at the oil-water interface following acetone displacement from the oily nanodroplets.  An attempt was made to elucidate the mechanism of formation in terms of interfacial turbulence between two unequilibrated liq. phases involving flow, diffusion and surface tension decrease (Marangoni effect).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj1GdEAMzx0rVg90H21EOLACvtfcHk0lia6lYbocraOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtF2hsbs%253D&md5=261e4b745df8b522f0b87f5934a17552</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2F0378-5173%2889%2990281-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-5173%252889%252990281-0%26sid%3Dliteratum%253Aachs%26aulast%3DFessi%26aufirst%3DH.%26aulast%3DPuisieux%26aufirst%3DF.%26aulast%3DDevissaguet%26aufirst%3DJ.%2BP.%26aulast%3DAmmoury%26aufirst%3DN.%26aulast%3DBenita%26aufirst%3DS.%26atitle%3DNanocapsule%2520formation%2520by%2520interfacial%2520polymer%2520deposition%2520following%2520solvent%2520displacement%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D1989%26volume%3D55%26spage%3DR1%26epage%3DR4%26doi%3D10.1016%2F0378-5173%2889%2990281-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Byrne, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betancourt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannon-Peppas, L.</span><span> </span><span class="NLM_article-title">Active targeting schemes for nanoparticle systems in cancer therapeutics</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1615</span><span class="NLM_x">–</span> <span class="NLM_lpage">1626</span><span class="refDoi"> DOI: 10.1016/j.addr.2008.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.addr.2008.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=18840489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=1615-1626&author=J.+D.+Byrneauthor=T.+Betancourtauthor=L.+Brannon-Peppas&title=Active+targeting+schemes+for+nanoparticle+systems+in+cancer+therapeutics&doi=10.1016%2Fj.addr.2008.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Active targeting schemes for nanoparticle systems in cancer therapeutics</span></div><div class="casAuthors">Byrne, James D.; Betancourt, Tania; Brannon-Peppas, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1615-1626</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The objective of this review is to outline current major cancer targets for nanoparticle systems and give insight into the direction of the field.  The major targeting strategies that have been used for the delivery of therapeutic or imaging agents to cancer have been broken into three sections.  These sections are angiogenesis-assocd. targeting, targeting to uncontrolled cell proliferation markers, and tumor cell targeting.  The targeting schemes explored for many of the reported nanoparticle systems suggest the great potential of targeted delivery to revolutionize cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7soOyI6FoYLVg90H21EOLACvtfcHk0lia6lYbocraOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP&md5=aeeb388245fec939e63fda98fb154d99</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2008.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2008.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DByrne%26aufirst%3DJ.%2BD.%26aulast%3DBetancourt%26aufirst%3DT.%26aulast%3DBrannon-Peppas%26aufirst%3DL.%26atitle%3DActive%2520targeting%2520schemes%2520for%2520nanoparticle%2520systems%2520in%2520cancer%2520therapeutics%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2008%26volume%3D60%26spage%3D1615%26epage%3D1626%26doi%3D10.1016%2Fj.addr.2008.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Abdelwahed, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degobert, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stainmesse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fessi, H.</span><span> </span><span class="NLM_article-title">Freeze-drying of nanoparticles: formulation, process and storage considerations</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1688</span><span class="NLM_x">–</span> <span class="NLM_lpage">1713</span><span class="refDoi"> DOI: 10.1016/j.addr.2006.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.addr.2006.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=17118485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kmtb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=1688-1713&author=W.+Abdelwahedauthor=G.+Degobertauthor=S.+Stainmesseauthor=H.+Fessi&title=Freeze-drying+of+nanoparticles%3A+formulation%2C+process+and+storage+considerations&doi=10.1016%2Fj.addr.2006.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Freeze-drying of nanoparticles: Formulation, process and storage considerations</span></div><div class="casAuthors">Abdelwahed, Wassim; Degobert, Ghania; Stainmesse, Serge; Fessi, Hatem</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1688-1713</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Freeze-drying has been considered as a good technique to improve the long-term stability of colloidal nanoparticles.  The poor stability in an aq. medium of these systems forms a real barrier against the clin. use of nanoparticles.  This article reviews the state of the art of freeze-drying nanoparticles.  It discusses the most important parameters that influence the success of freeze-drying of these fragile systems, and provides an overview of nanoparticles freeze-drying process and formulation strategies with a focus on the impact of formulation and process on particle stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotDuGqiKZVYbVg90H21EOLACvtfcHk0lgqDMs3j8Zjyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kmtb7E&md5=83c4c293417e5fbacf6f4a5c46da5b8c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2006.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2006.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelwahed%26aufirst%3DW.%26aulast%3DDegobert%26aufirst%3DG.%26aulast%3DStainmesse%26aufirst%3DS.%26aulast%3DFessi%26aufirst%3DH.%26atitle%3DFreeze-drying%2520of%2520nanoparticles%253A%2520formulation%252C%2520process%2520and%2520storage%2520considerations%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D1688%26epage%3D1713%26doi%3D10.1016%2Fj.addr.2006.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Zheng, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suntharalingam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">8790</span><span class="NLM_x">–</span> <span class="NLM_lpage">8798</span><span class="refDoi"> DOI: 10.1021/ja5038269</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5038269" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=8790-8798&author=Y.+R.+Zhengauthor=K.+Suntharalingamauthor=T.+C.+Johnstoneauthor=H.+Yooauthor=W.+Linauthor=J.+G.+Brooksauthor=S.+J.+Lippard&title=Pt%28IV%29+prodrugs+designed+to+bind+non-covalently+to+human+serum+albumin+for+drug+delivery&doi=10.1021%2Fja5038269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span></div><div class="casAuthors">Zheng, Yao-Rong; Suntharalingam, Kogularamanan; Johnstone, Timothy C.; Yoo, Hyunsuk; Lin, Wei; Brooks, Jamar G.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8790-8798</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Albumin is the most abundant protein in human serum and drugs that are administered i.v. inevitably interact with it.  We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery.  This goal is achieved by asym. functionalizing the axial ligands of the prodrug so as to mimic the overall features of a fatty acid.  Systematic variation of the length of the aliph. tail tunes the cellular uptake and, consequently, the cytotoxicity of cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2COOH)(OCONHR)], 4, where R is a linear alkyl group.  Investigation of an analog bearing a fluorophore conjugated to the succinate ligand confirmed that these compds. are reduced by biol. reductants with loss of the axial ligands.  Intracellular release of cisplatin from 4 was further confirmed by observing the characteristic effects of cisplatin on the cell cycle and morphol. following treatment with the prodrug.  The most potent member of series 4, for which R is a hexadecyl chain, interacts with HSA in a 1:1 stoichiometry to form the platinum-protein complex 7.  The interaction is non-covalent and extn. with octanol completely removes the prodrug from an aq. soln. of HSA.  Construct 7 is robust and can be isolated following fast protein liq. chromatog.  The nature of the tight interaction was investigated computationally, and these studies suggest that the prodrug is buried below the surface of the protein.  Consequently, complexation to HSA is able to reduce the rate of redn. of the prodrug by ascorbate.  The lead compd. from series 4 also exhibited significant stability in whole human blood, attributed to its interaction with HSA.  This favorable redox profile, in conjunction with the established nonimmunogenicity, biocompatibility, and enhanced tumor accumulation of HSA, produces a system that holds significant therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOojHJiVKj17Vg90H21EOLACvtfcHk0lgqDMs3j8Zjyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D&md5=541fe9e155e3f4e2f8d6f61f3d81ee5a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fja5038269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5038269%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DYoo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DBrooks%26aufirst%3DJ.%2BG.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPt%2528IV%2529%2520prodrugs%2520designed%2520to%2520bind%2520non-covalently%2520to%2520human%2520serum%2520albumin%2520for%2520drug%2520delivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D8790%26epage%3D8798%26doi%3D10.1021%2Fja5038269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Graf, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bielenberg, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolishetti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banyard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">alpha(V)beta(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug</span> <span class="citation_source-journal">ACS Nano</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">4530</span><span class="NLM_x">–</span> <span class="NLM_lpage">4539</span><span class="refDoi"> DOI: 10.1021/nn301148e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn301148e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFGhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=4530-4539&author=N.+Grafauthor=D.+R.+Bielenbergauthor=N.+Kolishettiauthor=C.+Muusauthor=J.+Banyardauthor=O.+C.+Farokhzadauthor=S.+J.+Lippard&title=alpha%28V%29beta%283%29+integrin-targeted+PLGA-PEG+nanoparticles+for+enhanced+anti-tumor+efficacy+of+a+Pt%28IV%29+prodrug&doi=10.1021%2Fnn301148e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug</span></div><div class="casAuthors">Graf, Nora; Bielenberg, Diane R.; Kolishetti, Nagesh; Muus, Christoph; Banyard, Jacqueline; Farokhzad, Omid C.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">4530-4539</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted delivery of therapeutics to tumor neovasculature is potentially a powerful approach for selective cancer treatment.  Integrins are heterodimeric transmembrane proteins involved in cell adhesion and cell signaling, and their expression is commonly upregulated in cancers and inflammatory diseases.  The αvβ3 integrin is differentially upregulated on angiogenic endothelial cells as well as on many cancer cells.  Here we demonstrate the differential targeting of cisplatin prodrug-encapsulated poly(D,L-lactic-co-glycolic acid)-block-polyethylene glycol (PLGA-PEG) nanoparticles (NPs) to the αvβ3 integrin on cancer cells using the cyclic pentapeptide c(RGDfK).  Cisplatin is one of the most widely used anticancer drugs, and approaches that can improve its therapeutic index are of broad importance.  The RGD-targeted Pt(IV)-encapsulated NPs displayed enhanced cytotoxicity as compared to cisplatin administered in its conventional dosage form in model prostate and breast cancer epithelial cells in vitro.  Cytotoxicities were also elevated in comparison to those of previously reported systems, a small mol. Pt(IV)-RGD conjugate and a Pt(IV) nanoscale coordination polymer carrying RGD moieties.  This result encouraged us also to evaluate the anticancer effect of the new construct in an animal model.  The RGD-targeted PLGA-PEG NPs were more efficacious and better tolerated by comparison to cisplatin in an orthotopic human breast cancer xenograft model in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAV6ynbyup7Vg90H21EOLACvtfcHk0lgqDMs3j8Zjyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFGhu70%253D&md5=7650624390ad2befa90ce40577b2edcd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fnn301148e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn301148e%26sid%3Dliteratum%253Aachs%26aulast%3DGraf%26aufirst%3DN.%26aulast%3DBielenberg%26aufirst%3DD.%2BR.%26aulast%3DKolishetti%26aufirst%3DN.%26aulast%3DMuus%26aufirst%3DC.%26aulast%3DBanyard%26aufirst%3DJ.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3Dalpha%2528V%2529beta%25283%2529%2520integrin-targeted%2520PLGA-PEG%2520nanoparticles%2520for%2520enhanced%2520anti-tumor%2520efficacy%2520of%2520a%2520Pt%2528IV%2529%2520prodrug%26jtitle%3DACS%2520Nano%26date%3D2012%26volume%3D6%26spage%3D4530%26epage%3D4539%26doi%3D10.1021%2Fnn301148e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Varbanov, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valiahdi, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakupec, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span> </span><span class="NLM_article-title">Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5456</span><span class="NLM_x">–</span> <span class="NLM_lpage">5464</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2011.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.ejmech.2011.09.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=5456-5464&author=H.+Varbanovauthor=S.+M.+Valiahdiauthor=A.+A.+Leginauthor=M.+A.+Jakupecauthor=A.+Rollerauthor=M.+Galanskiauthor=B.+K.+Keppler&title=Synthesis+and+characterization+of+novel+bis%28carboxylato%29dichloridobis%28ethylamine%29platinum%28IV%29+complexes+with+higher+cytotoxicity+than+cisplatin&doi=10.1016%2Fj.ejmech.2011.09.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DVarbanov%26aufirst%3DH.%26aulast%3DValiahdi%26aufirst%3DS.%2BM.%26aulast%3DLegin%26aufirst%3DA.%2BA.%26aulast%3DJakupec%26aufirst%3DM.%2BA.%26aulast%3DRoller%26aufirst%3DA.%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520novel%2520bis%2528carboxylato%2529dichloridobis%2528ethylamine%2529platinum%2528IV%2529%2520complexes%2520with%2520higher%2520cytotoxicity%2520than%2520cisplatin%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D5456%26epage%3D5464%26doi%3D10.1016%2Fj.ejmech.2011.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Zak, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turanek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroutil, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sova, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikolin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaluska, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neca, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sindlerova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozubik, A.</span><span> </span><span class="NLM_article-title">Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span><span class="refDoi"> DOI: 10.1021/jm030858+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030858%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=761-763&author=F.+Zakauthor=J.+Turanekauthor=A.+Kroutilauthor=P.+Sovaauthor=A.+Mistrauthor=A.+Poulovaauthor=P.+Mikolinauthor=Z.+Zakauthor=A.+Kasnaauthor=D.+Zaluskaauthor=J.+Necaauthor=L.+Sindlerovaauthor=A.+Kozubik&title=Platinum%28IV%29+complex+with+adamantylamine+as+nonleaving+amine+group%3A+synthesis%2C+characterization%2C+and+in+vitro+antitumor+activity+against+a+panel+of+cisplatin-resistant+cancer+cell+lines&doi=10.1021%2Fjm030858%2B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm030858%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030858%252B%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DF.%26aulast%3DTuranek%26aufirst%3DJ.%26aulast%3DKroutil%26aufirst%3DA.%26aulast%3DSova%26aufirst%3DP.%26aulast%3DMistr%26aufirst%3DA.%26aulast%3DPoulova%26aufirst%3DA.%26aulast%3DMikolin%26aufirst%3DP.%26aulast%3DZak%26aufirst%3DZ.%26aulast%3DKasna%26aufirst%3DA.%26aulast%3DZaluska%26aufirst%3DD.%26aulast%3DNeca%26aufirst%3DJ.%26aulast%3DSindlerova%26aufirst%3DL.%26aulast%3DKozubik%26aufirst%3DA.%26atitle%3DPlatinum%2528IV%2529%2520complex%2520with%2520adamantylamine%2520as%2520nonleaving%2520amine%2520group%253A%2520synthesis%252C%2520characterization%252C%2520and%2520in%2520vitro%2520antitumor%2520activity%2520against%2520a%2520panel%2520of%2520cisplatin-resistant%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D761%26epage%3D763%26doi%3D10.1021%2Fjm030858%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Neumann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarosi, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghebreselasie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marnett, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hey-Hawkins, E.</span><span> </span><span class="NLM_article-title">Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1002/cmdc.201402353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1002%2Fcmdc.201402353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=25318459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFamtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=183-192&author=W.+Neumannauthor=B.+C.+Crewsauthor=M.+B.+Sarosiauthor=C.+M.+Danielauthor=K.+Ghebreselasieauthor=M.+S.+Scholzauthor=L.+J.+Marnettauthor=E.+Hey-Hawkins&title=Conjugation+of+cisplatin+analogues+and+cyclooxygenase+inhibitors+to+overcome+cisplatin+resistance&doi=10.1002%2Fcmdc.201402353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance</span></div><div class="casAuthors">Neumann, Wilma; Crews, Brenda C.; Sarosi, Menyhart B.; Daniel, Cristina M.; Ghebreselasie, Kebreab; Scholz, Matthias S.; Marnett, Lawrence J.; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-192</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cyclooxygenase (COX) is an enzyme involved in tumorigenesis and is assocd. with tumor cell resistance against platinum-based antitumor drugs.  Cisplatin analogs were conjugated with COX inhibitors (indomethacin, ibuprofen) to study the synergistic effects that were previously obsd. in combination treatments.  The conjugates ensure concerted transport of both drugs into cells, and subsequent intracellular cleavage enables a dual-action mode.  Whereas the platinum(II) complexes showed cytotoxicities similar to those of cisplatin, the platinum(IV) conjugates revealed highly increased cytotoxic activities and were able to completely overcome cisplatin-related resistance.  Although some of the complexes are potent COX inhibitors, the conjugates appear to execute their cytotoxic action via COX-independent mechanisms.  Instead, the increased lipophilicity and kinetic inertness of the conjugates seem to facilitate cellular accumulation of the platinum drugs and thus improve the efficacy of the antitumor agents.  These conjugates are important tools for the elucidation of the direct influence of COX inhibitors on platinum-based anticancer drugs in tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmcKFi4NrXWLVg90H21EOLACvtfcHk0lh1Z6bIxYNHgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFamtr3N&md5=481952d7103a69c0e1f8d395e044fd7e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402353%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DW.%26aulast%3DCrews%26aufirst%3DB.%2BC.%26aulast%3DSarosi%26aufirst%3DM.%2BB.%26aulast%3DDaniel%26aufirst%3DC.%2BM.%26aulast%3DGhebreselasie%26aufirst%3DK.%26aulast%3DScholz%26aufirst%3DM.%2BS.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DConjugation%2520of%2520cisplatin%2520analogues%2520and%2520cyclooxygenase%2520inhibitors%2520to%2520overcome%2520cisplatin%2520resistance%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D183%26epage%3D192%26doi%3D10.1002%2Fcmdc.201402353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Novohradsky, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerzankova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepankova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrana, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raveendran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasparkova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brabec, V.</span><span> </span><span class="NLM_article-title">Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands</span> <span class="citation_source-journal">J. Inorg. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1016/j.jinorgbio.2014.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.jinorgbio.2014.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=25063910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Khu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2014&pages=72-79&author=V.+Novohradskyauthor=L.+Zerzankovaauthor=J.+Stepankovaauthor=O.+Vranaauthor=R.+Raveendranauthor=D.+Gibsonauthor=J.+Kasparkovaauthor=V.+Brabec&title=Antitumor+platinum%28IV%29+derivatives+of+oxaliplatin+with+axial+valproato+ligands&doi=10.1016%2Fj.jinorgbio.2014.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands</span></div><div class="casAuthors">Novohradsky, Vojtech; Zerzankova, Lenka; Stepankova, Jana; Vrana, Oldrich; Raveendran, Raji; Gibson, Dan; Kasparkova, Jana; Brabec, Viktor</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-79</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We report new anticancer prodrugs, platinum(IV) derivs. of oxaliplatin conjugated with valproic acid (VPA), a well-known drug having histone deacetylase inhibitory activity.  Like most platinum(IV) derivs., the cytotoxicity of the conjugates was lower in cell culture than that of oxaliplatin, but greater than those of its Pt(IV) deriv. contg. biol. inactive axial ligands in several cancer cell lines.  Notably, these conjugates display activity in both cisplatin sensitive- and resistant tumor cells capable of both markedly enhanced accumulation in tumor cells and acting in a dual threat manner, concurrently targeting histone deacetylase and genomic DNA.  These results demonstrate the dual targeting strategy to be a valuable route to pursue in the design of platinum agents which may be more effective in cancer types that are typically resistant to therapy by conventional cisplatin.  Moreover, platinum(IV) derivs. contg. VPA axial ligands seem to be promising dual-targeting candidates for addnl. preclin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUyC3cksfQ2rVg90H21EOLACvtfcHk0lh1Z6bIxYNHgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Khu7rL&md5=9bb753b45976997c1ab2b0416d1fd89a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2014.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2014.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DNovohradsky%26aufirst%3DV.%26aulast%3DZerzankova%26aufirst%3DL.%26aulast%3DStepankova%26aufirst%3DJ.%26aulast%3DVrana%26aufirst%3DO.%26aulast%3DRaveendran%26aufirst%3DR.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DKasparkova%26aufirst%3DJ.%26aulast%3DBrabec%26aufirst%3DV.%26atitle%3DAntitumor%2520platinum%2528IV%2529%2520derivatives%2520of%2520oxaliplatin%2520with%2520axial%2520valproato%2520ligands%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2014%26volume%3D140%26spage%3D72%26epage%3D79%26doi%3D10.1016%2Fj.jinorgbio.2014.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Zhang, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexselblatt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, D.</span><span> </span><span class="NLM_article-title">Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">849</span><span class="refDoi"> DOI: 10.1039/C1CC16647F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1039%2FC1CC16647F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22124352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ersbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=847-849&author=J.+Z.+Zhangauthor=E.+Wexselblattauthor=T.+W.+Hambleyauthor=D.+Gibson&title=Pt%28IV%29+analogs+of+oxaliplatin+that+do+not+follow+the+expected+correlation+between+electrochemical+reduction+potential+and+rate+of+reduction+by+ascorbate&doi=10.1039%2FC1CC16647F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate</span></div><div class="casAuthors">Zhang, Jenny Z.; Wexselblatt, Ezequiel; Hambley, Trevor W.; Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">847-849</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In contrast to the Pt(IV) derivs. of cisplatin, Pt(IV) derivs. of oxaliplatin do not show the expected correlation between the electrochem. redn. potentials and rates of redn. by ascorbate.  This is probably due to the lower ability of the amine and carboxylato ligands to form a bridge with the reducing agents to facilitate electron transfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ueBJeBlazLVg90H21EOLACvtfcHk0lgvS6tAEgNipw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ersbfE&md5=c28a1148f32a79389fe6b2509f014e26</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2FC1CC16647F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC1CC16647F%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%2BZ.%26aulast%3DWexselblatt%26aufirst%3DE.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DPt%2528IV%2529%2520analogs%2520of%2520oxaliplatin%2520that%2520do%2520not%2520follow%2520the%2520expected%2520correlation%2520between%2520electrochemical%2520reduction%2520potential%2520and%2520rate%2520of%2520reduction%2520by%2520ascorbate%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2012%26volume%3D48%26spage%3D847%26epage%3D849%26doi%3D10.1039%2FC1CC16647F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Khokhar, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">al-Baker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shamsuddin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddik, Z. H.</span><span> </span><span class="NLM_article-title">Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1021/jm960587l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960587l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=112-116&author=A.+R.+Khokharauthor=S.+al-Bakerauthor=S.+Shamsuddinauthor=Z.+H.+Siddik&title=Chemical+and+biological+studies+on+a+series+of+novel+%28trans-%281R%2C2R%29-%2C+trans-%281S%2C2S%29-%2C+and+cis-1%2C2-diaminocyclohexane%29platinum%28IV%29+carboxylate+complexes&doi=10.1021%2Fjm960587l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm960587l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960587l%26sid%3Dliteratum%253Aachs%26aulast%3DKhokhar%26aufirst%3DA.%2BR.%26aulast%3Dal-Baker%26aufirst%3DS.%26aulast%3DShamsuddin%26aufirst%3DS.%26aulast%3DSiddik%26aufirst%3DZ.%2BH.%26atitle%3DChemical%2520and%2520biological%2520studies%2520on%2520a%2520series%2520of%2520novel%2520%2528trans-%25281R%252C2R%2529-%252C%2520trans-%25281S%252C2S%2529-%252C%2520and%2520cis-1%252C2-diaminocyclohexane%2529platinum%2528IV%2529%2520carboxylate%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D112%26epage%3D116%26doi%3D10.1021%2Fjm960587l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murrer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giandomenico, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrap, K. R.</span><span> </span><span class="NLM_article-title">Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">822</span><span class="NLM_x">–</span> <span class="NLM_lpage">828</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1992&pages=822-828&author=L.+R.+Kellandauthor=B.+A.+Murrerauthor=G.+Abelauthor=C.+M.+Giandomenicoauthor=P.+Mistryauthor=K.+R.+Harrap&title=Ammine%2Famine+platinum%28IV%29+dicarboxylates%3A+a+novel+class+of+platinum+complex+exhibiting+selective+cytotoxicity+to+intrinsically+cisplatin-resistant+human+ovarian+carcinoma+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DMurrer%26aufirst%3DB.%2BA.%26aulast%3DAbel%26aufirst%3DG.%26aulast%3DGiandomenico%26aufirst%3DC.%2BM.%26aulast%3DMistry%26aufirst%3DP.%26aulast%3DHarrap%26aufirst%3DK.%2BR.%26atitle%3DAmmine%252Famine%2520platinum%2528IV%2529%2520dicarboxylates%253A%2520a%2520novel%2520class%2520of%2520platinum%2520complex%2520exhibiting%2520selective%2520cytotoxicity%2520to%2520intrinsically%2520cisplatin-resistant%2520human%2520ovarian%2520carcinoma%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1992%26volume%3D52%26spage%3D822%26epage%3D828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Ellis, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Er, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">The Influence of the axial ligands of a series of platinum(IV) anti-cancer complexes on their reduction to platinum(II) and reaction with DNA</span> <span class="citation_source-journal">Aust. J. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">806</span><span class="refDoi"> DOI: 10.1071/CH9950793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1071%2FCH9950793" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1995&pages=793-806&author=L.+T.+Ellisauthor=H.+M.+Erauthor=T.+W.+Hambley&title=The+Influence+of+the+axial+ligands+of+a+series+of+platinum%28IV%29+anti-cancer+complexes+on+their+reduction+to+platinum%28II%29+and+reaction+with+DNA&doi=10.1071%2FCH9950793"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1071%2FCH9950793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1071%252FCH9950793%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%2BT.%26aulast%3DEr%26aufirst%3DH.%2BM.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DThe%2520Influence%2520of%2520the%2520axial%2520ligands%2520of%2520a%2520series%2520of%2520platinum%2528IV%2529%2520anti-cancer%2520complexes%2520on%2520their%2520reduction%2520to%2520platinum%2528II%2529%2520and%2520reaction%2520with%2520DNA%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D1995%26volume%3D48%26spage%3D793%26epage%3D806%26doi%3D10.1071%2FCH9950793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Cui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porschke, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamacher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassack, M. U.</span><span> </span><span class="NLM_article-title">Bispidine analogues of cisplatin, carboplatin, and oxaliplatin. synthesis, structures, and cytotoxicity</span> <span class="citation_source-journal">Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3371</span><span class="NLM_x">–</span> <span class="NLM_lpage">3384</span><span class="refDoi"> DOI: 10.1021/ic402737f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic402737f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3371-3384&author=H.+Cuiauthor=R.+Goddardauthor=K.+R.+Porschkeauthor=A.+Hamacherauthor=M.+U.+Kassack&title=Bispidine+analogues+of+cisplatin%2C+carboplatin%2C+and+oxaliplatin.+synthesis%2C+structures%2C+and+cytotoxicity&doi=10.1021%2Fic402737f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fic402737f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic402737f%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DH.%26aulast%3DGoddard%26aufirst%3DR.%26aulast%3DPorschke%26aufirst%3DK.%2BR.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26atitle%3DBispidine%2520analogues%2520of%2520cisplatin%252C%2520carboplatin%252C%2520and%2520oxaliplatin.%2520synthesis%252C%2520structures%252C%2520and%2520cytotoxicity%26jtitle%3DInorg.%2520Chem.%26date%3D2014%26volume%3D53%26spage%3D3371%26epage%3D3384%26doi%3D10.1021%2Fic402737f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Buss, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalayda, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reithofer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaehde, U.</span><span> </span><span class="NLM_article-title">Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues</span> <span class="citation_source-journal">JBIC, J. Biol. Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">–</span> <span class="NLM_lpage">708</span><span class="refDoi"> DOI: 10.1007/s00775-012-0889-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1007%2Fs00775-012-0889-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22456982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVWit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=699-708&author=I.+Bussauthor=G.+V.+Kalaydaauthor=A.+Lindauerauthor=M.+R.+Reithoferauthor=M.+Galanskiauthor=B.+K.+Kepplerauthor=U.+Jaehde&title=Effect+of+reactivity+on+cellular+accumulation+and+cytotoxicity+of+oxaliplatin+analogues&doi=10.1007%2Fs00775-012-0889-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues</span></div><div class="casAuthors">Buss, Irina; Kalayda, Ganna V.; Lindauer, Andreas; Reithofer, Michael R.; Galanski, Markus; Keppler, Bernhard K.; Jaehde, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">JBIC, Journal of Biological Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">699-708</span>CODEN:
                <span class="NLM_cas:coden">JJBCFA</span>;
        ISSN:<span class="NLM_cas:issn">0949-8257</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The purpose of this study was to systematically investigate the relationships between reactivity, cellular accumulation, and cytotoxicity of a panel of oxaliplatin analogs with different leaving groups in human carcinoma cells.  The reactivity of the complexes towards the nucleotides 2'-deoxyguanosine 5'-monophosphate and 2'-deoxyadenosine 5'-monophosphate was studied using capillary electrophoresis.  Cellular accumulation and cytotoxicity were measured in an oxaliplatin-sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cell line pair (HCT-8/HCT-8ox).  Platinum concns. were detd. by flameless at. absorption spectrometry.  The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was used to assess cytotoxicity.  Early cellular platinum accumulation was predominantly affected by lipophilicity.  A relation between reactivity and cellular accumulation was obsd. for three of four platinum complexes investigated, whereas the most lipophilic oxaliplatin analog was an exception.  Increased reactivity and reduced lipophilicity were assocd. with high cytotoxic activity.  Resistance was influenced by lipophilicity but not by reactivity.  The obsd. relationships may help in the design of analogs with high antitumoral activity in oxaliplatin-sensitive as well as oxaliplatin-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6wukIWqJE0bVg90H21EOLACvtfcHk0ljlYhNkixNqvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVWit78%253D&md5=cfa35a41a798d1785e66eca2a2cac937</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00775-012-0889-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00775-012-0889-9%26sid%3Dliteratum%253Aachs%26aulast%3DBuss%26aufirst%3DI.%26aulast%3DKalayda%26aufirst%3DG.%2BV.%26aulast%3DLindauer%26aufirst%3DA.%26aulast%3DReithofer%26aufirst%3DM.%2BR.%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26aulast%3DJaehde%26aufirst%3DU.%26atitle%3DEffect%2520of%2520reactivity%2520on%2520cellular%2520accumulation%2520and%2520cytotoxicity%2520of%2520oxaliplatin%2520analogues%26jtitle%3DJBIC%252C%2520J.%2520Biol.%2520Inorg.%2520Chem.%26date%3D2012%26volume%3D17%26spage%3D699%26epage%3D708%26doi%3D10.1007%2Fs00775-012-0889-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Kozubik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaculova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soucek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vondracek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turanek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmanova, J.</span><span> </span><span class="NLM_article-title">Novel anticancer platinum(IV) complexes with adamantylamine: their efficiency and innovative chemotherapy strategies modifying lipid metabolism</span> <span class="citation_source-journal">Met.-Based Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2008</span><span class="NLM_x">, </span> <span class="NLM_fpage">417897</span><span class="refDoi"> DOI: 10.1155/2008/417897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1155%2F2008%2F417897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=18414587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A280%3ADC%252BD1c3lsVSksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2008&publication_year=2008&pages=417897&author=A.+Kozubikauthor=A.+Vaculovaauthor=K.+Soucekauthor=J.+Vondracekauthor=J.+Turanekauthor=J.+Hofmanova&title=Novel+anticancer+platinum%28IV%29+complexes+with+adamantylamine%3A+their+efficiency+and+innovative+chemotherapy+strategies+modifying+lipid+metabolism&doi=10.1155%2F2008%2F417897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism</span></div><div class="casAuthors">Kozubik Alois; Vaculova Alena; Soucek Karel; Vondracek Jan; Turanek Jaroslav; Hofmanova Jirina</div><div class="citationInfo"><span class="NLM_cas:title">Metal-based drugs</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2008</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">417897</span>
        ISSN:<span class="NLM_cas:issn">0793-0291</span>.
    </div><div class="casAbstract">The impressive impact of cisplatin on cancer on one side and severe side effects, as well as the development of drug resistance during treatment on the other side, were the factors motivating scientists to design and synthesize new more potent analogues lacking disadvantages of cisplatin.  Platinum(IV) complexes represent one of the perspective groups of platinum-based drugs.  In this review, we summarize recent findings on both in vitro and in vivo effects of platinum(IV) complexes with adamantylamine.  Based on a literary overview of the mechanisms of activity of platinum-based cytostatics, we discuss opportunities for modulating the effects of novel platinum complexes through interactions with apoptotic signaling pathways and with cellular lipids, including modulations of the mitochondrial cell death pathway, oxidative stress, signaling of death ligands, lipid metabolism/signaling, or intercellular communication.  These approaches might significantly enhance the efficacy of both novel and established platinum-based cytostatics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwTaw6zIjXY-R_TJajKxJDfW6udTcc2eaGzCURmOzbG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3lsVSksg%253D%253D&md5=bb26de47c209644aaec6efdcf53a5317</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1155%2F2008%2F417897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2008%252F417897%26sid%3Dliteratum%253Aachs%26aulast%3DKozubik%26aufirst%3DA.%26aulast%3DVaculova%26aufirst%3DA.%26aulast%3DSoucek%26aufirst%3DK.%26aulast%3DVondracek%26aufirst%3DJ.%26aulast%3DTuranek%26aufirst%3DJ.%26aulast%3DHofmanova%26aufirst%3DJ.%26atitle%3DNovel%2520anticancer%2520platinum%2528IV%2529%2520complexes%2520with%2520adamantylamine%253A%2520their%2520efficiency%2520and%2520innovative%2520chemotherapy%2520strategies%2520modifying%2520lipid%2520metabolism%26jtitle%3DMet.-Based%2520Drugs%26date%3D2008%26volume%3D2008%26spage%3D417897%26doi%3D10.1155%2F2008%2F417897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Karra, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benita, S.</span><span> </span><span class="NLM_article-title">The ligand nanoparticle conjugation approach for targeted cancer therapy</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.2174/138920012798356899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.2174%2F138920012798356899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=21892918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVehsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=22-41&author=N.+Karraauthor=S.+Benita&title=The+ligand+nanoparticle+conjugation+approach+for+targeted+cancer+therapy&doi=10.2174%2F138920012798356899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The ligand nanoparticle conjugation approach for targeted cancer therapy</span></div><div class="casAuthors">Karra, Nour; Benita, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-41</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer therapy often requires frequent and high drug dosing.  Yet, despite the significant progress in cancer research and the wide versatility of potent available drugs, treatment efficacy is still hurdled and often failed by the lack of pharmaco-selectivity to diseased cells, indiscriminate drug toxicities and poor patient compliance.  Thus, innovative pharmaceutical solns. are needed to effectively deliver the cytotoxic drugs specifically to the tumor site while minimizing systemic exposure to frequent and high drug doses.  Polymeric nanocarriers, particularly nanoparticles, were extensively studied for improved oncol. use.  Such nanocarriers hold great potential in cancer treatment as they can be biocompatible, adapted to specific needs, tolerated and deliver high drug payloads while targeting tumors.  Active targeting, as opposed to passive targeting, should add value to selective and site specific treatment.  Active targeting of nanosized drug delivery systems is firmly rooted in the Magic Bullet Concept as was envisioned by Paul Ehrlich over 100 years ago.  This targeting strategy is based on the mol. recognition of tumor biomarkers which are over-expressed on cancer cells, via specific vector mols. conjugated to the surface of the drug carrier.  These vector mols. dictate the carrier's biodistribution and its biol. affinity to the desired site of action.  Many recent publications have shown encouraging results suggesting that targeting nanocarriers represent a highly-promising strategy for improved cancer treatment.  This chapter will focus mainly on polymeric nanoparticles as the main drug carriers to be conjugated to various ligands able to deliver the drug to the specific desired pathol. tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM_XjavVzKgbVg90H21EOLACvtfcHk0lgiUh_BYKmzeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVehsrk%253D&md5=90cd0d48c6124311681eea7b909d5836</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2174%2F138920012798356899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012798356899%26sid%3Dliteratum%253Aachs%26aulast%3DKarra%26aufirst%3DN.%26aulast%3DBenita%26aufirst%3DS.%26atitle%3DThe%2520ligand%2520nanoparticle%2520conjugation%2520approach%2520for%2520targeted%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D22%26epage%3D41%26doi%3D10.2174%2F138920012798356899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Fatemeh, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebrahimi Shahmabadi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abedi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alavi, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Movahedi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koohi Moftakhari Esfahani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zadeh Mehrizi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akbarzadeh, A.</span><span> </span><span class="NLM_article-title">Polybutylcyanoacrylate nanoparticles and drugs of the platinum family: last status</span> <span class="citation_source-journal">Indian J. Clin. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span><span class="refDoi"> DOI: 10.1007/s12291-013-0364-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1007%2Fs12291-013-0364-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=24966482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaktrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=333-338&author=D.+R.+Fatemehauthor=H.+Ebrahimi+Shahmabadiauthor=A.+Abediauthor=S.+E.+Alaviauthor=F.+Movahediauthor=M.+Koohi+Moftakhari+Esfahaniauthor=T.+Zadeh+Mehriziauthor=A.+Akbarzadeh&title=Polybutylcyanoacrylate+nanoparticles+and+drugs+of+the+platinum+family%3A+last+status&doi=10.1007%2Fs12291-013-0364-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Polybutylcyanoacrylate Nanoparticles and Drugs of the Platinum Family: Last Status</span></div><div class="casAuthors">Fatemeh, Dashti Rahmat Abadi; Ebrahimi Shahmabadi, Hasan; Abedi, Anita; Alavi, Seyed Ebrahim; Movahedi, Fatemeh; Koohi Moftakhari Esfahani, Maedeh; Zadeh Mehrizi, Tahereh; Akbarzadeh, Azim</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Clinical Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-338</span>CODEN:
                <span class="NLM_cas:coden">IJCBEY</span>;
        ISSN:<span class="NLM_cas:issn">0974-0422</span>.
    
            (<span class="NLM_cas:orgname">Springer (India) Private Ltd.</span>)
        </div><div class="casAbstract">Cisplatinum and carboplatinum drugs from platinum-contg. family are anti-cancer drugs.  Using these drugs causes side effects.  Targeted and selective prescription decreases side effects of the drugs.  This can be achieved using nanotechnol.  In this study, cisplatinum and carboplatinum drugs were loaded on polybutylcyanoacrylate nanoparticles using emulsion polymn. method.  To det. amt. of loaded drug onto nanoparticle, spectrophotometry method was used.  Evaluation of cytotoxicity of such nanoparticles was performed on MCF-7 cell line using MTT assay.  Loading percentage of cisplatinum and carboplatinum drugs on nanoparticles were estd. 4 and 6 %, resp.  Cytotoxicity survival rate for cisplatinum and nanoparticle contg. cisplatinum at the lowest concn. (p < 0.01) (20 μM) were estd. 64 ± 1 and 67 ± 0.5 %, resp.  These values at the highest concn. (p < 0.01) (160 μM) were measured 28 ± 0.7 and 31 ± 0.4 %.  Addnl. for carboplatinum and nanoparticles contg. carboplatinum at the concn. (p < 0.01) (20 μM) amts. were estd. to be 80 ± 0.6 and 84 ± 0.6 %, while at the concn. (p < 0.01) (160 μM) were identified to be 44 ± 0.5 and 51 ± 0.2 %, resp.  Probably, due to low level of loading, cytotoxicity of both drugs at nano particle status was decreased in comparison with their std. form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc4LbZC9c82LVg90H21EOLACvtfcHk0lgiUh_BYKmzeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaktrrN&md5=ea93bdf8e99482747fb2a984ddfddef9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs12291-013-0364-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12291-013-0364-6%26sid%3Dliteratum%253Aachs%26aulast%3DFatemeh%26aufirst%3DD.%2BR.%26aulast%3DEbrahimi%2BShahmabadi%26aufirst%3DH.%26aulast%3DAbedi%26aufirst%3DA.%26aulast%3DAlavi%26aufirst%3DS.%2BE.%26aulast%3DMovahedi%26aufirst%3DF.%26aulast%3DKoohi%2BMoftakhari%2BEsfahani%26aufirst%3DM.%26aulast%3DZadeh%2BMehrizi%26aufirst%3DT.%26aulast%3DAkbarzadeh%26aufirst%3DA.%26atitle%3DPolybutylcyanoacrylate%2520nanoparticles%2520and%2520drugs%2520of%2520the%2520platinum%2520family%253A%2520last%2520status%26jtitle%3DIndian%2520J.%2520Clin.%2520Biochem.%26date%3D2014%26volume%3D29%26spage%3D333%26epage%3D338%26doi%3D10.1007%2Fs12291-013-0364-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Avgoustakis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletsi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panagi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klepetsanis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karydas, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ithakissios, D. S.</span><span> </span><span class="NLM_article-title">PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">135</span><span class="refDoi"> DOI: 10.1016/S0168-3659(01)00530-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2FS0168-3659%2801%2900530-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2002&pages=123-135&author=K.+Avgoustakisauthor=A.+Beletsiauthor=Z.+Panagiauthor=P.+Klepetsanisauthor=A.+G.+Karydasauthor=D.+S.+Ithakissios&title=PLGA-mPEG+nanoparticles+of+cisplatin%3A+in+vitro+nanoparticle+degradation%2C+in+vitro+drug+release+and+in+vivo+drug+residence+in+blood+properties&doi=10.1016%2FS0168-3659%2801%2900530-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0168-3659%2801%2900530-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-3659%252801%252900530-2%26sid%3Dliteratum%253Aachs%26aulast%3DAvgoustakis%26aufirst%3DK.%26aulast%3DBeletsi%26aufirst%3DA.%26aulast%3DPanagi%26aufirst%3DZ.%26aulast%3DKlepetsanis%26aufirst%3DP.%26aulast%3DKarydas%26aufirst%3DA.%2BG.%26aulast%3DIthakissios%26aufirst%3DD.%2BS.%26atitle%3DPLGA-mPEG%2520nanoparticles%2520of%2520cisplatin%253A%2520in%2520vitro%2520nanoparticle%2520degradation%252C%2520in%2520vitro%2520drug%2520release%2520and%2520in%2520vivo%2520drug%2520residence%2520in%2520blood%2520properties%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2002%26volume%3D79%26spage%3D123%26epage%3D135%26doi%3D10.1016%2FS0168-3659%2801%2900530-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Aryal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span> </span><span class="NLM_article-title">Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery</span> <span class="citation_source-journal">ACS Nano</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span><span class="refDoi"> DOI: 10.1021/nn9014032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn9014032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1alu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=251-258&author=S.+Aryalauthor=C.+M.+Huauthor=L.+Zhang&title=Polymer%2D%2Dcisplatin+conjugate+nanoparticles+for+acid-responsive+drug+delivery&doi=10.1021%2Fnn9014032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Polymer-Cisplatin Conjugate Nanoparticles for Acid-Responsive Drug Delivery</span></div><div class="casAuthors">Aryal, Santosh; Hu, Che-Ming Jack; Zhang, Liangfang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-258</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis of novel acid-responsive therapeutic nanoparticles (NPs) with sub-100 nm size consisting of polymer-cisplatin conjugates.  The uniqueness of these drug delivery polymeric NPs lies in the covalent conjugation of each cisplatin drug to the hydrophobic segment of two biocompatible diblock copolymer chains through a hydrazone bond, resulting in highly differential drug release profile at different environmental acidity.  We demonstrate that the synthesized polymer-cisplatin conjugates can readily ppt. to form sub-100 nm NPs in aq. soln. due to their very low crit. micelle concn. (CMC).  The resulting NPs show well-controlled cisplatin loading yield, excellent acid-responsive drug release kinetics, and enhanced in vitro cytotoxicity against ovarian cancer cells as compared to free cisplatin.  As an environmentally sensitive drug delivery vehicle, these NPs can potentially minimize the drug loss during NP circulation in the blood, where the pH value is neutral, and trigger rapid intracellular drug release after the NPs are endocytosed by the target cells.  This characteristic drug release profile holds the promise to suppress cancer cell chemoresistance by rapidly releasing a high dose of chemotherapy drugs inside the tumor cells, thereby improving the therapeutic efficacy of the drug payload.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV_42W2iyJk7Vg90H21EOLACvtfcHk0ljFNX862GrKEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1alu7%252FP&md5=c1de368e7df18df3f2b13e64f7be4963</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fnn9014032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn9014032%26sid%3Dliteratum%253Aachs%26aulast%3DAryal%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DC.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DPolymer--cisplatin%2520conjugate%2520nanoparticles%2520for%2520acid-responsive%2520drug%2520delivery%26jtitle%3DACS%2520Nano%26date%3D2010%26volume%3D4%26spage%3D251%26epage%3D258%26doi%3D10.1021%2Fnn9014032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Brown, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nativo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirling, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venugopal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flint, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plumb, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheate, N. J.</span><span> </span><span class="NLM_article-title">Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">4678</span><span class="NLM_x">–</span> <span class="NLM_lpage">4684</span><span class="refDoi"> DOI: 10.1021/ja908117a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja908117a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFOqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=4678-4684&author=S.+D.+Brownauthor=P.+Nativoauthor=J.+A.+Smithauthor=D.+Stirlingauthor=P.+R.+Edwardsauthor=B.+Venugopalauthor=D.+J.+Flintauthor=J.+A.+Plumbauthor=D.+Grahamauthor=N.+J.+Wheate&title=Gold+nanoparticles+for+the+improved+anticancer+drug+delivery+of+the+active+component+of+oxaliplatin&doi=10.1021%2Fja908117a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin</span></div><div class="casAuthors">Brown, Sarah D.; Nativo, Paola; Smith, Jo-Ann; Stirling, David; Edwards, Paul R.; Venugopal, Balaji; Flint, David J.; Plumb, Jane A.; Graham, Duncan; Wheate, Nial J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4678-4684</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platinum-based anticancer drugs cisplatin, carboplatin, and oxaliplatin are an important component of chemotherapy but are limited by severe dose-limiting side effects and the ability of tumors to develop resistance rapidly.  These drugs can be improved through the use of drug-delivery vehicles that are able to target cancers passively or actively.  In this study, we have tethered the active component of the anticancer drug oxaliplatin to a gold nanoparticle for improved drug delivery.  Naked gold nanoparticles were functionalized with a thiolated poly(ethylene glycol) (PEG) monolayer capped with a carboxylate group. [Pt(1R,2R-diaminocyclohexane)(H2O)2]2NO3 was added to the PEG surface to yield a supramol. complex with 280 (±20) drug mols. per nanoparticle.  The platinum-tethered nanoparticles were examd. for cytotoxicity, drug uptake, and localization in the A549 lung epithelial cancer cell line and the colon cancer cell lines HCT116, HCT15, HT29, and RKO.  The platinum-tethered nanoparticles demonstrated as good as, or significantly better, cytotoxicity than oxaliplatin alone in all of the cell lines and an unusual ability to penetrate the nucleus in the lung cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUk6dJnl0UHLVg90H21EOLACvtfcHk0ljFNX862GrKEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFOqsLY%253D&md5=43e99fc4fd527cc738b59adf226e00e9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fja908117a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja908117a%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BD.%26aulast%3DNativo%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DStirling%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DP.%2BR.%26aulast%3DVenugopal%26aufirst%3DB.%26aulast%3DFlint%26aufirst%3DD.%2BJ.%26aulast%3DPlumb%26aufirst%3DJ.%2BA.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26atitle%3DGold%2520nanoparticles%2520for%2520the%2520improved%2520anticancer%2520drug%2520delivery%2520of%2520the%2520active%2520component%2520of%2520oxaliplatin%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D4678%26epage%3D4684%26doi%3D10.1021%2Fja908117a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Paraskar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papa, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengupta, S.</span><span> </span><span class="NLM_article-title">Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy</span> <span class="citation_source-journal">Nanotechnology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">075103</span><span class="refDoi"> DOI: 10.1088/0957-4484/23/7/075103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1088%2F0957-4484%2F23%2F7%2F075103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22275055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFOmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=075103&author=A.+Paraskarauthor=S.+Soniauthor=B.+Royauthor=A.+L.+Papaauthor=S.+Sengupta&title=Rationally+designed+oxaliplatin-nanoparticle+for+enhanced+antitumor+efficacy&doi=10.1088%2F0957-4484%2F23%2F7%2F075103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy</span></div><div class="casAuthors">Paraskar, Abhimanyu; Soni, Shivani; Roy, Bhaskar; Papa, Anne-Laure; Sengupta, Shiladitya</div><div class="citationInfo"><span class="NLM_cas:title">Nanotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">075103/1-075103/9</span>CODEN:
                <span class="NLM_cas:coden">NNOTER</span>;
        ISSN:<span class="NLM_cas:issn">1361-6528</span>.
    
            (<span class="NLM_cas:orgname">Institute of Physics Publishing</span>)
        </div><div class="casAbstract">Nanoscale drug delivery vehicles have been extensively studied as carriers for cancer chemotherapeutics.  However, the formulation of platinum chemotherapeutics in nanoparticles has been a challenge arising from their physicochem. properties.  There are only a few reports describing oxaliplatin nanoparticles.  In this study, we derivatized the monomeric units of a polyisobutylene maleic acid copolymer with glucosamine, which chelates trans-1,2-diaminocyclohexane (DACH) platinum (II) through a novel monocarboxylato and O → Pt coordination linkage.  At a specific polymer to platinum ratio, the complex self-assembled into a nanoparticle, where the polymeric units act as the leaving group, releasing DACH-platinum in a sustained pH-dependent manner.  Sizing was done using dynamic light scatter and electron microscopy.  The nanoparticles were evaluated for efficacy in vitro and in vivo.  Biodistribution was quantified using inductively coupled plasma at. absorption spectroscopy (ICP-AAS).  The PIMA-GA-DACH-platinum nanoparticle was found to be more active than free oxaliplatin in vitro.  In vivo, the nanoparticles resulted in greater tumor inhibition than oxaliplatin (equiv. to 5 mg kg-1 platinum dose) with minimal nephrotoxicity or body wt. loss.  ICP-AAS revealed significant preferential tumor accumulation of platinum with reduced biodistribution to the kidney or liver following PIMA-GA-DACH-platinum nanoparticle administration as compared with free oxaliplatin.  These results indicate that the rational engineering of a novel polymeric nanoparticle inspired by the bioactivation of oxaliplatin results in increased antitumor potency with reduced systemic toxicity compared with the parent cytotoxic.  Rational design can emerge as an exciting strategy in the synthesis of nanomedicines for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOVl2RPeRX-7Vg90H21EOLACvtfcHk0ljFNX862GrKEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFOmu7w%253D&md5=bcf5dbd1d6de2e129d1e2bc9820d784e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1088%2F0957-4484%2F23%2F7%2F075103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F0957-4484%252F23%252F7%252F075103%26sid%3Dliteratum%253Aachs%26aulast%3DParaskar%26aufirst%3DA.%26aulast%3DSoni%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DB.%26aulast%3DPapa%26aufirst%3DA.%2BL.%26aulast%3DSengupta%26aufirst%3DS.%26atitle%3DRationally%2520designed%2520oxaliplatin-nanoparticle%2520for%2520enhanced%2520antitumor%2520efficacy%26jtitle%3DNanotechnology%26date%3D2012%26volume%3D23%26spage%3D075103%26doi%3D10.1088%2F0957-4484%2F23%2F7%2F075103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Owen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doak, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wassam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Colloidal aggregation affects the efficacy of anticancer drugs in cell culture</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1429</span><span class="NLM_x">–</span> <span class="NLM_lpage">1435</span><span class="refDoi"> DOI: 10.1021/cb300189b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300189b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFOmsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1429-1435&author=S.+C.+Owenauthor=A.+K.+Doakauthor=P.+Wassamauthor=M.+S.+Shoichetauthor=B.+K.+Shoichet&title=Colloidal+aggregation+affects+the+efficacy+of+anticancer+drugs+in+cell+culture&doi=10.1021%2Fcb300189b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Colloidal Aggregation Affects the Efficacy of Anticancer Drugs in Cell Culture</span></div><div class="casAuthors">Owen, Shawn C.; Doak, Allison K.; Wassam, Pascal; Shoichet, Molly S.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1429-1435</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many small mols., including bioactive mols. and approved drugs, spontaneously form colloidal aggregates in aq. soln. at micromolar concns.  Though it is widely accepted that aggregation leads to artifacts in screens for ligands of sol. proteins, the effects of colloid formation in cell-based assays have not been studied.  Here, seven anticancer drugs and one diagnostic reagent were found to form colloids in both biochem. buffer and in cell culture media.  In cell-based assays, the antiproliferative activities of three of the drugs were substantially reduced when in colloidal form as compared to monomeric form; a new formulation method ensured the presence of drug colloids vs. drug monomers in soln.  We also found that Evans Blue, a dye classically used to measure vascular permeability and to demonstrate the "enhanced permeability and retention (EPR) effect" in solid tumors, forms colloids that adsorb albumin, as opposed to older literature that suggested the reverse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN47RUN9WrPrVg90H21EOLACvtfcHk0lga5jyhP9qarA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFOmsrs%253D&md5=207a6f05e2ee718392562b28d2c52f89</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fcb300189b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300189b%26sid%3Dliteratum%253Aachs%26aulast%3DOwen%26aufirst%3DS.%2BC.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DWassam%26aufirst%3DP.%26aulast%3DShoichet%26aufirst%3DM.%2BS.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DColloidal%2520aggregation%2520affects%2520the%2520efficacy%2520of%2520anticancer%2520drugs%2520in%2520cell%2520culture%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1429%26epage%3D1435%26doi%3D10.1021%2Fcb300189b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Oh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. H.</span><span> </span><span class="NLM_article-title">Endocytosis and exocytosis of nanoparticles in mammalian cells</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.2147/IJN.S26592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.2147%2FIJN.S26592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=24872703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ynt7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=51-63&issue=Suppl+1&author=N.+Ohauthor=J.+H.+Park&title=Endocytosis+and+exocytosis+of+nanoparticles+in+mammalian+cells&doi=10.2147%2FIJN.S26592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Endocytosis and exocytosis of nanoparticles in mammalian cells</span></div><div class="casAuthors">Oh, Nuri; Park, Ji-Ho</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">51-63, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Engineered nanoparticles that can be injected into the human body hold tremendous potential to detect and treat complex diseases.  Understanding of the endocytosis and exocytosis mechanisms of nanoparticles is essential for safe and efficient therapeutic application.  In particular, exocytosis is of significance in the removal of nanoparticles with drugs and contrast agents from the body, while endocytosis is of great importance for the targeting of nanoparticles in disease sites.  Here, we review the recent research on the endocytosis and exocytosis of functionalized nanoparticles based on various sizes, shapes, and surface chemistries.  We believe that this review contributes to the design of safe nanoparticles that can efficiently enter and leave human cells and tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSAt0ZKnAmz7Vg90H21EOLACvtfcHk0lga5jyhP9qarA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ynt7rE&md5=10fcfd0a3107b852a052e51d8ac9a932</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.2147%2FIJN.S26592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S26592%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DN.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26atitle%3DEndocytosis%2520and%2520exocytosis%2520of%2520nanoparticles%2520in%2520mammalian%2520cells%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2014%26volume%3D9%26issue%3DSuppl%25201%26spage%3D51%26epage%3D63%26doi%3D10.2147%2FIJN.S26592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Sahay, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alakhova, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabanov, A. V.</span><span> </span><span class="NLM_article-title">Endocytosis of nanomedicines</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">182</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2010.01.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.jconrel.2010.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=20226220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosF2ntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2010&pages=182-195&author=G.+Sahayauthor=D.+Y.+Alakhovaauthor=A.+V.+Kabanov&title=Endocytosis+of+nanomedicines&doi=10.1016%2Fj.jconrel.2010.01.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Endocytosis of nanomedicines</span></div><div class="casAuthors">Sahay, Gaurav; Alakhova, Daria Y.; Kabanov, Alexander V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">182-195</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Novel nanomaterials are being developed to improve diagnosis and therapy of diseases through effective delivery of drugs, biopharmaceutical mols. and imaging agents to target cells in disease sites.  Such diagnostic and therapeutic nanomaterials, also termed "nanomedicines", often require site-specific cellular entry to deliver their payload to sub-cellular locations hidden beneath cell membranes.  Nanomedicines can employ multiple pathways for cellular entry, which are currently insufficiently understood.  This review, first, classifies various mechanisms of endocytosis available to nanomedicines including phagocytosis and pinocytosis through clathrin-dependent and clathrin-independent pathways.  Second, it describes the current exptl. tools to study endocytosis of nanomedicines.  Third, it provides specific examples from recent literature and the authors' own work on endocytosis of nanomedicines.  Finally, these examples are used to ascertain (1) the role of particle size, shape, material compn., surface chem. and/or charge for utilization of a selected pathway(s); (2) the effect of cell type on the processing of nanomedicines; and (3) the effect of nanomaterial-cell interactions on the processes of endocytosis, the fate of the nanomedicines and the resulting cellular responses.  This review will be useful to a diverse audience of students and scientists who are interested in understanding endocytosis of nanomedicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX2G8IickFdbVg90H21EOLACvtfcHk0lga5jyhP9qarA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosF2ntbY%253D&md5=1423604a78852ba1fb912262a19058e1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2010.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2010.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DSahay%26aufirst%3DG.%26aulast%3DAlakhova%26aufirst%3DD.%2BY.%26aulast%3DKabanov%26aufirst%3DA.%2BV.%26atitle%3DEndocytosis%2520of%2520nanomedicines%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2010%26volume%3D145%26spage%3D182%26epage%3D195%26doi%3D10.1016%2Fj.jconrel.2010.01.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lykotrafitis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suresh, S.</span><span> </span><span class="NLM_article-title">Size-dependent endocytosis of nanoparticles</span> <span class="citation_source-journal">Adv. Mater.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1002/adma.200801393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1002%2Fadma.200801393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=19606281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVSiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=419-424&author=S.+Zhangauthor=J.+Liauthor=G.+Lykotrafitisauthor=G.+Baoauthor=S.+Suresh&title=Size-dependent+endocytosis+of+nanoparticles&doi=10.1002%2Fadma.200801393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Size-dependent endocytosis of nanoparticles</span></div><div class="casAuthors">Zhang, Sulin; Li, Ju; Lykotrafitis, George; Bao, Gang; Suresh, Subra</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Materials (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-424</span>CODEN:
                <span class="NLM_cas:coden">ADVMEW</span>;
        ISSN:<span class="NLM_cas:issn">0935-9648</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The cellular uptake of nanoparticles by living cells is predicted to be strongly size-dependent, according the thermodn. anal., and an optimal particle radius of ∼ 25-30 nm at which the cellular uptake reaches a max. of several thousand is shown to exist.  The theor. prediction provides valuable guidance for the rational design of nanoparticle-based drug-delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopRULIAIihu7Vg90H21EOLACvtfcHk0litdTwgt1FzBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVSiur4%253D&md5=242bf02e151f139ff830f37d401fadb5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fadma.200801393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadma.200801393%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLykotrafitis%26aufirst%3DG.%26aulast%3DBao%26aufirst%3DG.%26aulast%3DSuresh%26aufirst%3DS.%26atitle%3DSize-dependent%2520endocytosis%2520of%2520nanoparticles%26jtitle%3DAdv.%2520Mater.%26date%3D2009%26volume%3D21%26spage%3D419%26epage%3D424%26doi%3D10.1002%2Fadma.200801393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Karra, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassar, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripin, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwob, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borlak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benita, S.</span><span> </span><span class="NLM_article-title">Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model</span> <span class="citation_source-journal">Small</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">4221</span><span class="NLM_x">–</span> <span class="NLM_lpage">4236</span><span class="refDoi"> DOI: 10.1002/smll.201301417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1002%2Fsmll.201301417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=23873835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFemur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=4221-4236&author=N.+Karraauthor=T.+Nassarauthor=A.+N.+Ripinauthor=O.+Schwobauthor=J.+Borlakauthor=S.+Benita&title=Antibody+conjugated+PLGA+nanoparticles+for+targeted+delivery+of+paclitaxel+palmitate%3A+efficacy+and+biofate+in+a+lung+cancer+mouse+model&doi=10.1002%2Fsmll.201301417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody Conjugated PLGA Nanoparticles for Targeted Delivery of Paclitaxel Palmitate: Efficacy and Biofate in a Lung Cancer Mouse Model</span></div><div class="casAuthors">Karra, Nour; Nassar, Taher; Ripin, Alina Nemirovski; Schwob, Ouri; Borlak, Juergen; Benita, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Small</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4221-4236</span>CODEN:
                <span class="NLM_cas:coden">SMALBC</span>;
        ISSN:<span class="NLM_cas:issn">1613-6810</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Aberrant signaling of the epidermal growth factor receptor (EGFR) is common to a variety of human cancers and is also found to be over-expressed in most cases of non-small cell lung cancer.  For the development of a molecularly targeted therapy, cetuximab-conjugated nanoparticles (immunonanoparticles, INPs) are designed and loaded with the lipophilic paclitaxel palmitate (pcpl) prodrug.  Oleyl cysteineamide (OCA) is synthesized whereby its amphiphilic nature enables interfacial anchoring and thiol surface functionalization of PLGA NPs, facilitating bioconjugation to cetuximab by thioether bonds.  It is demonstrated that the in vitro targeting efficiency and improved cellular internalization and cytotoxicity of this targeted delivery system in lung cancer cells over-expressing EGFR.  A quant. measure of the high binding affinity of INPs to EGFR is demonstrated using surface plasmon resonance.  In vivo tolerability and enhanced efficacy of cetuximab pcpl INPs in a metastatic lung cancer model are reported.  Its therapeutic efficacy in A549-luc-C8 lung tumors is shown using non-invasive bioluminescent imaging.  I.v. administration of cetuximab pcpl INPs to mice results in significantly higher inhibition of tumor growth and increased survival rates as compared to the non-targeted drug soln., drug-loaded nanoparticles or blank INPs.  Pharmacokinetics and organ biodistribution of the prodrug and parent drug are evaluated by LC-MS/MS in lung tumor bearing mice.  No enhanced total accumulation of nanoparticles or INPs is found at the tumor tissue.  However, persistent pcpl levels with sustained conversion and release of paclitaxel are obsd. for the encapsulated prodrug possibly suggesting the formation of a drug reservoir.  The overall results indicate the potential of this promising targeted platform for the improved treatment of lung cancer and other EGFR pos. tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBQ-RvTX7NK7Vg90H21EOLACvtfcHk0litdTwgt1FzBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFemur%252FP&md5=d72f0727e44c88429bd05a96f36502c4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fsmll.201301417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsmll.201301417%26sid%3Dliteratum%253Aachs%26aulast%3DKarra%26aufirst%3DN.%26aulast%3DNassar%26aufirst%3DT.%26aulast%3DRipin%26aufirst%3DA.%2BN.%26aulast%3DSchwob%26aufirst%3DO.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DBenita%26aufirst%3DS.%26atitle%3DAntibody%2520conjugated%2520PLGA%2520nanoparticles%2520for%2520targeted%2520delivery%2520of%2520paclitaxel%2520palmitate%253A%2520efficacy%2520and%2520biofate%2520in%2520a%2520lung%2520cancer%2520mouse%2520model%26jtitle%3DSmall%26date%3D2013%26volume%3D9%26spage%3D4221%26epage%3D4236%26doi%3D10.1002%2Fsmll.201301417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">Platinum(IV) antitumour compounds: their bioinorganic chemistry</span> <span class="citation_source-journal">Coord. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x"> (</span><span class="NLM_issue">1–2</span><span class="NLM_x">) </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1016/S0010-8545(02)00026-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2FS0010-8545%2802%2900026-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD38XntF2ktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2002&pages=49-67&issue=1%E2%80%932&author=M.+D.+Hallauthor=T.+W.+Hambley&title=Platinum%28IV%29+antitumour+compounds%3A+their+bioinorganic+chemistry&doi=10.1016%2FS0010-8545%2802%2900026-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(IV) antitumour compounds: their bioinorganic chemistry</span></div><div class="casAuthors">Hall, Matthew D.; Hambley, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">49-67</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  This article reviews the studies undertaken into Pt(IV) antitumor compds. since Barnett Rosenberg 1st noted the activity of Pt(IV) complexes.  The chem. and pharmacol. properties of the drugs are discussed and both the reactions with individual biomols., which have received attention and the characterization of biotransformation products from animal and clin. trials are reviewed.  The bioinorg. chem. of Pt(IV) complexes has not previously been reviewed, and the purpose here is to provide insight into the requirements for the antitumor activity of Pt(IV) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkHxf962L07rVg90H21EOLACvtfcHk0litdTwgt1FzBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntF2ktbs%253D&md5=200992ab1e4313bea2f5c9b3f60ac26f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0010-8545%2802%2900026-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0010-8545%252802%252900026-7%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DPlatinum%2528IV%2529%2520antitumour%2520compounds%253A%2520their%2520bioinorganic%2520chemistry%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2002%26volume%3D232%26issue%3D1%25E2%2580%25932%26spage%3D49%26epage%3D67%26doi%3D10.1016%2FS0010-8545%2802%2900026-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Johnstone, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulak, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pridgen, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties</span> <span class="citation_source-journal">ACS Nano</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">–</span> <span class="NLM_lpage">5683</span><span class="refDoi"> DOI: 10.1021/nn401905g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn401905g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotV2ksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=5675-5683&author=T.+C.+Johnstoneauthor=N.+Kulakauthor=E.+M.+Pridgenauthor=O.+C.+Farokhzadauthor=R.+Langerauthor=S.+J.+Lippard&title=Nanoparticle+encapsulation+of+mitaplatin+and+the+effect+thereof+on+in+vivo+properties&doi=10.1021%2Fnn401905g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle Encapsulation of Mitaplatin and the Effect Thereof on In Vivo Properties</span></div><div class="casAuthors">Johnstone, Timothy C.; Kulak, Nora; Pridgen, Eric M.; Farokhzad, Omid C.; Langer, Robert; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5675-5683</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nanoparticle (NP) therapeutics have the potential to significantly alter the in vivo biol. properties of the pharmaceutically active agents that they carry.  Here we describe the development of a polymeric NP, termed M-NP, comprising poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-PEG), stabilized with poly(vinyl alc.) (PVA), and loaded with a water-sol. platinum(IV) [Pt(IV)] prodrug, mitaplatin.  Mitaplatin, c,c,t-[PtCl2(NH3)2(OOCCHCl2)2], is a compd. designed to release cisplatin, an anticancer drug in widespread clin. use, and the orphan drug dichloroacetate following chem. redn.  An optimized prepn. of M-NP by double emulsion and its phys. characterization are reported, and the influence of encapsulation on the properties of the platinum agent is evaluated in vivo.  Encapsulation increases the circulation time of Pt in the bloodstream of rats.  The biodistribution of Pt in mice is also affected by nanoparticle encapsulation, resulting in reduced accumulation in the kidneys.  Finally, the efficacy of both free mitaplatin and M-NP, measured by tumor growth inhibition in a mouse xenograft model of triple-neg. breast cancer, reveals that controlled release of mitaplatin over time from the nanoparticle treatment produces long-term efficacy comparable to that of free mitaplatin, which might limit toxic side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnDKITCPYSzrVg90H21EOLACvtfcHk0litdTwgt1FzBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotV2ksbg%253D&md5=cfbe9f3c377ab22f494d9d145ff08615</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fnn401905g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn401905g%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DKulak%26aufirst%3DN.%26aulast%3DPridgen%26aufirst%3DE.%2BM.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DNanoparticle%2520encapsulation%2520of%2520mitaplatin%2520and%2520the%2520effect%2520thereof%2520on%2520in%2520vivo%2520properties%26jtitle%3DACS%2520Nano%26date%3D2013%26volume%3D7%26spage%3D5675%26epage%3D5683%26doi%3D10.1021%2Fnn401905g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Bast, R. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennessy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span> </span><span class="NLM_article-title">The biology of ovarian cancer: new opportunities for translation</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">428</span><span class="refDoi"> DOI: 10.1038/nrc2644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1038%2Fnrc2644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=19461667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmt1Skt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=415-428&author=R.+C.+Bastauthor=B.+Hennessyauthor=G.+B.+Mills&title=The+biology+of+ovarian+cancer%3A+new+opportunities+for+translation&doi=10.1038%2Fnrc2644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The biology of ovarian cancer: new opportunities for translation</span></div><div class="casAuthors">Bast, Robert C.; Hennessy, Bryan; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">415-428</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past two decades, the 5-yr survival for ovarian cancer patients has substantially improved owing to more effective surgery and treatment with empirically optimized combinations of cytotoxic drugs, but the overall cure rate remains approx. 30%.  Many investigators think that further empirical trials using combinations of conventional agents are likely to produce only modest incremental improvements in outcome.  Given the heterogeneity of this disease, increases in long-term survival might be achieved by translating recent insights at the mol. and cellular levels to personalize individual strategies for treatment and to optimize early detection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPoLW_Fq0TYrVg90H21EOLACvtfcHk0lgsZp-G1Mgw3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmt1Skt7g%253D&md5=42b5e0e351dbb9cfeb44df1d7ec7b3ee</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnrc2644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2644%26sid%3Dliteratum%253Aachs%26aulast%3DBast%26aufirst%3DR.%2BC.%26aulast%3DHennessy%26aufirst%3DB.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DThe%2520biology%2520of%2520ovarian%2520cancer%253A%2520new%2520opportunities%2520for%2520translation%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D415%26epage%3D428%26doi%3D10.1038%2Fnrc2644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Sankhala, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adinin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamagata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuno, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujisawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, A.</span><span> </span><span class="NLM_article-title">A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">15S</span><span class="NLM_x">) </span> <span class="NLM_fpage">2535</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=2535&issue=15S&author=K.+K.+Sankhalaauthor=A.+C.+Mitaauthor=R.+Adininauthor=L.+Woodauthor=M.+Beeramauthor=S.+Bullockauthor=N.+Yamagataauthor=K.+Matsunoauthor=T.+Fujisawaauthor=A.+Phan&title=A+phase+I+pharmacokinetic+%28PK%29+study+of+MBP-426%2C+a+novel+liposome+encapsulated+oxaliplatin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSankhala%26aufirst%3DK.%2BK.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DAdinin%26aufirst%3DR.%26aulast%3DWood%26aufirst%3DL.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DBullock%26aufirst%3DS.%26aulast%3DYamagata%26aufirst%3DN.%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DFujisawa%26aufirst%3DT.%26aulast%3DPhan%26aufirst%3DA.%26atitle%3DA%2520phase%2520I%2520pharmacokinetic%2520%2528PK%2529%2520study%2520of%2520MBP-426%252C%2520a%2520novel%2520liposome%2520encapsulated%2520oxaliplatin%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26issue%3D15S%26spage%3D2535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabral, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kano, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, K.</span><span> </span><span class="NLM_article-title">Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">64ra2</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3001385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1126%2Fscitranslmed.3001385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=21209412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=64ra2&author=M.+Murakamiauthor=H.+Cabralauthor=Y.+Matsumotoauthor=S.+Wuauthor=M.+R.+Kanoauthor=T.+Yamoriauthor=N.+Nishiyamaauthor=K.+Kataoka&title=Improving+drug+potency+and+efficacy+by+nanocarrier-mediated+subcellular+targeting&doi=10.1126%2Fscitranslmed.3001385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting</span></div><div class="casAuthors">Murakami, Mami; Cabral, Horacio; Matsumoto, Yu; Wu, Shourong; Kano, Mitsunobu R.; Yamori, Takao; Nishiyama, Nobuhiro; Kataoka, Kazunori</div><div class="citationInfo"><span class="NLM_cas:title">Science Translational Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">64</span>),
    <span class="NLM_cas:pages">64ra2</span>CODEN:
                <span class="NLM_cas:coden">STMCBQ</span>;
        ISSN:<span class="NLM_cas:issn">1946-6242</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Nanocarrier-mediated drug targeting is an emerging strategy for cancer therapy and is being used, for example, with chemotherapeutic agents for ovarian cancer.  Nanocarriers are selectively accumulated in tumors as a result of their enhanced permeability and retention of macromols., thereby enhancing the antitumor activity of the nanocarrier-assocd. drugs.  We investigated the real-time subcellular fate of polymeric micelles incorporating (1,2-diaminocyclohexane) platinum(II) (DACHPt/m), the parent complex of oxaliplatin, in tumor tissues by fluorescence-based assessment of their kinetic stability.  These observations revealed that DACHPt/m was extravasated from blood vessels to the tumor tissue and dissocd. inside each cell.  Furthermore, DACHPt/m selectively dissocd. within late endosomes, enhancing drug delivery to the nearby nucleus relative to free oxaliplatin, likely by circumvention of the cytoplasmic detoxification systems such as metallothionein and methionine synthase.  Thus, these drug-loaded micelles exhibited higher antitumor activity than did oxaliplatin alone, even against oxaliplatin-resistant tumors.  These findings suggest that nanocarriers targeting subcellular compartments may have considerable benefits in clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWKR-rRV0SYLVg90H21EOLACvtfcHk0lgsZp-G1Mgw3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWisb0%253D&md5=5231121539f9a5707a7976a12f16c127</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001385%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DCabral%26aufirst%3DH.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DKano%26aufirst%3DM.%2BR.%26aulast%3DYamori%26aufirst%3DT.%26aulast%3DNishiyama%26aufirst%3DN.%26aulast%3DKataoka%26aufirst%3DK.%26atitle%3DImproving%2520drug%2520potency%2520and%2520efficacy%2520by%2520nanocarrier-mediated%2520subcellular%2520targeting%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D64ra2%26doi%3D10.1126%2Fscitranslmed.3001385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Campone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rademaker-Lakhai, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howell, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowotnik, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span> </span><span class="NLM_article-title">Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1007/s00280-006-0397-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1007%2Fs00280-006-0397-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=17308894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFKntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=523-533&author=M.+Camponeauthor=J.+M.+Rademaker-Lakhaiauthor=J.+Bennounaauthor=S.+B.+Howellauthor=D.+P.+Nowotnikauthor=J.+H.+Beijnenauthor=J.+H.+Schellens&title=Phase+I+and+pharmacokinetic+trial+of+AP5346%2C+a+DACH-platinum-polymer+conjugate%2C+administered+weekly+for+three+out+of+every+4+weeks+to+advanced+solid+tumor+patients&doi=10.1007%2Fs00280-006-0397-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients</span></div><div class="casAuthors">Campone, Mario; Rademaker-Lakhai, Jeany M.; Bennouna, Jaafar; Howell, Stephen B.; Nowotnik, David P.; Beijnen, Jos H.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-533</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To det. the max. tolerated dose (MTD) safety and pharmacokinetics of AP5346, a copolymer-linked 1,2-diaminocyclohexane(DACH)-platinum compd., in advanced solid tumor patients.  Exptl. design: AP5346 was administered as a 1-h IV infusion on days 1, 8, 15 of a 28-day cycle.  Seven dose levels (DL) were explored: DL1: 40 mg platinum (Pt)/m2 (1 patient); DL2: 80 (1); DL3: 160 (3); DL4: 320 (3); DL5: 640 (6); DL6: 850 (6); DL7: 1280 (6) mg Pt/m2.  Dose-limiting toxicity (DLT) included infusion omission and cycle delay >2 wk.  Results: Twenty-six patients received 41 cycles (median 1/patient, range 1-4).  No DLT occurred in DL 1-4; 1 DLT in DL5 (RD; renal insufficiency), two in DL6 (MTD; vomiting; fatigue) and 5 in DL7 (neutropenic infection with diarrhea; neutropenia with vomiting; vomiting with fatigue; renal insufficiency; and fatigue).  Two deaths occurred due to renal insufficiency (DL5); in both cases patients had disease in or surrounding genitourinary tract whose contribution could not be accurately discerned.  Grade 1-2 creatinine abnormalities occurred in seven patients.  Nausea/emesis was frequent (92%), reaching grade 3-4 (23%), but controlled by antiemetics.  Grade 2-4 allergic reactions occurred in 4 patients.  C max and AUC increased linearly with dose for total plasma platinum and ultrafiltrate platinum.  Antitumor activity included two partial responses in metastatic melanoma and ovarian cancer, and an addnl. CA-125 normalization (from 133 IU/l) in a suspected ovarian cancer.  Conclusions: AP5346 administered weekly for 3 wk out of every four is tolerated up to a dose of 640 mg Pt/m2 on the first cycle when given with antiemetic prophylaxis.  The pharmacokinetics of AP5346 indicates a prolonged half-life, and evidence of antitumor activity was obsd. at this dose level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTrOqvqg8AeLVg90H21EOLACvtfcHk0ljVf1g6XGv2JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFKntrk%253D&md5=eda0f0004a1065f5fef5eb3385b71a18</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0397-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0397-0%26sid%3Dliteratum%253Aachs%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DRademaker-Lakhai%26aufirst%3DJ.%2BM.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DHowell%26aufirst%3DS.%2BB.%26aulast%3DNowotnik%26aufirst%3DD.%2BP.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DPhase%2520I%2520and%2520pharmacokinetic%2520trial%2520of%2520AP5346%252C%2520a%2520DACH-platinum-polymer%2520conjugate%252C%2520administered%2520weekly%2520for%2520three%2520out%2520of%2520every%25204%2520weeks%2520to%2520advanced%2520solid%2520tumor%2520patients%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2007%26volume%3D60%26spage%3D523%26epage%3D533%26doi%3D10.1007%2Fs00280-006-0397-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Z. X.</span><span> </span><span class="NLM_article-title">PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1621</span><span class="NLM_x">–</span> <span class="NLM_lpage">1628</span><span class="refDoi"> DOI: 10.3892/or.2011.1238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.3892%2For.2011.1238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=21455585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVWht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1621-1628&author=C.+Yangauthor=H.+Z.+Liuauthor=W.+D.+Luauthor=Z.+X.+Fu&title=PEG-liposomal+oxaliplatin+potentialization+of+antitumor+efficiency+in+a+nude+mouse+tumor-xenograft+model+of+colorectal+carcinoma&doi=10.3892%2For.2011.1238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma</span></div><div class="casAuthors">Yang, Chuang; Liu, Hai-Zhong; Lu, Wei-Dong; Fu, Zhong-Xue</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1621-1628</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">The non-selectivity of chemotherapeutics between normal tissue and pathol. sites poses a challenge for the treatment strategy for advanced colorectal carcinoma.  To obtain sufficient antitumor activity, optimization of the therapeutic regimen is of great importance.  We investigated PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.  A tumor-bearing nude mouse model, i.v. injections of (Dio)-labeled PEG-liposomes via tail vein and fluorescence imaging with in vivo imaging system were employed.  Mice were treated with free L-oHP, PEG-liposomal L-oHP via the tail vein, followed by anal. of the accumulation of L-oHP in tumor tissues by high-performance liq. chromatog. (HPLC), observation of the tumor vol. and the survival rate.  Apoptosis and proliferation of tumors were detected by TUNEL assay and immunohistochem.  The mRNA and protein levels of Bcl-2, Bax, caspase-3 (P17) and Ki-67 were detd. by RT-PCR and Western blotting.  Fluorescence imaging with in vivo imaging showed PEG-liposome targeting in tumor tissues.  After i.v. injections of PEG-liposomal oxaliplatin, tumor tissue max. accumulation of L-oHP was 9.37±0.79 μg/g at 24 h; The tumor vol. was significantly suppressed, and mice showed longer survival, compared with the free oxaliplatin group.  Apoptosis increased, but proliferation decreased in tumor tissues.  The mRNA expression of Bcl-2 and Ki-67 was down-regulated, while Bax and caspase-3 expression was up-regulated.  Protein expression of Bcl-2 was down-regulated, while Bax and P17 expression was up-regulated.  The results indicate that PEG-liposomal oxaliplatin can improve antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-cLzsXaTfLLVg90H21EOLACvtfcHk0ljVf1g6XGv2JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVWht78%253D&md5=1dc0e7f4001d6b20807052362830712c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.3892%2For.2011.1238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2011.1238%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DH.%2BZ.%26aulast%3DLu%26aufirst%3DW.%2BD.%26aulast%3DFu%26aufirst%3DZ.%2BX.%26atitle%3DPEG-liposomal%2520oxaliplatin%2520potentialization%2520of%2520antitumor%2520efficiency%2520in%2520a%2520nude%2520mouse%2520tumor-xenograft%2520model%2520of%2520colorectal%2520carcinoma%26jtitle%3DOncol.%2520Rep.%26date%3D2011%26volume%3D25%26spage%3D1621%26epage%3D1628%26doi%3D10.3892%2For.2011.1238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 37 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jumana Far, Muhammad Abdel-Haq, Maayan Gruber, <span class="NLM_string-name hlFld-ContribAuthor">Aiman Abu Ammar</span>. </span><span class="cited-content_cbyCitation_article-title">Developing Biodegradable Nanoparticles Loaded with Mometasone Furoate for Potential Nasal Drug Delivery. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (13)
                                     , 7432-7439. <a href="https://doi.org/10.1021/acsomega.0c00111" title="DOI URL">https://doi.org/10.1021/acsomega.0c00111</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c00111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c00111%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDeveloping%252BBiodegradable%252BNanoparticles%252BLoaded%252Bwith%252BMometasone%252BFuroate%252Bfor%252BPotential%252BNasal%252BDrug%252BDelivery%26aulast%3DFar%26aufirst%3DJumana%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09012020%26date%3D16032020%26date%3D25032020%26volume%3D5%26issue%3D13%26spage%3D7432%26epage%3D7439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhikun Liu, Meng Wang, Hengshan Wang, Lei Fang, <span class="NLM_string-name hlFld-ContribAuthor">Shaohua Gou</span>. </span><span class="cited-content_cbyCitation_article-title">Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 186-204. <a href="https://doi.org/10.1021/acs.jmedchem.9b01223" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01223%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPlatinum-Based%252BModification%252Bof%252BStyrylbenzylsulfones%252Bas%252BMultifunctional%252BAntitumor%252BAgents%25253A%252BTargeting%252Bthe%252BRAS%25252FRAF%252BPathway%25252C%252BEnhancing%252BAntitumor%252BActivity%25252C%252Band%252BOvercoming%252BMultidrug%252BResistance%26aulast%3DLiu%26aufirst%3DZhikun%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D28072019%26date%3D26122019%26date%3D10122019%26volume%3D63%26issue%3D1%26spage%3D186%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ran Zhang, Xue-Qing Song, Rui-Ping Liu, Zhong-Ying Ma, <span class="NLM_string-name hlFld-ContribAuthor">Jing-Yuan Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Fuplatin: An Efficient and Low-Toxic Dual-Prodrug. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4543-4554. <a href="https://doi.org/10.1021/acs.jmedchem.9b00128" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00128</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00128%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFuplatin%25253A%252BAn%252BEfficient%252Band%252BLow-Toxic%252BDual-Prodrug%26aulast%3DZhang%26aufirst%3DRan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22012019%26date%3D30042019%26date%3D19042019%26volume%3D62%26issue%3D9%26spage%3D4543%26epage%3D4554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maurizio Sabbatini, Ilaria Zanellato, Mauro Ravera, Elisabetta Gabano, Elena Perin, Beatrice Rangone, <span class="NLM_string-name hlFld-ContribAuthor">Domenico Osella</span>. </span><span class="cited-content_cbyCitation_article-title">Pt(IV) Bifunctional Prodrug Containing 2-(2-Propynyl)octanoato Axial Ligand: Induction of Immunogenic Cell Death on Colon Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (7)
                                     , 3395-3406. <a href="https://doi.org/10.1021/acs.jmedchem.8b01860" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01860</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01860%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPt%252528IV%252529%252BBifunctional%252BProdrug%252BContaining%252B2-%2525282-Propynyl%252529octanoato%252BAxial%252BLigand%25253A%252BInduction%252Bof%252BImmunogenic%252BCell%252BDeath%252Bon%252BColon%252BCancer%26aulast%3DSabbatini%26aufirst%3DMaurizio%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D28112018%26date%3D27032019%26date%3D16032019%26volume%3D62%26issue%3D7%26spage%3D3395%26epage%3D3406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aiman  Abu Ammar</span>, <span class="hlFld-ContribAuthor ">Muhammad  Abdel-Haq</span>, <span class="hlFld-ContribAuthor ">Kareem  Abd-Rbo</span>, <span class="hlFld-ContribAuthor ">Haytam  Kasem</span>. </span><span class="cited-content_cbyCitation_article-title">Developing Novel Poly(Lactic-Co-Glycolic Acid) (PLGA) Films with Enhanced Adhesion Capacity by Biomimetic Mushroom-Shaped Microstructures. </span><span class="cited-content_cbyCitation_journal-name">Biotribology</span><span> <strong>2021,</strong> <em>27 </em>, 100184. <a href="https://doi.org/10.1016/j.biotri.2021.100184" title="DOI URL">https://doi.org/10.1016/j.biotri.2021.100184</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biotri.2021.100184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biotri.2021.100184%26sid%3Dliteratum%253Aachs%26jtitle%3DBiotribology%26atitle%3DDeveloping%252BNovel%252BPoly%252528Lactic-Co-Glycolic%252BAcid%252529%252B%252528PLGA%252529%252BFilms%252Bwith%252BEnhanced%252BAdhesion%252BCapacity%252Bby%252BBiomimetic%252BMushroom-Shaped%252BMicrostructures%26aulast%3DAbu%2BAmmar%26aufirst%3DAiman%26date%3D2021%26volume%3D27%26spage%3D100184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nidhi  Raval</span>, <span class="hlFld-ContribAuthor ">Rahul  Maheshwari</span>, <span class="hlFld-ContribAuthor ">Havish  Shukla</span>, <span class="hlFld-ContribAuthor ">Kiran  Kalia</span>, <span class="hlFld-ContribAuthor ">Vladimir P.  Torchilin</span>, <span class="hlFld-ContribAuthor ">Rakesh K.  Tekade</span>. </span><span class="cited-content_cbyCitation_article-title">Multifunctional polymeric micellar nanomedicine in the diagnosis and treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">Materials Science and Engineering: C</span><span> <strong>2021,</strong> <em>126 </em>, 112186. <a href="https://doi.org/10.1016/j.msec.2021.112186" title="DOI URL">https://doi.org/10.1016/j.msec.2021.112186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.msec.2021.112186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.msec.2021.112186%26sid%3Dliteratum%253Aachs%26jtitle%3DMaterials%2520Science%2520and%2520Engineering%253A%2520C%26atitle%3DMultifunctional%252Bpolymeric%252Bmicellar%252Bnanomedicine%252Bin%252Bthe%252Bdiagnosis%252Band%252Btreatment%252Bof%252Bcancer%26aulast%3DRaval%26aufirst%3DNidhi%26date%3D2021%26volume%3D126%26spage%3D112186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li-Qin  Qin</span>, <span class="hlFld-ContribAuthor ">Zu-Zhuang  Wei</span>, <span class="hlFld-ContribAuthor ">Lin  Yang</span>, <span class="hlFld-ContribAuthor ">Qi-Pin  Qin</span>, <span class="hlFld-ContribAuthor ">Jia-Jing  Zeng</span>, <span class="hlFld-ContribAuthor ">Ming-Xiong  Tan</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Strong in vitro and in vivo cytotoxic effects of two platinum(II) complexes with cryptolepine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2021,</strong> <em>30 </em>
                                    (7)
                                     , 1419-1426. <a href="https://doi.org/10.1007/s00044-021-02739-0" title="DOI URL">https://doi.org/10.1007/s00044-021-02739-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-021-02739-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-021-02739-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DStrong%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Bcytotoxic%252Beffects%252Bof%252Btwo%252Bplatinum%252528II%252529%252Bcomplexes%252Bwith%252Bcryptolepine%252Bderivatives%26aulast%3DQin%26aufirst%3DLi-Qin%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D7%26spage%3D1419%26epage%3D1426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J.  Zajda</span>, <span class="hlFld-ContribAuthor ">A.  Wróblewska</span>, <span class="hlFld-ContribAuthor ">L.  Ruzik</span>, <span class="hlFld-ContribAuthor ">M.  Matczuk</span>. </span><span class="cited-content_cbyCitation_article-title">Methodology for characterization of platinum-based drug's targeted delivery nanosystems. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2021,</strong> <em>335 </em>, 178-190. <a href="https://doi.org/10.1016/j.jconrel.2021.05.022" title="DOI URL">https://doi.org/10.1016/j.jconrel.2021.05.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2021.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2021.05.022%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DMethodology%252Bfor%252Bcharacterization%252Bof%252Bplatinum-based%252Bdrug%252527s%252Btargeted%252Bdelivery%252Bnanosystems%26aulast%3DZajda%26aufirst%3DJ.%26date%3D2021%26volume%3D335%26spage%3D178%26epage%3D190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikhil  Biswas</span>, <span class="hlFld-ContribAuthor ">Aiman  Abu Ammar</span>, <span class="hlFld-ContribAuthor ">Marina  Frušić-Zlotkin</span>, <span class="hlFld-ContribAuthor ">Naama  Adi-Hen</span>, <span class="hlFld-ContribAuthor ">Yonat  Lehman-Katabi</span>, <span class="hlFld-ContribAuthor ">Yael  Levi-Kalisman</span>, <span class="hlFld-ContribAuthor ">Taher  Nassar</span>, <span class="hlFld-ContribAuthor ">Simon  Benita</span>. </span><span class="cited-content_cbyCitation_article-title">Biodistribution and efficacy of the anticancer drug, oxaliplatin palmitate acetate, in mice. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2021,</strong> <em>604 </em>, 120740. <a href="https://doi.org/10.1016/j.ijpharm.2021.120740" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2021.120740</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2021.120740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2021.120740%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DBiodistribution%252Band%252Befficacy%252Bof%252Bthe%252Banticancer%252Bdrug%25252C%252Boxaliplatin%252Bpalmitate%252Bacetate%25252C%252Bin%252Bmice%26aulast%3DBiswas%26aufirst%3DNikhil%26date%3D2021%26volume%3D604%26spage%3D120740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng-Xue  Wei</span>, <span class="hlFld-ContribAuthor ">Jia-Ying  Yu</span>, <span class="hlFld-ContribAuthor ">Xin-Xin  Liu</span>, <span class="hlFld-ContribAuthor ">Xue-Qiang  Li</span>, <span class="hlFld-ContribAuthor ">Jin-Hui  Yang</span>, <span class="hlFld-ContribAuthor ">Meng-Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Pei-Wen  Yang</span>, <span class="hlFld-ContribAuthor ">Si-Si  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  He</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel artemisone–piperazine–tetronamide hybrids. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (30)
                                     , 18333-18341. <a href="https://doi.org/10.1039/D1RA00750E" title="DOI URL">https://doi.org/10.1039/D1RA00750E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1RA00750E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1RA00750E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bartemisone%2525E2%252580%252593piperazine%2525E2%252580%252593tetronamide%252Bhybrids%26aulast%3DWei%26aufirst%3DMeng-Xue%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D30%26spage%3D18333%26epage%3D18341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad  Abdel-Haq</span>, <span class="hlFld-ContribAuthor ">Rayan  Alyan</span>, <span class="hlFld-ContribAuthor ">Kareem  Abd-Rbo</span>, <span class="hlFld-ContribAuthor ">Haytam  Kasem</span>, <span class="hlFld-ContribAuthor ">Aiman  Abu Ammar</span>. </span><span class="cited-content_cbyCitation_article-title">Biomimetic clotrimazole-loaded PLGA films with enhanced adhesiveness for controlled drug release. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2021,</strong> <em>601 </em>, 120578. <a href="https://doi.org/10.1016/j.ijpharm.2021.120578" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2021.120578</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2021.120578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2021.120578%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DBiomimetic%252Bclotrimazole-loaded%252BPLGA%252Bfilms%252Bwith%252Benhanced%252Badhesiveness%252Bfor%252Bcontrolled%252Bdrug%252Brelease%26aulast%3DAbdel-Haq%26aufirst%3DMuhammad%26date%3D2021%26volume%3D601%26spage%3D120578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cláudia  Camacho</span>, <span class="hlFld-ContribAuthor ">Helena  Tomás</span>, <span class="hlFld-ContribAuthor ">João  Rodrigues</span>. </span><span class="cited-content_cbyCitation_article-title">Use of Half-Generation PAMAM Dendrimers (G0.5–G3.5) with Carboxylate End-Groups to Improve the DACHPtCl2 and 5-FU Efficacy as Anticancer Drugs. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (10)
                                     , 2924. <a href="https://doi.org/10.3390/molecules26102924" title="DOI URL">https://doi.org/10.3390/molecules26102924</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26102924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26102924%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DUse%252Bof%252BHalf-Generation%252BPAMAM%252BDendrimers%252B%252528G0.5%2525E2%252580%252593G3.5%252529%252Bwith%252BCarboxylate%252BEnd-Groups%252Bto%252BImprove%252Bthe%252BDACHPtCl2%252Band%252B5-FU%252BEfficacy%252Bas%252BAnticancer%252BDrugs%26aulast%3DCamacho%26aufirst%3DCl%25C3%25A1udia%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D10%26spage%3D2924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Chu</span>, <span class="hlFld-ContribAuthor ">Xiyu  Mo</span>, <span class="hlFld-ContribAuthor ">Zilu  Chen</span>, <span class="hlFld-ContribAuthor ">Mingling  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuning  Liang</span>, <span class="hlFld-ContribAuthor ">Huancheng  Hu</span>, <span class="hlFld-ContribAuthor ">Dongcheng  Liu</span>, <span class="hlFld-ContribAuthor ">Fupei  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and anticancer activity of mixed ligand 3d metal complexes. </span><span class="cited-content_cbyCitation_journal-name">Metallomics</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     <a href="https://doi.org/10.1093/mtomcs/mfab011" title="DOI URL">https://doi.org/10.1093/mtomcs/mfab011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/mtomcs/mfab011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fmtomcs%2Fmfab011%26sid%3Dliteratum%253Aachs%26jtitle%3DMetallomics%26atitle%3DSynthesis%252Band%252Banticancer%252Bactivity%252Bof%252Bmixed%252Bligand%252B3d%252Bmetal%252Bcomplexes%26aulast%3DChu%26aufirst%3DBo%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanhua  Zhang</span>, <span class="hlFld-ContribAuthor ">Yang  Dong</span>, <span class="hlFld-ContribAuthor ">Hao  Fu</span>, <span class="hlFld-ContribAuthor ">Hui  Huang</span>, <span class="hlFld-ContribAuthor ">Zhihua  Wu</span>, <span class="hlFld-ContribAuthor ">Meng  Zhao</span>, <span class="hlFld-ContribAuthor ">Xupeng  Yang</span>, <span class="hlFld-ContribAuthor ">Qianqian  Guo</span>, <span class="hlFld-ContribAuthor ">Yourong  Duan</span>, <span class="hlFld-ContribAuthor ">Ying  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Multifunctional tumor-targeted PLGA nanoparticles delivering Pt(IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance. </span><span class="cited-content_cbyCitation_journal-name">Biomaterials</span><span> <strong>2021,</strong> <em>269 </em>, 120478. <a href="https://doi.org/10.1016/j.biomaterials.2020.120478" title="DOI URL">https://doi.org/10.1016/j.biomaterials.2020.120478</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biomaterials.2020.120478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biomaterials.2020.120478%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomaterials%26atitle%3DMultifunctional%252Btumor-targeted%252BPLGA%252Bnanoparticles%252Bdelivering%252BPt%252528IV%252529%25252FsiBIRC5%252Bfor%252BUS%25252FMRI%252Bimaging%252Band%252Bovercoming%252Bovarian%252Bcancer%252Bresistance%26aulast%3DZhang%26aufirst%3DYanhua%26date%3D2021%26volume%3D269%26spage%3D120478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chilaluck C.  Konkankit</span>, <span class="hlFld-ContribAuthor ">Brett A.  Vaughn</span>, <span class="hlFld-ContribAuthor ">Zhouyang  Huang</span>, <span class="hlFld-ContribAuthor ">Eszter  Boros</span>, <span class="hlFld-ContribAuthor ">Justin J.  Wilson</span>. </span><span class="cited-content_cbyCitation_article-title">Systematically altering the lipophilicity of rhenium(
              i
              ) tricarbonyl anticancer agents to tune the rate at which they induce cell death. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2020,</strong> <em>49 </em>
                                    (45)
                                     , 16062-16066. <a href="https://doi.org/10.1039/D0DT01097A" title="DOI URL">https://doi.org/10.1039/D0DT01097A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0DT01097A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0DT01097A%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DSystematically%252Baltering%252Bthe%252Blipophilicity%252Bof%252Brhenium%252528%252Bi%252B%252529%252Btricarbonyl%252Banticancer%252Bagents%252Bto%252Btune%252Bthe%252Brate%252Bat%252Bwhich%252Bthey%252Binduce%252Bcell%252Bdeath%26aulast%3DKonkankit%26aufirst%3DChilaluck%2BC.%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D45%26spage%3D16062%26epage%3D16066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K. Shitaljit  Sharma</span>, <span class="hlFld-ContribAuthor ">Akhil K.  Dubey</span>, <span class="hlFld-ContribAuthor ">Arunkumar S.  Koijam</span>, <span class="hlFld-ContribAuthor ">Chandan  Kumar</span>, <span class="hlFld-ContribAuthor ">Anand  Ballal</span>, <span class="hlFld-ContribAuthor ">Sudip  Mukherjee</span>, <span class="hlFld-ContribAuthor ">Prasad P.  Phadnis</span>, <span class="hlFld-ContribAuthor ">Rajesh K.  Vatsa</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 2-deoxy-
              d
              -glucose coated Fe
              3
              O
              4
              nanoparticles for application in targeted delivery of the Pt(
              iv
              ) prodrug of cisplatin – a novel approach in chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (32)
                                     , 13863-13874. <a href="https://doi.org/10.1039/C9NJ05989J" title="DOI URL">https://doi.org/10.1039/C9NJ05989J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9NJ05989J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9NJ05989J%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DSynthesis%252Bof%252B2-deoxy-%252Bd%252B-glucose%252Bcoated%252BFe%252B3%252BO%252B4%252Bnanoparticles%252Bfor%252Bapplication%252Bin%252Btargeted%252Bdelivery%252Bof%252Bthe%252BPt%252528%252Biv%252B%252529%252Bprodrug%252Bof%252Bcisplatin%252B%2525E2%252580%252593%252Ba%252Bnovel%252Bapproach%252Bin%252Bchemotherapy%26aulast%3DSharma%26aufirst%3DK.%2BShitaljit%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D32%26spage%3D13863%26epage%3D13874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingguang  Li</span>, <span class="hlFld-ContribAuthor ">Kexin  Yue</span>, <span class="hlFld-ContribAuthor ">Linrong  Li</span>, <span class="hlFld-ContribAuthor ">Jie  Niu</span>, <span class="hlFld-ContribAuthor ">Hanfang  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Ma</span>, <span class="hlFld-ContribAuthor ">Songqiang  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">A Pt(IV)-based mononitro-naphthalimide conjugate with minimized side-effects targeting DNA damage response via a dual-DNA-damage approach to overcome cisplatin resistance. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>101 </em>, 104011. <a href="https://doi.org/10.1016/j.bioorg.2020.104011" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252BPt%252528IV%252529-based%252Bmononitro-naphthalimide%252Bconjugate%252Bwith%252Bminimized%252Bside-effects%252Btargeting%252BDNA%252Bdamage%252Bresponse%252Bvia%252Ba%252Bdual-DNA-damage%252Bapproach%252Bto%252Bovercome%252Bcisplatin%252Bresistance%26aulast%3DLi%26aufirst%3DYingguang%26date%3D2020%26volume%3D101%26spage%3D104011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junyi  Chen</span>, <span class="hlFld-ContribAuthor ">Yadan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhao  Meng</span>, <span class="hlFld-ContribAuthor ">Lei  Guo</span>, <span class="hlFld-ContribAuthor ">Xingyi  Yuan</span>, <span class="hlFld-ContribAuthor ">Yahan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yao  Chai</span>, <span class="hlFld-ContribAuthor ">Jonathan L.  Sessler</span>, <span class="hlFld-ContribAuthor ">Qingbin  Meng</span>, <span class="hlFld-ContribAuthor ">Chunju  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Supramolecular combination chemotherapy: a pH-responsive co-encapsulation drug delivery system. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (24)
                                     , 6275-6282. <a href="https://doi.org/10.1039/D0SC01756F" title="DOI URL">https://doi.org/10.1039/D0SC01756F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC01756F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC01756F%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DSupramolecular%252Bcombination%252Bchemotherapy%25253A%252Ba%252BpH-responsive%252Bco-encapsulation%252Bdrug%252Bdelivery%252Bsystem%26aulast%3DChen%26aufirst%3DJunyi%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D24%26spage%3D6275%26epage%3D6282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunshuang  Zhong</span>, <span class="hlFld-ContribAuthor ">Chunyan  Jia</span>, <span class="hlFld-ContribAuthor ">Xinzhong  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiali  Liao</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Yanwei  Cong</span>, <span class="hlFld-ContribAuthor ">Shaoping  Pu</span>, <span class="hlFld-ContribAuthor ">Chuanzhu  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, characterization, and antitumor activity of novel tumor‐targeted platinum(IV) complexes. </span><span class="cited-content_cbyCitation_journal-name">Applied Organometallic Chemistry</span><span> <strong>2020,</strong> <em>34 </em>
                                    (5)
                                     <a href="https://doi.org/10.1002/aoc.5577" title="DOI URL">https://doi.org/10.1002/aoc.5577</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/aoc.5577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Faoc.5577%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Organometallic%2520Chemistry%26atitle%3DSynthesis%25252C%252Bcharacterization%25252C%252Band%252Bantitumor%252Bactivity%252Bof%252Bnovel%252Btumor%2525E2%252580%252590targeted%252Bplatinum%252528IV%252529%252Bcomplexes%26aulast%3DZhong%26aufirst%3DYunshuang%26date%3D2020%26volume%3D34%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunshuang  Zhong</span>, <span class="hlFld-ContribAuthor ">Chunyan  Jia</span>, <span class="hlFld-ContribAuthor ">Xinzhong  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiali  Liao</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Yanwei  Cong</span>, <span class="hlFld-ContribAuthor ">Shaoping  Pu</span>, <span class="hlFld-ContribAuthor ">Chuanzhu  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>194 </em>, 112229. <a href="https://doi.org/10.1016/j.ejmech.2020.112229" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112229%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Bdrug%252Bdelivery%252Bsystem%252Bfor%252Bplatinum%252528%2525E2%252585%2525A3%252529-Based%252Bantitumor%252Bcomplexes%26aulast%3DZhong%26aufirst%3DYunshuang%26date%3D2020%26volume%3D194%26spage%3D112229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eolann  Kitteringham</span>, <span class="hlFld-ContribAuthor ">Aoife M.  McKeon</span>, <span class="hlFld-ContribAuthor ">Paul  O'Dowd</span>, <span class="hlFld-ContribAuthor ">Marc  Devocelle</span>, <span class="hlFld-ContribAuthor ">Brona M.  Murphy</span>, <span class="hlFld-ContribAuthor ">Darren M.  Griffith</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and characterisation of a novel mono functionalisable Pt(IV) oxaliplatin-type complex and its peptide conjugate. </span><span class="cited-content_cbyCitation_journal-name">Inorganica Chimica Acta</span><span> <strong>2020,</strong> <em>505 </em>, 119492. <a href="https://doi.org/10.1016/j.ica.2020.119492" title="DOI URL">https://doi.org/10.1016/j.ica.2020.119492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ica.2020.119492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ica.2020.119492%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganica%2520Chimica%2520Acta%26atitle%3DSynthesis%252Band%252Bcharacterisation%252Bof%252Ba%252Bnovel%252Bmono%252Bfunctionalisable%252BPt%252528IV%252529%252Boxaliplatin-type%252Bcomplex%252Band%252Bits%252Bpeptide%252Bconjugate%26aulast%3DKitteringham%26aufirst%3DEolann%26date%3D2020%26volume%3D505%26spage%3D119492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan‐Cheng  Liu</span>, <span class="hlFld-ContribAuthor ">Jessica J.  Miller</span>. </span><span class="cited-content_cbyCitation_article-title">Platinum‐Based Anticancer Drugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-19. <a href="https://doi.org/10.1002/9781119951438.eibc0178.pub2" title="DOI URL">https://doi.org/10.1002/9781119951438.eibc0178.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119951438.eibc0178.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119951438.eibc0178.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DPlatinum%2525E2%252580%252590Based%252BAnticancer%252BDrugs%26aulast%3DLiu%26aufirst%3DYan%25E2%2580%2590Cheng%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D19%26pub%3DWiley%26atitle%3DEncyclopedia%252Bof%252BInorganic%252Band%252BBioinorganic%252BChemistry%26aulast%3DScott%26aufirst%3DRobert%2BA%26date%3D2011%26date%3D2011%26volume%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Jing  Ding</span>, <span class="hlFld-ContribAuthor ">Ran  Zhang</span>, <span class="hlFld-ContribAuthor ">Rui-Ping  Liu</span>, <span class="hlFld-ContribAuthor ">Xue-Qing  Song</span>, <span class="hlFld-ContribAuthor ">Xin  Qiao</span>, <span class="hlFld-ContribAuthor ">Cheng-Zhi  Xie</span>, <span class="hlFld-ContribAuthor ">Xiu-He  Zhao</span>, <span class="hlFld-ContribAuthor ">Jing-Yuan  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">A class of Pt(
              iv
              ) triple-prodrugs targeting nucleic acids, thymidylate synthases and histone deacetylases. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry Frontiers</span><span> <strong>2020,</strong> <em>7 </em>
                                    (5)
                                     , 1220-1228. <a href="https://doi.org/10.1039/C9QI01453E" title="DOI URL">https://doi.org/10.1039/C9QI01453E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QI01453E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QI01453E%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%2520Frontiers%26atitle%3DA%252Bclass%252Bof%252BPt%252528%252Biv%252B%252529%252Btriple-prodrugs%252Btargeting%252Bnucleic%252Bacids%25252C%252Bthymidylate%252Bsynthases%252Band%252Bhistone%252Bdeacetylases%26aulast%3DDing%26aufirst%3DXiao-Jing%26date%3D2020%26date%3D2020%26volume%3D7%26issue%3D5%26spage%3D1220%26epage%3D1228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Quan</span>, <span class="hlFld-ContribAuthor ">Zuantao  Lin</span>, <span class="hlFld-ContribAuthor ">Yuebin  Lin</span>, <span class="hlFld-ContribAuthor ">Yanchun  Wei</span>, <span class="hlFld-ContribAuthor ">Liu  Lei</span>, <span class="hlFld-ContribAuthor ">Yaxi  Li</span>, <span class="hlFld-ContribAuthor ">Gongjun  Tan</span>, <span class="hlFld-ContribAuthor ">Min  Xiao</span>, <span class="hlFld-ContribAuthor ">Tianfu  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Glucose-modification of cisplatin to facilitate cellular uptake, mitigate toxicity to normal cells, and improve anti-cancer effect in cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2020,</strong> <em>1203 </em>, 127361. <a href="https://doi.org/10.1016/j.molstruc.2019.127361" title="DOI URL">https://doi.org/10.1016/j.molstruc.2019.127361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2019.127361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2019.127361%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DGlucose-modification%252Bof%252Bcisplatin%252Bto%252Bfacilitate%252Bcellular%252Buptake%25252C%252Bmitigate%252Btoxicity%252Bto%252Bnormal%252Bcells%25252C%252Band%252Bimprove%252Banti-cancer%252Beffect%252Bin%252Bcancer%252Bcells%26aulast%3DQuan%26aufirst%3DLi%26date%3D2020%26volume%3D1203%26spage%3D127361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Behnaz  Hatamluyi</span>, <span class="hlFld-ContribAuthor ">Alireza  Hashemzadeh</span>, <span class="hlFld-ContribAuthor ">Majid  Darroudi</span>. </span><span class="cited-content_cbyCitation_article-title">A novel molecularly imprinted polymer decorated by <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="96d5c7d2e5d6ded4d8d8c5">[email protected]</a> nanocomposite and UiO-66-NH2 for ultra-selective electrochemical sensing of Oxaliplatin in biological samples. </span><span class="cited-content_cbyCitation_journal-name">Sensors and Actuators B: Chemical</span><span> <strong>2020,</strong> <em>307 </em>, 127614. <a href="https://doi.org/10.1016/j.snb.2019.127614" title="DOI URL">https://doi.org/10.1016/j.snb.2019.127614</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.snb.2019.127614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.snb.2019.127614%26sid%3Dliteratum%253Aachs%26jtitle%3DSensors%2520and%2520Actuators%2520B%253A%2520Chemical%26atitle%3DA%252Bnovel%252Bmolecularly%252Bimprinted%252Bpolymer%252Bdecorated%252Bby%252BCQDs%252540HBNNS%252Bnanocomposite%252Band%252BUiO-66-NH2%252Bfor%252Bultra-selective%252Belectrochemical%252Bsensing%252Bof%252BOxaliplatin%252Bin%252Bbiological%252Bsamples%26aulast%3DHatamluyi%26aufirst%3DBehnaz%26date%3D2020%26volume%3D307%26spage%3D127614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuren  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Wang</span>, <span class="hlFld-ContribAuthor ">Zijian  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design of anticancer platinum(IV) prodrugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 149-182. <a href="https://doi.org/10.1016/bs.adioch.2019.10.009" title="DOI URL">https://doi.org/10.1016/bs.adioch.2019.10.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.adioch.2019.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.adioch.2019.10.009%26sid%3Dliteratum%253Aachs%26atitle%3DRational%252Bdesign%252Bof%252Banticancer%252Bplatinum%252528IV%252529%252Bprodrugs%26aulast%3DZhang%26aufirst%3DShuren%26date%3D2020%26spage%3D149%26epage%3D182%26pub%3DElsevier%26atitle%3DMedicinal%252BChemistry%26date%3D2020%26volume%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carolina G.  Oliveira</span>, <span class="hlFld-ContribAuthor ">Isolda  Romero-Canelón</span>, <span class="hlFld-ContribAuthor ">Monize M.  Silva</span>, <span class="hlFld-ContribAuthor ">James P. C.  Coverdale</span>, <span class="hlFld-ContribAuthor ">Pedro Ivo S.  Maia</span>, <span class="hlFld-ContribAuthor ">Alzir A.  Batista</span>, <span class="hlFld-ContribAuthor ">Silvia  Castelli</span>, <span class="hlFld-ContribAuthor ">Alessandro  Desideri</span>, <span class="hlFld-ContribAuthor ">Peter J.  Sadler</span>, <span class="hlFld-ContribAuthor ">Victor M.  Deflon</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium(
              ii
              ) complexes with thiosemicarbazones derived from pyrene as topoisomerase IB inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2019,</strong> <em>48 </em>
                                    (44)
                                     , 16509-16517. <a href="https://doi.org/10.1039/C9DT02570G" title="DOI URL">https://doi.org/10.1039/C9DT02570G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9DT02570G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9DT02570G%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DPalladium%252528%252Bii%252B%252529%252Bcomplexes%252Bwith%252Bthiosemicarbazones%252Bderived%252Bfrom%252Bpyrene%252Bas%252Btopoisomerase%252BIB%252Binhibitors%26aulast%3DOliveira%26aufirst%3DCarolina%2BG.%26date%3D2019%26date%3D2019%26volume%3D48%26issue%3D44%26spage%3D16509%26epage%3D16517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fengfan  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Dong</span>, <span class="hlFld-ContribAuthor ">Qiwen  Shi</span>, <span class="hlFld-ContribAuthor ">Jianli  Chen</span>, <span class="hlFld-ContribAuthor ">Weike  Su</span>. </span><span class="cited-content_cbyCitation_article-title">Improving the anticancer activity of platinum(
              iv
              ) prodrugs using a dual-targeting strategy with a dichloroacetate axial ligand. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (39)
                                     , 22240-22247. <a href="https://doi.org/10.1039/C9RA03690C" title="DOI URL">https://doi.org/10.1039/C9RA03690C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA03690C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA03690C%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DImproving%252Bthe%252Banticancer%252Bactivity%252Bof%252Bplatinum%252528%252Biv%252B%252529%252Bprodrugs%252Busing%252Ba%252Bdual-targeting%252Bstrategy%252Bwith%252Ba%252Bdichloroacetate%252Baxial%252Bligand%26aulast%3DLiu%26aufirst%3DFengfan%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D39%26spage%3D22240%26epage%3D22247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia-Ying  Yu</span>, <span class="hlFld-ContribAuthor ">Xue-Qiang  Li</span>, <span class="hlFld-ContribAuthor ">Meng-Xue  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological activities of artemisinin-piperazine-dithiocarbamate derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>169 </em>, 21-28. <a href="https://doi.org/10.1016/j.ejmech.2019.02.071" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.071%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bactivities%252Bof%252Bartemisinin-piperazine-dithiocarbamate%252Bderivatives%26aulast%3DYu%26aufirst%3DJia-Ying%26date%3D2019%26volume%3D169%26spage%3D21%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aiman  Abu Ammar</span>, <span class="hlFld-ContribAuthor ">Abed  Nasereddin</span>, <span class="hlFld-ContribAuthor ">Suheir  Ereqat</span>, <span class="hlFld-ContribAuthor ">Mary  Dan-Goor</span>, <span class="hlFld-ContribAuthor ">Charles L.  Jaffe</span>, <span class="hlFld-ContribAuthor ">Eyal  Zussman</span>, <span class="hlFld-ContribAuthor ">Ziad  Abdeen</span>. </span><span class="cited-content_cbyCitation_article-title">Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis. </span><span class="cited-content_cbyCitation_journal-name">Drug Delivery and Translational Research</span><span> <strong>2019,</strong> <em>9 </em>
                                    (1)
                                     , 76-84. <a href="https://doi.org/10.1007/s13346-018-00603-0" title="DOI URL">https://doi.org/10.1007/s13346-018-00603-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13346-018-00603-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13346-018-00603-0%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Delivery%2520and%2520Translational%2520Research%26atitle%3DAmphotericin%252BB-loaded%252Bnanoparticles%252Bfor%252Blocal%252Btreatment%252Bof%252Bcutaneous%252Bleishmaniasis%26aulast%3DAbu%2BAmmar%26aufirst%3DAiman%26date%3D2019%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D76%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Li</span>, <span class="hlFld-ContribAuthor ">Binbin  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">The cytotoxicity activity of Hohenbuehelia serotina polyphenols on HeLa cells via induction of cell apoptosis and cell cycle arrest. </span><span class="cited-content_cbyCitation_journal-name">Food and Chemical Toxicology</span><span> <strong>2019,</strong> <em>124 </em>, 239-248. <a href="https://doi.org/10.1016/j.fct.2018.12.001" title="DOI URL">https://doi.org/10.1016/j.fct.2018.12.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.fct.2018.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.fct.2018.12.001%26sid%3Dliteratum%253Aachs%26jtitle%3DFood%2520and%2520Chemical%2520Toxicology%26atitle%3DThe%252Bcytotoxicity%252Bactivity%252Bof%252BHohenbuehelia%252Bserotina%252Bpolyphenols%252Bon%252BHeLa%252Bcells%252Bvia%252Binduction%252Bof%252Bcell%252Bapoptosis%252Band%252Bcell%252Bcycle%252Barrest%26aulast%3DWang%26aufirst%3DLu%26date%3D2019%26volume%3D124%26spage%3D239%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E.  Gabano</span>, <span class="hlFld-ContribAuthor ">M.  Ravera</span>, <span class="hlFld-ContribAuthor ">E.  Perin</span>, <span class="hlFld-ContribAuthor ">I.  Zanellato</span>, <span class="hlFld-ContribAuthor ">B.  Rangone</span>, <span class="hlFld-ContribAuthor ">M. J.  McGlinchey</span>, <span class="hlFld-ContribAuthor ">D.  Osella</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and characterization of cyclohexane-1
              R
              ,2
              R
              -diamine-based Pt(
              iv
              ) dicarboxylato anticancer prodrugs: their selective activity against human colon cancer cell lines. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2019,</strong> <em>48 </em>
                                    (2)
                                     , 435-445. <a href="https://doi.org/10.1039/C8DT03950J" title="DOI URL">https://doi.org/10.1039/C8DT03950J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8DT03950J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8DT03950J%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DSynthesis%252Band%252Bcharacterization%252Bof%252Bcyclohexane-1%252BR%252B%25252C2%252BR%252B-diamine-based%252BPt%252528%252Biv%252B%252529%252Bdicarboxylato%252Banticancer%252Bprodrugs%25253A%252Btheir%252Bselective%252Bactivity%252Bagainst%252Bhuman%252Bcolon%252Bcancer%252Bcell%252Blines%26aulast%3DGabano%26aufirst%3DE.%26date%3D2019%26date%3D2019%26volume%3D48%26issue%3D2%26spage%3D435%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dariusz  Śmiłowicz</span>, <span class="hlFld-ContribAuthor ">Nils  Metzler-Nolte</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of monofunctional platinum(
              iv
              ) carboxylate precursors for use in Pt(
              iv
              )–peptide bioconjugates. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2018,</strong> <em>47 </em>
                                    (43)
                                     , 15465-15476. <a href="https://doi.org/10.1039/C8DT03082K" title="DOI URL">https://doi.org/10.1039/C8DT03082K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8DT03082K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8DT03082K%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DSynthesis%252Bof%252Bmonofunctional%252Bplatinum%252528%252Biv%252B%252529%252Bcarboxylate%252Bprecursors%252Bfor%252Buse%252Bin%252BPt%252528%252Biv%252B%252529%2525E2%252580%252593peptide%252Bbioconjugates%26aulast%3D%25C5%259Ami%25C5%2582owicz%26aufirst%3DDariusz%26date%3D2018%26date%3D2018%26volume%3D47%26issue%3D43%26spage%3D15465%26epage%3D15476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhong-Ying  Ma</span>, <span class="hlFld-ContribAuthor ">Dong-Bo  Wang</span>, <span class="hlFld-ContribAuthor ">Xue-Qing  Song</span>, <span class="hlFld-ContribAuthor ">Yi-Gang  Wu</span>, <span class="hlFld-ContribAuthor ">Qian  Chen</span>, <span class="hlFld-ContribAuthor ">Chun-Lai  Zhao</span>, <span class="hlFld-ContribAuthor ">Jing-Yi  Li</span>, <span class="hlFld-ContribAuthor ">Shi-Hao  Cheng</span>, <span class="hlFld-ContribAuthor ">Jing-Yuan  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 1292-1299. <a href="https://doi.org/10.1016/j.ejmech.2018.08.065" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.08.065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.08.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.08.065%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChlorambucil-conjugated%252Bplatinum%252528IV%252529%252Bprodrugs%252Bto%252Btreat%252Btriple-negative%252Bbreast%252Bcancer%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%26aulast%3DMa%26aufirst%3DZhong-Ying%26date%3D2018%26volume%3D157%26spage%3D1292%26epage%3D1299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linxiang  Cai</span>, <span class="hlFld-ContribAuthor ">Congtao  Yu</span>, <span class="hlFld-ContribAuthor ">Linkui  Ba</span>, <span class="hlFld-ContribAuthor ">Qinghua  Liu</span>, <span class="hlFld-ContribAuthor ">Yunxu  Qian</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Chuanzhu  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer platinum-based complexes with non-classical structures. </span><span class="cited-content_cbyCitation_journal-name">Applied Organometallic Chemistry</span><span> <strong>2018,</strong> <em>32 </em>
                                    (4)
                                     , e4228. <a href="https://doi.org/10.1002/aoc.4228" title="DOI URL">https://doi.org/10.1002/aoc.4228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/aoc.4228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Faoc.4228%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Organometallic%2520Chemistry%26atitle%3DAnticancer%252Bplatinum-based%252Bcomplexes%252Bwith%252Bnon-classical%252Bstructures%26aulast%3DCai%26aufirst%3DLinxiang%26date%3D2018%26date%3D2018%26volume%3D32%26issue%3D4%26spage%3De4228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jae Sik  Yu</span>, <span class="hlFld-ContribAuthor ">Dahae  Lee</span>, <span class="hlFld-ContribAuthor ">Seoung Rak  Lee</span>, <span class="hlFld-ContribAuthor ">Jae Wook  Lee</span>, <span class="hlFld-ContribAuthor ">Chang-Ik  Choi</span>, <span class="hlFld-ContribAuthor ">Tae Su  Jang</span>, <span class="hlFld-ContribAuthor ">Ki Sung  Kang</span>, <span class="hlFld-ContribAuthor ">Ki Hyun  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical characterization of cytotoxic indole acetic acid derivative from mulberry fruit ( Morus alba L.) against human cervical cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>76 </em>, 28-36. <a href="https://doi.org/10.1016/j.bioorg.2017.10.015" title="DOI URL">https://doi.org/10.1016/j.bioorg.2017.10.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2017.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2017.10.015%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DChemical%252Bcharacterization%252Bof%252Bcytotoxic%252Bindole%252Bacetic%252Bacid%252Bderivative%252Bfrom%252Bmulberry%252Bfruit%252B%252528%252BMorus%252Balba%252BL.%252529%252Bagainst%252Bhuman%252Bcervical%252Bcancer%26aulast%3DYu%26aufirst%3DJae%2BSik%26date%3D2018%26volume%3D76%26spage%3D28%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linkui  Bai</span>, <span class="hlFld-ContribAuthor ">Chuanzhu  Gao</span>, <span class="hlFld-ContribAuthor ">Qinghua  Liu</span>, <span class="hlFld-ContribAuthor ">Congtao  Yu</span>, <span class="hlFld-ContribAuthor ">Zhuxin  Zhang</span>, <span class="hlFld-ContribAuthor ">Linxiang  Cai</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Yunxu  Qian</span>, <span class="hlFld-ContribAuthor ">Jian  Yang</span>, <span class="hlFld-ContribAuthor ">Xiali  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Research progress in modern structure of platinum complexes. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>140 </em>, 349-382. <a href="https://doi.org/10.1016/j.ejmech.2017.09.034" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.034%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DResearch%252Bprogress%252Bin%252Bmodern%252Bstructure%252Bof%252Bplatinum%252Bcomplexes%26aulast%3DBai%26aufirst%3DLinkui%26date%3D2017%26volume%3D140%26spage%3D349%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Structure of OXA and Lipophilic Pt(IV) Compound <b>1</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Morphological evaluation of <b>2</b>: (A) SEM secondary electron image. (B) SEM backscattered electron image. (C,D) TEM micrographs of uranyl acetate negatively stained NPs at different areas of the grid, scale bar = 200 nm. (E,F) Two and three-dimensional AFM images of NPs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Platinum accumulation in whole cells following incubation with 35 μM of OXA, <b>1</b>, and <b>2</b> following a 24 h exposure to SKOV-3 cells as measured by ICP-MS. Values are the means ± SD obtained from three independent experiments. Statistical analysis revealed that the observed difference in platinum accumulation values was significant (<i>p</i> < 0.01, one-way ANOVA). (B) The extent of DNA platination following 24 h exposure to SKOV-3 cells as measured by ICP-MS. Values are mean ± SD obtained from seven independent experiments. Statistical analysis revealed that the observed difference in DNA platination values was significant (<i>p</i> < 0.01, one-way ANOVA). (C) Cellular distribution of Pt compounds in different fractions. The amount of Pt per 5.0 × 10<sup>4</sup> cells in cell membrane, cytosol, nucleus, and cytoskeleton fractions. Cells were exposed to 35 μM of Pt compounds for 24 h. Values are means ± SD. Nuclear fraction described by the manufacturer as follows: total nucleus soluble proteins, including the nuclear membrane proteins. Cytosol fraction: total cellular soluble proteins from cytoplasm. Membrane/particulate: total cellular membrane proteins including cellular organelles and organelle membrane proteins (excluding the nuclear membrane proteins). Cytoskeletal fraction: total cellular insoluble proteins, genomic DNA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Intracellular uptake of NPs visualized by CLSM. (A) Intracellular uptake of PE lissamine rhodamine B-loaded NPs (red) by SKOV-3 cells was evaluated following 0–60 min incubation with two formulation dilutions, 1:100 and 1:200; nuclei were stained with DAPI (blue). (B) <i>Z</i>-stack confocal imaging of SKOV-3 cells incubated with PE lissamine rhodamine B-loaded NPs (red) for 6 h (dilution 1:100).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Efficacy study. (A) Longitudinal detection and quantification of SKOV3-luc-D3 ovarian tumor growth in live mice by the bioluminescent luciferase imaging assay using a CCCD camera. Tumor size is designated by the total luminescence intensity of the dorsal and ventral images, expressed in radiance units (photons/(s·cm<sup>2</sup>·sr)). Arrows indicate the treatment schedules on the 30th, 37th, 45th, and 52nd day. Results are presented as mean ± SE. Statistical analysis revealed that the observed differences at days 62 and 72 were significant (<i>p</i> < 0.01, one-way ANOVA). Post hoc analysis showed that there are significant differences between the control group and <b>1</b> and <b>2</b> treatment groups [<i>p</i> < 0.01, Dunnett test (2-sided)]. (B) Body weight follow-up beginning from tumor inoculation (day 0) through the study period. Changes were recorded as a percentage of the initial body weight observed on the day of tumor cells injection (100% at day 0). Results are presented as mean ± SD. (C) Kaplan–Meier survival curve from day of tumor cell injection until death. Death was recorded once animals fulfilled predetermined euthanasia criteria. ****<i>p</i> < 0.0001. The study was terminated on the 93rd day. (D) Representative ventral images of mice taken on weeks 4, 7, 9, and 10 following tumor inoculation are given.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/medium/jm-2016-00955j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Efficacy study. (A) Longitudinal detection and quantification of HCT 116–luc2 colon tumor growth in live mice by the bioluminescent luciferase imaging assay using a CCCD camera. Tumor size is designated by the luminescence intensity of the dorsal images, expressed in radiance units (photons/(s·cm<sup>2</sup>·sr)). Results are presented as mean ± SE. Statistical analysis revealed that the observed differences in radiance values on the 33rd day were significant (<i>p</i> < 0.01, one-way ANOVA). Post hoc analysis showed significant differences between <b>1</b>, <b>2</b>, and control on the 33rd day [<i>p</i> < 0.01, Dunnett test (2-sided)], whereas there was no significant difference between OXA and control. (B) Body weight follow-up beginning from tumor inoculation (day 0) through the study period. Changes were recorded as a percentage of the initial body weight observed on the day of tumor cell injection (100% at day 0). Results are presented as mean ± SD. (C) Kaplan–Meier survival curve from tumor cell injection day until death. Death was recorded once animals fulfilled predetermined euthanasia criteria. ****<i>p</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00955/20161007/images/large/jm-2016-00955j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00955&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10863" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10863" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 55 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Akbarzadeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikaeili, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarghami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barkhordari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davaran, S.</span><span> </span><span class="NLM_article-title">Preparation and in vitro evaluation of doxorubicin-loaded Fe(3)O(4) magnetic nanoparticles modified with biocompatible copolymers</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.2147/IJN.S24326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.2147%2FIJN.S24326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22334781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFaktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=511-526&author=A.+Akbarzadehauthor=H.+Mikaeiliauthor=N.+Zarghamiauthor=R.+Mohammadauthor=A.+Barkhordariauthor=S.+Davaran&title=Preparation+and+in+vitro+evaluation+of+doxorubicin-loaded+Fe%283%29O%284%29+magnetic+nanoparticles+modified+with+biocompatible+copolymers&doi=10.2147%2FIJN.S24326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers</span></div><div class="casAuthors">Akbarzadeh, Abolfazl; Mikaeili, Haleh; Zarghami, Nosratollah; Mohammad, Rahmati; Barkhordari, Amin; Davaran, Soodabeh</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">511-526</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Superparamagnetic iron oxide nanoparticles are attractive materials that have been widely used in medicine for drug delivery, diagnostic imaging, and therapeutic applications.  In our study, superparamagnetic iron oxide nanoparticles and the anticancer drug, doxorubicin hydrochloride, were encapsulated into poly (, -lactic-co-glycolic acid) poly (ethylene glycol) (PLGA-PEG) nanoparticles for local treatment.  The magnetic properties conferred by superparamagnetic iron oxide nanoparticles could help to maintain the nanoparticles in the joint with an external magnet.  Methods: A series of PLGA:PEG triblock copolymers were synthesized by ring-opening polymn. of , -lactide and glycolide with different mol. wts. of polyethylene glycol (PEG2000, PEG3000, and PEG4000) as an initiator.  The bulk properties of these copolymers were characterized using 1H NMR spectroscopy, gel permeation chromatog., Fourier transform IR spectroscopy, and differential scanning calorimetry.  In addn., the resulting particles were characterized by x-ray powder diffraction, SEM, and vibrating sample magnetometry.  Results: The doxorubicin encapsulation amt. was reduced for PLGA:PEG2000 and PLGA:PEG3000 triblock copolymers, but increased to a great extent for PLGA:PEG4000 triblock copolymer.  This is due to the increased water uptake capacity of the blended triblock copolymer, which encapsulated more doxorubicin mols. into a swollen copolymer matrix.  The drug encapsulation efficiency achieved for Fe3O4 magnetic nanoparticles modified with PLGA:PEG2000, PLGA:PEG3000, and PLGA:PEG4000 copolymers was 69.5%, 73%, and 78%, resp., and the release kinetics were controlled.  The in vitro cytotoxicity test showed that the Fe3O4-PLGA:PEG4000 magnetic nanoparticles had no cytotoxicity and were biocompatible.  Conclusion: There is potential for use of these nanoparticles for biomedical application.  Future work includes in vivo investigation of the targeting capability and effectiveness of these nanoparticles in the treatment of lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3e9SazMqoY7Vg90H21EOLACvtfcHk0lhpr9RFtQ-ddA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFaktr0%253D&md5=a530d4c7524e94d8c750bd5b112504d3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2147%2FIJN.S24326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S24326%26sid%3Dliteratum%253Aachs%26aulast%3DAkbarzadeh%26aufirst%3DA.%26aulast%3DMikaeili%26aufirst%3DH.%26aulast%3DZarghami%26aufirst%3DN.%26aulast%3DMohammad%26aufirst%3DR.%26aulast%3DBarkhordari%26aufirst%3DA.%26aulast%3DDavaran%26aufirst%3DS.%26atitle%3DPreparation%2520and%2520in%2520vitro%2520evaluation%2520of%2520doxorubicin-loaded%2520Fe%25283%2529O%25284%2529%2520magnetic%2520nanoparticles%2520modified%2520with%2520biocompatible%2520copolymers%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2012%26volume%3D7%26spage%3D511%26epage%3D526%26doi%3D10.2147%2FIJN.S24326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Oberoi, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukolova, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabanov, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronich, T. K.</span><span> </span><span class="NLM_article-title">Nanocarriers for delivery of platinum anticancer drugs</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1667</span><span class="NLM_x">–</span> <span class="NLM_lpage">1685</span><span class="refDoi"> DOI: 10.1016/j.addr.2013.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.addr.2013.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=24113520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWmurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1667-1685&author=H.+S.+Oberoiauthor=N.+V.+Nukolovaauthor=A.+V.+Kabanovauthor=T.+K.+Bronich&title=Nanocarriers+for+delivery+of+platinum+anticancer+drugs&doi=10.1016%2Fj.addr.2013.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarriers for delivery of platinum anticancer drugs</span></div><div class="casAuthors">Oberoi, Hardeep S.; Nukolova, Natalia V.; Kabanov, Alexander V.; Bronich, Tatiana K.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">1667-1685</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clin. use esp. for management of tumors of the ovary, testes, and the head and neck.  However, several dose limiting toxicities assocd. with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life.  These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy.  Nanocarrier-based delivery of platinum compds. is one such area of intense research effort beginning to provide encouraging preclin. and clin. results and may allow the development of the next generation of platinum chemotherapy.  This review highlights current understanding on the pharmacol. and limitations of platinum compds. in clin. use, and provides a comprehensive anal. of various platinum-polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9t-JIgD2CMrVg90H21EOLACvtfcHk0lhpr9RFtQ-ddA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWmurbO&md5=25ea0f4f9f5f2712c294c8f37bb541ce</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2013.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2013.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DOberoi%26aufirst%3DH.%2BS.%26aulast%3DNukolova%26aufirst%3DN.%2BV.%26aulast%3DKabanov%26aufirst%3DA.%2BV.%26aulast%3DBronich%26aufirst%3DT.%2BK.%26atitle%3DNanocarriers%2520for%2520delivery%2520of%2520platinum%2520anticancer%2520drugs%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1667%26epage%3D1685%26doi%3D10.1016%2Fj.addr.2013.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Kelland, L.</span><span> </span><span class="NLM_article-title">The resurgence of platinum-based cancer chemotherapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">584</span><span class="refDoi"> DOI: 10.1038/nrc2167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1038%2Fnrc2167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=17625587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=573-584&author=L.+Kelland&title=The+resurgence+of+platinum-based+cancer+chemotherapy&doi=10.1038%2Fnrc2167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of platinum-based cancer chemotherapy</span></div><div class="casAuthors">Kelland, Lloyd</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-584</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The accidental discovery of the anticancer properties of cisplatin and its clin. introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.  Although carboplatin - a second-generation analog that is safer but shows a similar spectrum of activity to cisplatin - was introduced in the 1980s, the pace of further improvements slowed for many years.  However, in the past several years interest in platinum drugs has increased.  Key developments include the elucidation of mechanisms of tumor resistance to these drugs, the introduction of new platinum-based agents (oxaliplatin, satraplatin and picoplatin), and clin. combination studies using platinum drugs with resistance modulators or new molecularly targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTEI4HRCjxQrVg90H21EOLACvtfcHk0lhpr9RFtQ-ddA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D&md5=9d55f600a83a19d7836a2524de20efbf</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2167%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%26atitle%3DThe%2520resurgence%2520of%2520platinum-based%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D573%26epage%3D584%26doi%3D10.1038%2Fnrc2167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">Basis for design and development of platinum(IV) anticancer complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">3403</span><span class="NLM_x">–</span> <span class="NLM_lpage">3411</span><span class="refDoi"> DOI: 10.1021/jm070280u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070280u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvFKqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3403-3411&author=M.+D.+Hallauthor=H.+R.+Mellorauthor=R.+Callaghanauthor=T.+W.+Hambley&title=Basis+for+design+and+development+of+platinum%28IV%29+anticancer+complexes&doi=10.1021%2Fjm070280u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Basis for Design and Development of Platinum(IV) Anticancer Complexes</span></div><div class="casAuthors">Hall, Matthew D.; Mellor, Howard R.; Callaghan, Richard; Hambley, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3403-3411</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Recent advances in design and development of anticancer Platinum(IV) Complexes are discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrST9_M1CnGgbVg90H21EOLACvtfcHk0lgGNIQDcOQj4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvFKqsLg%253D&md5=aaccf47b20d49d299f871846824cb61e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm070280u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070280u%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DMellor%26aufirst%3DH.%2BR.%26aulast%3DCallaghan%26aufirst%3DR.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DBasis%2520for%2520design%2520and%2520development%2520of%2520platinum%2528IV%2529%2520anticancer%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D3403%26epage%3D3411%26doi%3D10.1021%2Fjm070280u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Reithofer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bytzek, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valiahdi, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowol, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartinger, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakupec, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span> </span><span class="NLM_article-title">Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes</span> <span class="citation_source-journal">J. Inorg. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/j.jinorgbio.2010.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.jinorgbio.2010.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=21134601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFahsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=46-51&author=M.+R.+Reithoferauthor=A.+K.+Bytzekauthor=S.+M.+Valiahdiauthor=C.+R.+Kowolauthor=M.+Groesslauthor=C.+G.+Hartingerauthor=M.+A.+Jakupecauthor=M.+Galanskiauthor=B.+K.+Keppler&title=Tuning+of+lipophilicity+and+cytotoxic+potency+by+structural+variation+of+anticancer+platinum%28IV%29+complexes&doi=10.1016%2Fj.jinorgbio.2010.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes</span></div><div class="casAuthors">Reithofer, Michael R.; Bytzek, Anna K.; Valiahdi, Seied M.; Kowol, Christian R.; Groessl, Michael; Hartinger, Christian G.; Jakupec, Michael A.; Galanski, Markus; Keppler, Bernhard K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-51</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A series of bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) compds. with IC50 values ranging between 142 μM and 18 nM was investigated with respect to their lipophilicity (by the shake flask method as well as microemulsion electrokinetic chromatog.), redn. potential, as well as their cellular accumulation in cancer cells in vitro.  In general, the antiproliferative properties of the complexes correlated with their lipophilicity as well as their accumulation, whereas differences in antiproliferative potency could not be explained by redn. potentials since they do not vary significantly within the investigated series of compds.  Only minor effects for complexes featuring polar end groups were detected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbNpB_Ezgos7Vg90H21EOLACvtfcHk0lgGNIQDcOQj4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFahsrrI&md5=e3f3e1d4fc69d5f051b39ef9b7b255c7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2010.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2010.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DReithofer%26aufirst%3DM.%2BR.%26aulast%3DBytzek%26aufirst%3DA.%2BK.%26aulast%3DValiahdi%26aufirst%3DS.%2BM.%26aulast%3DKowol%26aufirst%3DC.%2BR.%26aulast%3DGroessl%26aufirst%3DM.%26aulast%3DHartinger%26aufirst%3DC.%2BG.%26aulast%3DJakupec%26aufirst%3DM.%2BA.%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26atitle%3DTuning%2520of%2520lipophilicity%2520and%2520cytotoxic%2520potency%2520by%2520structural%2520variation%2520of%2520anticancer%2520platinum%2528IV%2529%2520complexes%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2011%26volume%3D105%26spage%3D46%26epage%3D51%26doi%3D10.1016%2Fj.jinorgbio.2010.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Giandomenico, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murrer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollano, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rheinheimer, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyer, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossard, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J. D.</span><span> </span><span class="NLM_article-title">Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entr.acte.ee into orally active platinum(IV) antitumor agents</span> <span class="citation_source-journal">Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1021/ic00109a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic00109a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1995&pages=1015-1021&author=C.+M.+Giandomenicoauthor=M.+J.+Abramsauthor=B.+A.+Murrerauthor=J.+F.+Vollanoauthor=M.+I.+Rheinheimerauthor=S.+B.+Wyerauthor=G.+E.+Bossardauthor=J.+D.+Higgins&title=Carboxylation+of+kinetically+inert+platinum%28IV%29+hydroxy+complexes.+An+entr.acte.ee+into+orally+active+platinum%28IV%29+antitumor+agents&doi=10.1021%2Fic00109a004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fic00109a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic00109a004%26sid%3Dliteratum%253Aachs%26aulast%3DGiandomenico%26aufirst%3DC.%2BM.%26aulast%3DAbrams%26aufirst%3DM.%2BJ.%26aulast%3DMurrer%26aufirst%3DB.%2BA.%26aulast%3DVollano%26aufirst%3DJ.%2BF.%26aulast%3DRheinheimer%26aufirst%3DM.%2BI.%26aulast%3DWyer%26aufirst%3DS.%2BB.%26aulast%3DBossard%26aufirst%3DG.%2BE.%26aulast%3DHiggins%26aufirst%3DJ.%2BD.%26atitle%3DCarboxylation%2520of%2520kinetically%2520inert%2520platinum%2528IV%2529%2520hydroxy%2520complexes.%2520An%2520entr.acte.ee%2520into%2520orally%2520active%2520platinum%2528IV%2529%2520antitumor%2520agents%26jtitle%3DInorg.%2520Chem.%26date%3D1995%26volume%3D34%26spage%3D1015%26epage%3D1021%26doi%3D10.1021%2Fic00109a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Galanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span> </span><span class="NLM_article-title">Carboxylation of dihydroxoplatinum(IV) complexes via a new synthetic pathway</span> <span class="citation_source-journal">Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1709</span><span class="NLM_x">–</span> <span class="NLM_lpage">1711</span><span class="refDoi"> DOI: 10.1021/ic9509490</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic9509490" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1996&pages=1709-1711&author=M.+Galanskiauthor=B.+K.+Keppler&title=Carboxylation+of+dihydroxoplatinum%28IV%29+complexes+via+a+new+synthetic+pathway&doi=10.1021%2Fic9509490"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fic9509490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic9509490%26sid%3Dliteratum%253Aachs%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26atitle%3DCarboxylation%2520of%2520dihydroxoplatinum%2528IV%2529%2520complexes%2520via%2520a%2520new%2520synthetic%2520pathway%26jtitle%3DInorg.%2520Chem.%26date%3D1996%26volume%3D35%26spage%3D1709%26epage%3D1711%26doi%3D10.1021%2Fic9509490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Gibson, D.</span><span> </span><span class="NLM_article-title">The mechanism of action of platinum anticancer agents--what do we really know about it?</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">10681</span><span class="NLM_x">–</span> <span class="NLM_lpage">10689</span><span class="refDoi"> DOI: 10.1039/b918871c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1039%2Fb918871c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=10681-10689&author=D.+Gibson&title=The+mechanism+of+action+of+platinum+anticancer+agents%2D%2Dwhat+do+we+really+know+about+it%3F&doi=10.1039%2Fb918871c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1039%2Fb918871c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb918871c%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520platinum%2520anticancer%2520agents--what%2520do%2520we%2520really%2520know%2520about%2520it%253F%26jtitle%3DDalton%2520Trans.%26date%3D2009%26volume%3D48%26spage%3D10681%26epage%3D10689%26doi%3D10.1039%2Fb918871c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Loh, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrap, K. R.</span><span> </span><span class="NLM_article-title">Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1109</span><span class="NLM_x">–</span> <span class="NLM_lpage">1115</span><span class="refDoi"> DOI: 10.1038/bjc.1992.419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1038%2Fbjc.1992.419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1457352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADyaK3sXhtl2gu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1992&pages=1109-1115&author=S.+Y.+Lohauthor=P.+Mistryauthor=L.+R.+Kellandauthor=G.+Abelauthor=K.+R.+Harrap&title=Reduced+drug+accumulation+as+a+major+mechanism+of+acquired+resistance+to+cisplatin+in+a+human+ovarian+carcinoma+cell+line%3A+circumvention+studies+using+novel+platinum+%28II%29+and+%28IV%29+ammine%2Famine+complexes&doi=10.1038%2Fbjc.1992.419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line:  circumvention studies using novel platinum (II) and (IV) ammine/amine complexes</span></div><div class="casAuthors">Loh, S. Y.; Mistry, P.; Kelland, L. R.; Abel, G.; Harrap, K. R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1109-15</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">Acquired resistance to cisplatin (cis-diamminedichloroplatinum (II)) has been generated in vitro in the 41M human ovarian carcinoma cell line, established from a previously untreated patient.  Three cisplatin-resistant variants were selected at approx. 2, 4 and 6-fold resistance (in terms of 50% inhibitory concns.), in order to study the underlying mechanisms of acquired cisplatin resistance.  Compared to the parent line, platinum accumulation following exposure to equimolar concns. of cisplatin was on av. (across the entire concn. range) 2.9, 3.6 and 4.8-fold lower in the 41McsiR2, 41McisR4 and 41 McisR6 cell lines, resp.  Thus the difference in uptake corresponded closely with their resistance factor in the three resistant variants.  Moreover, a significant redn. in platinum accumulation was obsd. as early as 5 min after exposure to cisplatin in the 41M vs 41McisR6 cell lines.  Platinum accumulation was similar in all cell lines following exposure to equitoxic concns. (2 h IC50) of cisplatin.  Enhanced efflux of drug was not obsd. between the 41M and 41McisR6 cells.  In addn., there was no difference in intracellular glutathione (GSH) levels.  Our previous studies have shown no indication of metallothionein involvement and the decrease in cisplatin uptake in the 41McisR6 cells was reflected by a similar redn. in DNA interstrand cross-links (ISC) formation.  These results suggest that the mechanism of acquired resistance to cisplatin in the 41McisR6 cell line may be predominantly due to reduced drug uptake.  The 41McisR6 cells were not found to be cross-resistant to ouabain, a postulated specific inhibitor of sodium-potassium ATPase (Na+,K+-ATPase), suggesting that decreased cisplatin accumulation in these cells is probably not regulated by alterations in their Na+,K+-ATPase levels, and Na+ potential across the plasma membrane.  Cellular accumulation of a novel class of platinum (IV) ammine/cyclohexylamine dicarboxylates, which exhibit enhanced cytotoxicity over cisplatin and completely circumvent resistance to cisplatin in the 41McisR line, was also examd.  The data suggests that increased accumulation of these compds., as a result of their enhanced lipophilicity, could account for the dramatic increase in their potency over cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqmtI4v6PUS7Vg90H21EOLACvtfcHk0lhVZ-QihdkbDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtl2gu7Y%253D&md5=61bef5971f3ec0b9dfb116b4bb6e5a3f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1992.419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1992.419%26sid%3Dliteratum%253Aachs%26aulast%3DLoh%26aufirst%3DS.%2BY.%26aulast%3DMistry%26aufirst%3DP.%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DAbel%26aufirst%3DG.%26aulast%3DHarrap%26aufirst%3DK.%2BR.%26atitle%3DReduced%2520drug%2520accumulation%2520as%2520a%2520major%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520cisplatin%2520in%2520a%2520human%2520ovarian%2520carcinoma%2520cell%2520line%253A%2520circumvention%2520studies%2520using%2520novel%2520platinum%2520%2528II%2529%2520and%2520%2528IV%2529%2520ammine%252Famine%2520complexes%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1992%26volume%3D66%26spage%3D1109%26epage%3D1115%26doi%3D10.1038%2Fbjc.1992.419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Moeller, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kangarloo, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puscasu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, J. E.</span><span> </span><span class="NLM_article-title">Rational design of platinum chemotherapeutic drugs: hydrophobicity increases cytotoxicity</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4435</span><span class="NLM_x">–</span> <span class="NLM_lpage">4439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=11205284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVejsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=4435-4439&author=N.+Moellerauthor=B.+S.+Kangarlooauthor=I.+Puscasuauthor=C.+Mockauthor=B.+Krebsauthor=J.+E.+Wolff&title=Rational+design+of+platinum+chemotherapeutic+drugs%3A+hydrophobicity+increases+cytotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of platinum chemotherapeutic drugs: hydrophobicity increases cytotoxicity</span></div><div class="casAuthors">Moeller, Niclas; Kangarloo, Bill S.; Puscasu, Ina; Mock, Christian; Krebs, Bernt; Wolff, Johannes E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6B</span>),
    <span class="NLM_cas:pages">4435-4439</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: Malignant glioma are often resistant to cisplatin.  Numerous chem. modifications have been made to overcome this limitation.  Analyzing such novel compds., we previously hypothesized, that hydrophobicity improves the cytotoxicity of NH3 substituted platinum agents.  Materials and Methods: Testing this hypothesis, we synthesized further eight novel platinum agents, substituting the NH3 groups with various pyridyl ring systems.  The cytotoxicity was measured in MTT tests using the cisplatin resistant human U25 1 malignant glioma cell line as a model.  Soly. was measured in water using flameless at. absorption spectroscopy.  Results: Cytotoxicity correlated significantly with low water soly.  The relation of cells surviving 72-h of 1 OuM drug exposure was best described by a logarithmic formula: Surviving cells (% of control) = 6.4+38.4 log (water soly. in mg Pt/L) Adding an oxime group to the arom. substitute decreased cytotoxicity.  Conclusions: These data confirmed that increased hydophobicity increases cytotoxicity in this group.  This might be caused by better cellular penetration, or by shielding of DNA-adducts from repair processes.  The data created a further hypothesis: A pos. mesomeric effect as characteristic for the oxime-group might decrease DNA binding, a neg. mesomeric might improve it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQCdtstlb6zLVg90H21EOLACvtfcHk0lhVZ-QihdkbDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVejsLw%253D&md5=03f6935db832d62c6d76cf41a1b78714</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoeller%26aufirst%3DN.%26aulast%3DKangarloo%26aufirst%3DB.%2BS.%26aulast%3DPuscasu%26aufirst%3DI.%26aulast%3DMock%26aufirst%3DC.%26aulast%3DKrebs%26aufirst%3DB.%26aulast%3DWolff%26aufirst%3DJ.%2BE.%26atitle%3DRational%2520design%2520of%2520platinum%2520chemotherapeutic%2520drugs%253A%2520hydrophobicity%2520increases%2520cytotoxicity%26jtitle%3DAnticancer%2520Res.%26date%3D2000%26volume%3D20%26spage%3D4435%26epage%3D4439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Tallen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangopadhyay, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kangarloo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, J. E.</span><span> </span><span class="NLM_article-title">Overcoming cisplatin resistance: design of novel hydrophobic platinum compounds</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">–</span> <span class="NLM_lpage">449</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10769694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisl2ntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=445-449&author=G.+Tallenauthor=C.+Mockauthor=S.+B.+Gangopadhyayauthor=B.+Kangarlooauthor=B.+Krebsauthor=J.+E.+Wolff&title=Overcoming+cisplatin+resistance%3A+design+of+novel+hydrophobic+platinum+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming cisplatin resistance: design of novel hydrophobic platinum compounds</span></div><div class="casAuthors">Tallen, G.; Mock, C.; Gangopadhyay, S. B.; Kangarloo, B.; Krebs, B.; Wolff, J. E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1A</span>),
    <span class="NLM_cas:pages">445-449</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">The anticancer activity of cisplatin derives from its ability to crosslink DNA.  Cisplatin-resistance is partially caused by enhanced nucleotide excision repair (NER).  Major 1,2-intrastrand crosslinks can create a hydrophobic notch at the damage site, which can be specifically bound by damage-recognition proteins, thus shielded from NER-activity.  We aimed at preventing resistance by enhancing this mechanism using more hydrophobic platinum compds.  We synthesized three platinum analogs with increased hydrophobic characteristics.  Performing MTT-assays, the efficacy of cisplatin and the novel agents was compared in a fibroblast and eight brain tumor cell lines.  Among the novel compds., the most hydrophobic mol., methylpyridineplatinum, was most cytotoxic (LC50= 5.84 × 10-5M), followed by methylpyrazineplatinum, the second most hydrophobic (LC50=1.79 × 10-4M), and pyridineplatinum (LC50=2.76 × 10-4M).  Overall, cisplatin revealed highest cytotoxicity (LC50=8.77 × 10-6M).  Comparison of the novel compds. supports the hypothesis that increased hydrophobicity contributes to higher antitumor-activity.  Other advantageous characteristics of cisplatin might relate to its remaining highest efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpbybyZKhxQbVg90H21EOLACvtfcHk0lj_k9nTvvVTaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisl2ntLs%253D&md5=e1c9432f315e457a823c7dcbf9f15a0f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTallen%26aufirst%3DG.%26aulast%3DMock%26aufirst%3DC.%26aulast%3DGangopadhyay%26aufirst%3DS.%2BB.%26aulast%3DKangarloo%26aufirst%3DB.%26aulast%3DKrebs%26aufirst%3DB.%26aulast%3DWolff%26aufirst%3DJ.%2BE.%26atitle%3DOvercoming%2520cisplatin%2520resistance%253A%2520design%2520of%2520novel%2520hydrophobic%2520platinum%2520compounds%26jtitle%3DAnticancer%2520Res.%26date%3D2000%26volume%3D20%26spage%3D445%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Gelderblom, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nooter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparreboom, A.</span><span> </span><span class="NLM_article-title">Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1590</span><span class="NLM_x">–</span> <span class="NLM_lpage">1598</span><span class="refDoi"> DOI: 10.1016/S0959-8049(01)00171-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2FS0959-8049%2801%2900171-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=11527683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmt1Oqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2001&pages=1590-1598&author=H.+Gelderblomauthor=J.+Verweijauthor=K.+Nooterauthor=A.+Sparreboom&title=Cremophor+EL%3A+the+drawbacks+and+advantages+of+vehicle+selection+for+drug+formulation&doi=10.1016%2FS0959-8049%2801%2900171-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Cremophor EL the drawbacks and advantages of vehicle selection for drug formulation</span></div><div class="casAuthors">Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1590-1598</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Cremophor EL (CrEL) is a formulation vehicle used for various poorly-water sol. drugs, including the anticancer agent paclitaxel (Taxol).  In contrast to earlier reports, CrEL is not an inert vehicle, but exerts a range of biol. effects, some of which have important clin. implications.  Its use has been assocd. with severe anaphylactoid hypersensitivity reactions, hyperlipidemia, abnormal lipoprotein patterns, aggregation of erythrocytes and peripheral neuropathy.  The pharmacokinetic behavior of CrEL is dose-independent, although its clearance is highly influenced by duration of the infusion.  This is particularly important since CrEL can affect the disposition of various drugs by changing the unbound drug concn. through micellar encapsulation.  In addn., it has been shown that CrEL, as an integral component of paclitaxel chemotherapy, modifies the toxicity profile of certain anticancer agents given concomitantly, by mechanisms other than kinetic interference.  A clear understanding of the biol. and pharmacol. role of CrEL is essential to help oncologists avoid side-effects assocd. with the use of paclitaxel or other agents using this vehicle.  With the present development of various new anticancer agents, it is recommended that alternative formulation approaches should be pursued to allow a better control of the toxicity of the treatment and the pharmacol. interactions related to the use of CrEL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAU0VQq8SHerVg90H21EOLACvtfcHk0lj_k9nTvvVTaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmt1Oqtb0%253D&md5=0ec6b45267094be60ab04aefae474985</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0959-8049%2801%2900171-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-8049%252801%252900171-X%26sid%3Dliteratum%253Aachs%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DNooter%26aufirst%3DK.%26aulast%3DSparreboom%26aufirst%3DA.%26atitle%3DCremophor%2520EL%253A%2520the%2520drawbacks%2520and%2520advantages%2520of%2520vehicle%2520selection%2520for%2520drug%2520formulation%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2001%26volume%3D37%26spage%3D1590%26epage%3D1598%26doi%3D10.1016%2FS0959-8049%2801%2900171-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Savjani, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gajjar, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savjani, J. K.</span><span> </span><span class="NLM_article-title">Drug solubility: importance and enhancement techniques</span> <span class="citation_source-journal">ISRN Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2012</span><span class="NLM_x">, </span> <span class="NLM_fpage">195727</span><span class="refDoi"> DOI: 10.5402/2012/195727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.5402%2F2012%2F195727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22830056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A280%3ADC%252BC38fpslGjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=195727&author=K.+T.+Savjaniauthor=A.+K.+Gajjarauthor=J.+K.+Savjani&title=Drug+solubility%3A+importance+and+enhancement+techniques&doi=10.5402%2F2012%2F195727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Drug solubility: importance and enhancement techniques</span></div><div class="casAuthors">Savjani Ketan T; Gajjar Anuradha K; Savjani Jignasa K</div><div class="citationInfo"><span class="NLM_cas:title">ISRN pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">195727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Solubility, the phenomenon of dissolution of solute in solvent to give a homogenous system, is one of the important parameters to achieve desired concentration of drug in systemic circulation for desired (anticipated) pharmacological response.  Low aqueous solubility is the major problem encountered with formulation development of new chemical entities as well as for the generic development.  More than 40% NCEs (new chemical entities) developed in pharmaceutical industry are practically insoluble in water.  Solubility is a major challenge for formulation scientist.  Any drug to be absorbed must be present in the form of solution at the site of absorption.  Various techniques are used for the enhancement of the solubility of poorly soluble drugs which include physical and chemical modifications of drug and other methods like particle size reduction, crystal engineering, salt formation, solid dispersion, use of surfactant, complexation, and so forth.  Selection of solubility improving method depends on drug property, site of absorption, and required dosage form characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT3fbidYXcW67FU0A1HOshhfW6udTcc2eZsjy4rHWd6uLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fpslGjsg%253D%253D&md5=5dce666f4aaa82df009fcc5edeb9ff79</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.5402%2F2012%2F195727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5402%252F2012%252F195727%26sid%3Dliteratum%253Aachs%26aulast%3DSavjani%26aufirst%3DK.%2BT.%26aulast%3DGajjar%26aufirst%3DA.%2BK.%26aulast%3DSavjani%26aufirst%3DJ.%2BK.%26atitle%3DDrug%2520solubility%253A%2520importance%2520and%2520enhancement%2520techniques%26jtitle%3DISRN%2520Pharm.%26date%3D2012%26volume%3D2012%26spage%3D195727%26doi%3D10.5402%2F2012%2F195727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Shin, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alani, A. W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rockich, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, G. S.</span><span> </span><span class="NLM_article-title">Multidrug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2009.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.jconrel.2009.04.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2009&pages=294-300&issue=3&author=H.+C.+Shinauthor=A.+W.+G.+Alaniauthor=D.+A.+Raoauthor=N.+C.+Rockichauthor=G.+S.+Kwon&title=Multidrug+loaded+polymeric+micelles+for+simultaneous+delivery+of+poorly+soluble+anticancer+drugs&doi=10.1016%2Fj.jconrel.2009.04.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2009.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2009.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DH.%2BC.%26aulast%3DAlani%26aufirst%3DA.%2BW.%2BG.%26aulast%3DRao%26aufirst%3DD.%2BA.%26aulast%3DRockich%26aufirst%3DN.%2BC.%26aulast%3DKwon%26aufirst%3DG.%2BS.%26atitle%3DMultidrug%2520loaded%2520polymeric%2520micelles%2520for%2520simultaneous%2520delivery%2520of%2520poorly%2520soluble%2520anticancer%2520drugs%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2009%26volume%3D140%26issue%3D3%26spage%3D294%26epage%3D300%26doi%3D10.1016%2Fj.jconrel.2009.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Gradishar, W. J.</span><span> </span><span class="NLM_article-title">Albumin-bound paclitaxel: a next-generation taxane</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1041</span><span class="NLM_x">–</span> <span class="NLM_lpage">1053</span><span class="refDoi"> DOI: 10.1517/14656566.7.8.1041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1517%2F14656566.7.8.1041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=16722814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVOgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=1041-1053&author=W.+J.+Gradishar&title=Albumin-bound+paclitaxel%3A+a+next-generation+taxane&doi=10.1517%2F14656566.7.8.1041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin-bound paclitaxel: a next-generation taxane</span></div><div class="casAuthors">Gradishar, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1041-1053</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Taxanes are std. treatment for metastatic breast cancer; however, the solvents used as vehicles in these formulations cause severe toxicities.  The FDA recently approved a solvent-free formulation of paclitaxel for the treatment of metastatic breast cancer that utilizes 130-nm albumin-bound (nab) technol. (Abraxane nab-paclitaxel) to circumvent the requirement for solvents.  Nab-Paclitaxel utilizes the natural properties of albumin to reversibly bind paclitaxel, transport it across the endothelial cell and conc. it in areas of tumor.  The proposed mechanism of drug delivery involves, in part, glycoprotein 60-mediated endothelial cell transcytosis of paclitaxel-bound albumin and accumulation in the area of tumor by albumin binding to SPARC (secreted protein, acidic and rich in cysteine).  Clin. studies have shown that nab-paclitaxel is significantly more effective than paclitaxel formulated as Cremophor EL (CrEL, Taxol, CrEL-paclitaxel), with almost double the response rate, increased time to disease progression and increased survival in second-line patients.  The absence of CrEL from the formulation is assocd. with decreased neutropenia and rapid improvement of peripheral neuropathy with nab-paclitaxel, compared with CrEL-paclitaxel.  For these reasons, nab-paclitaxel can be administered using higher doses of paclitaxel than that achievable with CrEL-paclitaxel, with shorter infusion duration and without the requirement for corticosteroid and antihistamine premedication to reduce the risk of solvent-mediated hypersensitivity reactions.  Taken together, these studies have demonstrated that nab technol. has increased the therapeutic index of paclitaxel compared with the conventional, solvent-based formulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNKtA35_81WrVg90H21EOLACvtfcHk0ljjV05kpl5qhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVOgsrg%253D&md5=2a150fb09d4675e3ab64b189e84da4bc</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F14656566.7.8.1041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.7.8.1041%26sid%3Dliteratum%253Aachs%26aulast%3DGradishar%26aufirst%3DW.%2BJ.%26atitle%3DAlbumin-bound%2520paclitaxel%253A%2520a%2520next-generation%2520taxane%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2006%26volume%3D7%26spage%3D1041%26epage%3D1053%26doi%3D10.1517%2F14656566.7.8.1041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mei, L.</span><span> </span><span class="NLM_article-title">Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2679</span><span class="NLM_x">–</span> <span class="NLM_lpage">2688</span><span class="refDoi"> DOI: 10.2147/IJN.S25251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.2147%2FIJN.S25251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22114498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1entL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=2679-2688&author=Y.+Maauthor=Y.+Zhengauthor=X.+Zengauthor=L.+Jiangauthor=H.+Chenauthor=R.+Liuauthor=L.+Huangauthor=L.+Mei&title=Novel+docetaxel-loaded+nanoparticles+based+on+PCL-Tween+80+copolymer+for+cancer+treatment&doi=10.2147%2FIJN.S25251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment</span></div><div class="casAuthors">Ma, Yuandong; Zheng, Yi; Zeng, Xiaowei; Jiang, Liqin; Chen, Hongbo; Liu, Ranyi; Huang, Laiqiang; Mei, Lin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2679-2688</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: The formulation of docetaxel available for clin. use (Taxotere) contains a high concn. of polysorbate 80 (Tween 80).  After incorporation of Tween 80 into poly-.vepsiln.-caprolactone (PCL)-Tween 80 copolymer, the relative amt. of Tween 80 should be decreased and the advantages of PCL and Tween 80 should be combined.  Methods: A novel PCL-Tween 80 copolymer was synthesized from .vepsiln.-caprolactone and Tween 80 in the presence of stannous octoate as a catalyst via ring opening polymn.  Two types of nanoparticle formulation were made from com. PCL and a self-synthesized PCL-Tween 80 copolymer using a modified solvent extn./evapn. method.  Results: The nanoparticles were found by field emission SEM to have a spherical shape and be 200 nm in diam.  The copolymers could encapsulate 10% of the drug in the nanoparticles and release 34.9% of the encapsulated drug over 28 days.  PCL-Tween 80 nanoparticles could be internalized into the cells and had higher cellular uptake than the PCL nanoparticles.  The drug-loaded PCL-Tween 80 nanoparticles showed better in vitro cytotoxicity towards C6 cancer cells than com. Taxotere at the same drug concn.  Conclusion: Nanoparticles using PCL-Tween 80 copolymer as drug delivery vehicles may have a promising outcome for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnI_yHBWxx2bVg90H21EOLACvtfcHk0lghgkWjWK8OiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1entL7F&md5=e55202eeaf590bb9ed78df621d505baf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2147%2FIJN.S25251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S25251%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DMei%26aufirst%3DL.%26atitle%3DNovel%2520docetaxel-loaded%2520nanoparticles%2520based%2520on%2520PCL-Tween%252080%2520copolymer%2520for%2520cancer%2520treatment%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2011%26volume%3D6%26spage%3D2679%26epage%3D2688%26doi%3D10.2147%2FIJN.S25251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Ten Tije, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loos, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparreboom, A.</span><span> </span><span class="NLM_article-title">Pharmacological effects of formulation vehicles: implications for cancer chemotherapy</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">685</span><span class="refDoi"> DOI: 10.2165/00003088-200342070-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.2165%2F00003088-200342070-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=12844327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFShsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=665-685&author=A.+J.+Ten+Tijeauthor=J.+Verweijauthor=W.+J.+Loosauthor=A.+Sparreboom&title=Pharmacological+effects+of+formulation+vehicles%3A+implications+for+cancer+chemotherapy&doi=10.2165%2F00003088-200342070-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological effects of formulation vehicles: implications for cancer chemotherapy</span></div><div class="casAuthors">ten Tije, Albert J.; Verweij, Jaap; Loos, Walter J.; Sparreboom, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">665-685</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  The non-ionic surfactants Cremophor EL (CrEL; polyoxyethyleneglycerol triricinoleate 35) and polysorbate 80 (Tween 80; polyoxyethylene-sorbitan-20-monooleate) are widely used as drug formulation vehicles, including for the taxane anticancer agents paclitaxel and docetaxel.  A wealth of recent exptl. data has indicated that both solubilizers are biol. and pharmacol. active compds., and their use as drug formulation vehicles has been implicated in clin. important adverse effects, including acute hypersensitivity reactions and peripheral neuropathy.  CrEL and Tween 80 have also been demonstrated to influence the disposition of solubilized drugs that are administered i.v.  The overall resulting effect is a highly increased systemic drug exposure and a simultaneously decreased clearance, leading to alteration in the pharmacodynamic characteristics of the solubilized drug.  Kinetic expts. revealed that this effect is primarily caused by reduced cellular uptake of the drug from large spherical micellar-like structures with a highly hydrophobic interior, which act as the principal carrier of circulating drug.  Within the central blood compartment, this results in a profound alteration of drug accumulation in erythrocytes, thereby reducing the free drug fraction available for cellular partitioning and influencing drug distribution as well as elimination routes.  The existence of CrEL and Tween 80 in blood as large polar micelles has also raised addnl. complexities in the case of combination chemotherapy regimens with taxanes, such that the disposition of several coadministered drugs, including anthracyclines and epipodophyllotoxins, is significantly altered.  In contrast to the enhancing effects of Tweene 80, addn. of CrEL to the formulation of oral drug prepns. seems to result in significantly diminished drug uptake and reduced circulating concns.  The drawbacks presented by the presence of CrEL or Tween 80 in drug formulations have instigated extensive research to develop alternative delivery forms.  Currently, several strategies are in progress to develop Tween 80- and CrEL-free formulations of docetaxel and paclitaxel, which are based on pharmaceutical (e.g. albumin nanoparticles, emulsions and liposomes), chem. (e.g. polyglutamates, analogs and prodrugs), or biol. (e.g. oral drug administration) strategies.  These continued investigations should eventually lead to more rational and selective chemotherapeutic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpckWw2-u6jK7Vg90H21EOLACvtfcHk0lghgkWjWK8OiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFShsLo%253D&md5=62887dbfb8d69a5e4bf04032e777aebd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2165%2F00003088-200342070-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200342070-00005%26sid%3Dliteratum%253Aachs%26aulast%3DTen%2BTije%26aufirst%3DA.%2BJ.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DLoos%26aufirst%3DW.%2BJ.%26aulast%3DSparreboom%26aufirst%3DA.%26atitle%3DPharmacological%2520effects%2520of%2520formulation%2520vehicles%253A%2520implications%2520for%2520cancer%2520chemotherapy%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2003%26volume%3D42%26spage%3D665%26epage%3D685%26doi%3D10.2165%2F00003088-200342070-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Gabano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osella, D.</span><span> </span><span class="NLM_article-title">Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one</span> <span class="citation_source-journal">Dalton Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">9813</span><span class="NLM_x">–</span> <span class="NLM_lpage">9820</span><span class="refDoi"> DOI: 10.1039/c4dt00911h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1039%2Fc4dt00911h" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=9813-9820&author=E.+Gabanoauthor=M.+Raveraauthor=D.+Osella&title=Pros+and+cons+of+bifunctional+platinum%28IV%29+antitumor+prodrugs%3A+two+are+%28not+always%29+better+than+one&doi=10.1039%2Fc4dt00911h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2Fc4dt00911h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4dt00911h%26sid%3Dliteratum%253Aachs%26aulast%3DGabano%26aufirst%3DE.%26aulast%3DRavera%26aufirst%3DM.%26aulast%3DOsella%26aufirst%3DD.%26atitle%3DPros%2520and%2520cons%2520of%2520bifunctional%2520platinum%2528IV%2529%2520antitumor%2520prodrugs%253A%2520two%2520are%2520%2528not%2520always%2529%2520better%2520than%2520one%26jtitle%3DDalton%2520Trans.%26date%3D2014%26volume%3D43%26spage%3D9813%26epage%3D9820%26doi%3D10.1039%2Fc4dt00911h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O.</span><span> </span><span class="NLM_article-title">Cancer nanomedicine: from targeted delivery to combination therapy</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span><span class="refDoi"> DOI: 10.1016/j.molmed.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.molmed.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=25656384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=223-232&author=X.+Xuauthor=W.+Hoauthor=X.+Zhangauthor=N.+Bertrandauthor=O.+Farokhzad&title=Cancer+nanomedicine%3A+from+targeted+delivery+to+combination+therapy&doi=10.1016%2Fj.molmed.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer nanomedicine: from targeted delivery to combination therapy</span></div><div class="casAuthors">Xu, Xiaoyang; Ho, William; Zhang, Xueqing; Bertrand, Nicolas; Farokhzad, Omid</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The advent of nanomedicine marks an unparalleled opportunity to advance the treatment of various diseases, including cancer.  The unique properties of nanoparticles (NPs), such as large surface-to-vol. ratio, small size, the ability to encapsulate various drugs, and tunable surface chem., give them many advantages over their bulk counterparts.  This includes multivalent surface modification with targeting ligands, efficient navigation of the complex in vivo environment, increased intracellular trafficking, and sustained release of drug payload.  These advantages make NPs a mode of treatment potentially superior to conventional cancer therapies.  This review highlights the most recent developments in cancer treatment using NPs as drug delivery vehicles, including promising opportunities in targeted and combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN0lD-ZXqgVLVg90H21EOLACvtfcHk0lhFxqHHo42NoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVOhuw%253D%253D&md5=bbb8815e635f43b856dbaeddc7a3f37d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHo%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DBertrand%26aufirst%3DN.%26aulast%3DFarokhzad%26aufirst%3DO.%26atitle%3DCancer%2520nanomedicine%253A%2520from%2520targeted%2520delivery%2520to%2520combination%2520therapy%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D223%26epage%3D232%26doi%3D10.1016%2Fj.molmed.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Rizzo, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storm, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiessling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammers, T.</span><span> </span><span class="NLM_article-title">Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications</span> <span class="citation_source-journal">Curr. Opin. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1159</span><span class="NLM_x">–</span> <span class="NLM_lpage">1166</span><span class="refDoi"> DOI: 10.1016/j.copbio.2013.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.copbio.2013.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=23578464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1Shu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1159-1166&author=L.+Y.+Rizzoauthor=B.+Theekauthor=G.+Stormauthor=F.+Kiesslingauthor=T.+Lammers&title=Recent+progress+in+nanomedicine%3A+therapeutic%2C+diagnostic+and+theranostic+applications&doi=10.1016%2Fj.copbio.2013.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications</span></div><div class="casAuthors">Rizzo, Larissa Y.; Theek, Benjamin; Storm, Gert; Kiessling, Fabian; Lammers, Twan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Biotechnology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1159-1166</span>CODEN:
                <span class="NLM_cas:coden">CUOBE3</span>;
        ISSN:<span class="NLM_cas:issn">0958-1669</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In recent years, the use of nanomedicine formulations for therapeutic and diagnostic applications has increased exponentially.  Many different systems and strategies have been developed for drug targeting to pathol. sites, as well as for visualizing and quantifying important (patho-) physiol. processes.  In addn., ever more efforts have been undertaken to combine diagnostic and therapeutic properties within a single nanomedicine formulation.  These so-called nanotheranostics are able to provide valuable information on drug delivery, drug release and drug efficacy, and they are considered to be highly useful for personalizing nanomedicine-based (chemo-) therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSzWX8o4GMZrVg90H21EOLACvtfcHk0lg_7O8eVfaCtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1Shu7w%253D&md5=571653bab00fbe707b6243d3cfe6a7ee</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.copbio.2013.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.copbio.2013.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DRizzo%26aufirst%3DL.%2BY.%26aulast%3DTheek%26aufirst%3DB.%26aulast%3DStorm%26aufirst%3DG.%26aulast%3DKiessling%26aufirst%3DF.%26aulast%3DLammers%26aufirst%3DT.%26atitle%3DRecent%2520progress%2520in%2520nanomedicine%253A%2520therapeutic%252C%2520diagnostic%2520and%2520theranostic%2520applications%26jtitle%3DCurr.%2520Opin.%2520Biotechnol.%26date%3D2013%26volume%3D24%26spage%3D1159%26epage%3D1166%26doi%3D10.1016%2Fj.copbio.2013.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Mahapatro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, D. K.</span><span> </span><span class="NLM_article-title">Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines</span> <span class="citation_source-journal">J. Nanobiotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="refDoi"> DOI: 10.1186/1477-3155-9-55</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1186%2F1477-3155-9-55" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22123084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1Crug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=55&author=A.+Mahapatroauthor=D.+K.+Singh&title=Biodegradable+nanoparticles+are+excellent+vehicle+for+site+directed+in-vivo+delivery+of+drugs+and+vaccines&doi=10.1186%2F1477-3155-9-55"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines</span></div><div class="casAuthors">Mahapatro, Anil; Singh, Dinesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nanobiotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55</span>CODEN:
                <span class="NLM_cas:coden">JNOAAO</span>;
        ISSN:<span class="NLM_cas:issn">1477-3155</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Biodegradable nanoparticles (NPs) are gaining increased attention for their ability to serve as a viable carrier for site specific delivery of vaccines, genes, drugs and other biomols. in the body.  They offer enhanced biocompatibility, superior drug/vaccine encapsulation, and convenient release profiles for a no. of drugs, vaccines and biomols. to be used in a variety of applications in the field of medicine.  In this manuscript, the methods of prepn. of biodegradable NPs, different factors affecting optimal drug encapsulation, factors affecting drug release rates, various surface modifications of nanoparticles to enhance in-vivo circulation, distribution and multimodal functionalities along with the specific applications such as tumor targeting, oral delivery, and delivery of these particles to the central nervous system have been reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpY_XiZnOqnrVg90H21EOLACvtfcHk0lg_7O8eVfaCtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1Crug%253D%253D&md5=46713b2574a145f930a5f7f51aa3e0b8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2F1477-3155-9-55&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1477-3155-9-55%26sid%3Dliteratum%253Aachs%26aulast%3DMahapatro%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DD.%2BK.%26atitle%3DBiodegradable%2520nanoparticles%2520are%2520excellent%2520vehicle%2520for%2520site%2520directed%2520in-vivo%2520delivery%2520of%2520drugs%2520and%2520vaccines%26jtitle%3DJ.%2520Nanobiotechnol.%26date%3D2011%26volume%3D9%26spage%3D55%26doi%3D10.1186%2F1477-3155-9-55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Fessi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devissaguet, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ammoury, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benita, S.</span><span> </span><span class="NLM_article-title">Nanocapsule formation by interfacial polymer deposition following solvent displacement</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">R1</span><span class="NLM_x">–</span> <span class="NLM_lpage">R4</span><span class="refDoi"> DOI: 10.1016/0378-5173(89)90281-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2F0378-5173%2889%2990281-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADyaL1MXmtF2hsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1989&pages=R1-R4&author=H.+Fessiauthor=F.+Puisieuxauthor=J.+P.+Devissaguetauthor=N.+Ammouryauthor=S.+Benita&title=Nanocapsule+formation+by+interfacial+polymer+deposition+following+solvent+displacement&doi=10.1016%2F0378-5173%2889%2990281-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocapsule formation by interfacial polymer deposition following solvent displacement</span></div><div class="casAuthors">Fessi, H.; Puisieux, F.; Devissaguet, J. P.; Ammoury, N.; Benita, S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">R1-R4</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    </div><div class="casAbstract">Indomethacin-loaded nanocapsules were prepd. by deposition of poly(DL-lactide) polymer at the oil-water interface following acetone displacement from the oily nanodroplets.  An attempt was made to elucidate the mechanism of formation in terms of interfacial turbulence between two unequilibrated liq. phases involving flow, diffusion and surface tension decrease (Marangoni effect).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj1GdEAMzx0rVg90H21EOLACvtfcHk0ljeNYfQliP8zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtF2hsbs%253D&md5=261e4b745df8b522f0b87f5934a17552</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2F0378-5173%2889%2990281-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-5173%252889%252990281-0%26sid%3Dliteratum%253Aachs%26aulast%3DFessi%26aufirst%3DH.%26aulast%3DPuisieux%26aufirst%3DF.%26aulast%3DDevissaguet%26aufirst%3DJ.%2BP.%26aulast%3DAmmoury%26aufirst%3DN.%26aulast%3DBenita%26aufirst%3DS.%26atitle%3DNanocapsule%2520formation%2520by%2520interfacial%2520polymer%2520deposition%2520following%2520solvent%2520displacement%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D1989%26volume%3D55%26spage%3DR1%26epage%3DR4%26doi%3D10.1016%2F0378-5173%2889%2990281-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Byrne, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betancourt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannon-Peppas, L.</span><span> </span><span class="NLM_article-title">Active targeting schemes for nanoparticle systems in cancer therapeutics</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1615</span><span class="NLM_x">–</span> <span class="NLM_lpage">1626</span><span class="refDoi"> DOI: 10.1016/j.addr.2008.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.addr.2008.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=18840489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=1615-1626&author=J.+D.+Byrneauthor=T.+Betancourtauthor=L.+Brannon-Peppas&title=Active+targeting+schemes+for+nanoparticle+systems+in+cancer+therapeutics&doi=10.1016%2Fj.addr.2008.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Active targeting schemes for nanoparticle systems in cancer therapeutics</span></div><div class="casAuthors">Byrne, James D.; Betancourt, Tania; Brannon-Peppas, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1615-1626</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The objective of this review is to outline current major cancer targets for nanoparticle systems and give insight into the direction of the field.  The major targeting strategies that have been used for the delivery of therapeutic or imaging agents to cancer have been broken into three sections.  These sections are angiogenesis-assocd. targeting, targeting to uncontrolled cell proliferation markers, and tumor cell targeting.  The targeting schemes explored for many of the reported nanoparticle systems suggest the great potential of targeted delivery to revolutionize cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7soOyI6FoYLVg90H21EOLACvtfcHk0ljeNYfQliP8zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP&md5=aeeb388245fec939e63fda98fb154d99</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2008.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2008.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DByrne%26aufirst%3DJ.%2BD.%26aulast%3DBetancourt%26aufirst%3DT.%26aulast%3DBrannon-Peppas%26aufirst%3DL.%26atitle%3DActive%2520targeting%2520schemes%2520for%2520nanoparticle%2520systems%2520in%2520cancer%2520therapeutics%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2008%26volume%3D60%26spage%3D1615%26epage%3D1626%26doi%3D10.1016%2Fj.addr.2008.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Abdelwahed, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degobert, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stainmesse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fessi, H.</span><span> </span><span class="NLM_article-title">Freeze-drying of nanoparticles: formulation, process and storage considerations</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1688</span><span class="NLM_x">–</span> <span class="NLM_lpage">1713</span><span class="refDoi"> DOI: 10.1016/j.addr.2006.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.addr.2006.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=17118485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kmtb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=1688-1713&author=W.+Abdelwahedauthor=G.+Degobertauthor=S.+Stainmesseauthor=H.+Fessi&title=Freeze-drying+of+nanoparticles%3A+formulation%2C+process+and+storage+considerations&doi=10.1016%2Fj.addr.2006.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Freeze-drying of nanoparticles: Formulation, process and storage considerations</span></div><div class="casAuthors">Abdelwahed, Wassim; Degobert, Ghania; Stainmesse, Serge; Fessi, Hatem</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1688-1713</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Freeze-drying has been considered as a good technique to improve the long-term stability of colloidal nanoparticles.  The poor stability in an aq. medium of these systems forms a real barrier against the clin. use of nanoparticles.  This article reviews the state of the art of freeze-drying nanoparticles.  It discusses the most important parameters that influence the success of freeze-drying of these fragile systems, and provides an overview of nanoparticles freeze-drying process and formulation strategies with a focus on the impact of formulation and process on particle stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotDuGqiKZVYbVg90H21EOLACvtfcHk0lgM-Po6LspzxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kmtb7E&md5=83c4c293417e5fbacf6f4a5c46da5b8c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2006.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2006.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelwahed%26aufirst%3DW.%26aulast%3DDegobert%26aufirst%3DG.%26aulast%3DStainmesse%26aufirst%3DS.%26aulast%3DFessi%26aufirst%3DH.%26atitle%3DFreeze-drying%2520of%2520nanoparticles%253A%2520formulation%252C%2520process%2520and%2520storage%2520considerations%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D1688%26epage%3D1713%26doi%3D10.1016%2Fj.addr.2006.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Zheng, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suntharalingam, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">8790</span><span class="NLM_x">–</span> <span class="NLM_lpage">8798</span><span class="refDoi"> DOI: 10.1021/ja5038269</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5038269" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=8790-8798&author=Y.+R.+Zhengauthor=K.+Suntharalingamauthor=T.+C.+Johnstoneauthor=H.+Yooauthor=W.+Linauthor=J.+G.+Brooksauthor=S.+J.+Lippard&title=Pt%28IV%29+prodrugs+designed+to+bind+non-covalently+to+human+serum+albumin+for+drug+delivery&doi=10.1021%2Fja5038269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span></div><div class="casAuthors">Zheng, Yao-Rong; Suntharalingam, Kogularamanan; Johnstone, Timothy C.; Yoo, Hyunsuk; Lin, Wei; Brooks, Jamar G.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8790-8798</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Albumin is the most abundant protein in human serum and drugs that are administered i.v. inevitably interact with it.  We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery.  This goal is achieved by asym. functionalizing the axial ligands of the prodrug so as to mimic the overall features of a fatty acid.  Systematic variation of the length of the aliph. tail tunes the cellular uptake and, consequently, the cytotoxicity of cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2COOH)(OCONHR)], 4, where R is a linear alkyl group.  Investigation of an analog bearing a fluorophore conjugated to the succinate ligand confirmed that these compds. are reduced by biol. reductants with loss of the axial ligands.  Intracellular release of cisplatin from 4 was further confirmed by observing the characteristic effects of cisplatin on the cell cycle and morphol. following treatment with the prodrug.  The most potent member of series 4, for which R is a hexadecyl chain, interacts with HSA in a 1:1 stoichiometry to form the platinum-protein complex 7.  The interaction is non-covalent and extn. with octanol completely removes the prodrug from an aq. soln. of HSA.  Construct 7 is robust and can be isolated following fast protein liq. chromatog.  The nature of the tight interaction was investigated computationally, and these studies suggest that the prodrug is buried below the surface of the protein.  Consequently, complexation to HSA is able to reduce the rate of redn. of the prodrug by ascorbate.  The lead compd. from series 4 also exhibited significant stability in whole human blood, attributed to its interaction with HSA.  This favorable redox profile, in conjunction with the established nonimmunogenicity, biocompatibility, and enhanced tumor accumulation of HSA, produces a system that holds significant therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOojHJiVKj17Vg90H21EOLACvtfcHk0lgM-Po6LspzxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D&md5=541fe9e155e3f4e2f8d6f61f3d81ee5a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fja5038269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5038269%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DYoo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DBrooks%26aufirst%3DJ.%2BG.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPt%2528IV%2529%2520prodrugs%2520designed%2520to%2520bind%2520non-covalently%2520to%2520human%2520serum%2520albumin%2520for%2520drug%2520delivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D8790%26epage%3D8798%26doi%3D10.1021%2Fja5038269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Graf, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bielenberg, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolishetti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banyard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">alpha(V)beta(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug</span> <span class="citation_source-journal">ACS Nano</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">4530</span><span class="NLM_x">–</span> <span class="NLM_lpage">4539</span><span class="refDoi"> DOI: 10.1021/nn301148e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn301148e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFGhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=4530-4539&author=N.+Grafauthor=D.+R.+Bielenbergauthor=N.+Kolishettiauthor=C.+Muusauthor=J.+Banyardauthor=O.+C.+Farokhzadauthor=S.+J.+Lippard&title=alpha%28V%29beta%283%29+integrin-targeted+PLGA-PEG+nanoparticles+for+enhanced+anti-tumor+efficacy+of+a+Pt%28IV%29+prodrug&doi=10.1021%2Fnn301148e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug</span></div><div class="casAuthors">Graf, Nora; Bielenberg, Diane R.; Kolishetti, Nagesh; Muus, Christoph; Banyard, Jacqueline; Farokhzad, Omid C.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">4530-4539</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted delivery of therapeutics to tumor neovasculature is potentially a powerful approach for selective cancer treatment.  Integrins are heterodimeric transmembrane proteins involved in cell adhesion and cell signaling, and their expression is commonly upregulated in cancers and inflammatory diseases.  The αvβ3 integrin is differentially upregulated on angiogenic endothelial cells as well as on many cancer cells.  Here we demonstrate the differential targeting of cisplatin prodrug-encapsulated poly(D,L-lactic-co-glycolic acid)-block-polyethylene glycol (PLGA-PEG) nanoparticles (NPs) to the αvβ3 integrin on cancer cells using the cyclic pentapeptide c(RGDfK).  Cisplatin is one of the most widely used anticancer drugs, and approaches that can improve its therapeutic index are of broad importance.  The RGD-targeted Pt(IV)-encapsulated NPs displayed enhanced cytotoxicity as compared to cisplatin administered in its conventional dosage form in model prostate and breast cancer epithelial cells in vitro.  Cytotoxicities were also elevated in comparison to those of previously reported systems, a small mol. Pt(IV)-RGD conjugate and a Pt(IV) nanoscale coordination polymer carrying RGD moieties.  This result encouraged us also to evaluate the anticancer effect of the new construct in an animal model.  The RGD-targeted PLGA-PEG NPs were more efficacious and better tolerated by comparison to cisplatin in an orthotopic human breast cancer xenograft model in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAV6ynbyup7Vg90H21EOLACvtfcHk0lgUQvwjUdZ_HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFGhu70%253D&md5=7650624390ad2befa90ce40577b2edcd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fnn301148e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn301148e%26sid%3Dliteratum%253Aachs%26aulast%3DGraf%26aufirst%3DN.%26aulast%3DBielenberg%26aufirst%3DD.%2BR.%26aulast%3DKolishetti%26aufirst%3DN.%26aulast%3DMuus%26aufirst%3DC.%26aulast%3DBanyard%26aufirst%3DJ.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3Dalpha%2528V%2529beta%25283%2529%2520integrin-targeted%2520PLGA-PEG%2520nanoparticles%2520for%2520enhanced%2520anti-tumor%2520efficacy%2520of%2520a%2520Pt%2528IV%2529%2520prodrug%26jtitle%3DACS%2520Nano%26date%3D2012%26volume%3D6%26spage%3D4530%26epage%3D4539%26doi%3D10.1021%2Fnn301148e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Varbanov, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valiahdi, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakupec, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span> </span><span class="NLM_article-title">Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5456</span><span class="NLM_x">–</span> <span class="NLM_lpage">5464</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2011.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.ejmech.2011.09.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=5456-5464&author=H.+Varbanovauthor=S.+M.+Valiahdiauthor=A.+A.+Leginauthor=M.+A.+Jakupecauthor=A.+Rollerauthor=M.+Galanskiauthor=B.+K.+Keppler&title=Synthesis+and+characterization+of+novel+bis%28carboxylato%29dichloridobis%28ethylamine%29platinum%28IV%29+complexes+with+higher+cytotoxicity+than+cisplatin&doi=10.1016%2Fj.ejmech.2011.09.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DVarbanov%26aufirst%3DH.%26aulast%3DValiahdi%26aufirst%3DS.%2BM.%26aulast%3DLegin%26aufirst%3DA.%2BA.%26aulast%3DJakupec%26aufirst%3DM.%2BA.%26aulast%3DRoller%26aufirst%3DA.%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520novel%2520bis%2528carboxylato%2529dichloridobis%2528ethylamine%2529platinum%2528IV%2529%2520complexes%2520with%2520higher%2520cytotoxicity%2520than%2520cisplatin%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D5456%26epage%3D5464%26doi%3D10.1016%2Fj.ejmech.2011.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Zak, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turanek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroutil, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sova, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikolin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaluska, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neca, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sindlerova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozubik, A.</span><span> </span><span class="NLM_article-title">Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span><span class="refDoi"> DOI: 10.1021/jm030858+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030858%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=761-763&author=F.+Zakauthor=J.+Turanekauthor=A.+Kroutilauthor=P.+Sovaauthor=A.+Mistrauthor=A.+Poulovaauthor=P.+Mikolinauthor=Z.+Zakauthor=A.+Kasnaauthor=D.+Zaluskaauthor=J.+Necaauthor=L.+Sindlerovaauthor=A.+Kozubik&title=Platinum%28IV%29+complex+with+adamantylamine+as+nonleaving+amine+group%3A+synthesis%2C+characterization%2C+and+in+vitro+antitumor+activity+against+a+panel+of+cisplatin-resistant+cancer+cell+lines&doi=10.1021%2Fjm030858%2B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm030858%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030858%252B%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DF.%26aulast%3DTuranek%26aufirst%3DJ.%26aulast%3DKroutil%26aufirst%3DA.%26aulast%3DSova%26aufirst%3DP.%26aulast%3DMistr%26aufirst%3DA.%26aulast%3DPoulova%26aufirst%3DA.%26aulast%3DMikolin%26aufirst%3DP.%26aulast%3DZak%26aufirst%3DZ.%26aulast%3DKasna%26aufirst%3DA.%26aulast%3DZaluska%26aufirst%3DD.%26aulast%3DNeca%26aufirst%3DJ.%26aulast%3DSindlerova%26aufirst%3DL.%26aulast%3DKozubik%26aufirst%3DA.%26atitle%3DPlatinum%2528IV%2529%2520complex%2520with%2520adamantylamine%2520as%2520nonleaving%2520amine%2520group%253A%2520synthesis%252C%2520characterization%252C%2520and%2520in%2520vitro%2520antitumor%2520activity%2520against%2520a%2520panel%2520of%2520cisplatin-resistant%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D761%26epage%3D763%26doi%3D10.1021%2Fjm030858%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Neumann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarosi, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghebreselasie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marnett, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hey-Hawkins, E.</span><span> </span><span class="NLM_article-title">Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1002/cmdc.201402353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1002%2Fcmdc.201402353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=25318459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFamtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=183-192&author=W.+Neumannauthor=B.+C.+Crewsauthor=M.+B.+Sarosiauthor=C.+M.+Danielauthor=K.+Ghebreselasieauthor=M.+S.+Scholzauthor=L.+J.+Marnettauthor=E.+Hey-Hawkins&title=Conjugation+of+cisplatin+analogues+and+cyclooxygenase+inhibitors+to+overcome+cisplatin+resistance&doi=10.1002%2Fcmdc.201402353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance</span></div><div class="casAuthors">Neumann, Wilma; Crews, Brenda C.; Sarosi, Menyhart B.; Daniel, Cristina M.; Ghebreselasie, Kebreab; Scholz, Matthias S.; Marnett, Lawrence J.; Hey-Hawkins, Evamarie</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-192</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cyclooxygenase (COX) is an enzyme involved in tumorigenesis and is assocd. with tumor cell resistance against platinum-based antitumor drugs.  Cisplatin analogs were conjugated with COX inhibitors (indomethacin, ibuprofen) to study the synergistic effects that were previously obsd. in combination treatments.  The conjugates ensure concerted transport of both drugs into cells, and subsequent intracellular cleavage enables a dual-action mode.  Whereas the platinum(II) complexes showed cytotoxicities similar to those of cisplatin, the platinum(IV) conjugates revealed highly increased cytotoxic activities and were able to completely overcome cisplatin-related resistance.  Although some of the complexes are potent COX inhibitors, the conjugates appear to execute their cytotoxic action via COX-independent mechanisms.  Instead, the increased lipophilicity and kinetic inertness of the conjugates seem to facilitate cellular accumulation of the platinum drugs and thus improve the efficacy of the antitumor agents.  These conjugates are important tools for the elucidation of the direct influence of COX inhibitors on platinum-based anticancer drugs in tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmcKFi4NrXWLVg90H21EOLACvtfcHk0lhGHWBdel4XeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFamtr3N&md5=481952d7103a69c0e1f8d395e044fd7e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402353%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DW.%26aulast%3DCrews%26aufirst%3DB.%2BC.%26aulast%3DSarosi%26aufirst%3DM.%2BB.%26aulast%3DDaniel%26aufirst%3DC.%2BM.%26aulast%3DGhebreselasie%26aufirst%3DK.%26aulast%3DScholz%26aufirst%3DM.%2BS.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26aulast%3DHey-Hawkins%26aufirst%3DE.%26atitle%3DConjugation%2520of%2520cisplatin%2520analogues%2520and%2520cyclooxygenase%2520inhibitors%2520to%2520overcome%2520cisplatin%2520resistance%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D183%26epage%3D192%26doi%3D10.1002%2Fcmdc.201402353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Novohradsky, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerzankova, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stepankova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrana, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raveendran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasparkova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brabec, V.</span><span> </span><span class="NLM_article-title">Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands</span> <span class="citation_source-journal">J. Inorg. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1016/j.jinorgbio.2014.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.jinorgbio.2014.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=25063910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Khu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2014&pages=72-79&author=V.+Novohradskyauthor=L.+Zerzankovaauthor=J.+Stepankovaauthor=O.+Vranaauthor=R.+Raveendranauthor=D.+Gibsonauthor=J.+Kasparkovaauthor=V.+Brabec&title=Antitumor+platinum%28IV%29+derivatives+of+oxaliplatin+with+axial+valproato+ligands&doi=10.1016%2Fj.jinorgbio.2014.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands</span></div><div class="casAuthors">Novohradsky, Vojtech; Zerzankova, Lenka; Stepankova, Jana; Vrana, Oldrich; Raveendran, Raji; Gibson, Dan; Kasparkova, Jana; Brabec, Viktor</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-79</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We report new anticancer prodrugs, platinum(IV) derivs. of oxaliplatin conjugated with valproic acid (VPA), a well-known drug having histone deacetylase inhibitory activity.  Like most platinum(IV) derivs., the cytotoxicity of the conjugates was lower in cell culture than that of oxaliplatin, but greater than those of its Pt(IV) deriv. contg. biol. inactive axial ligands in several cancer cell lines.  Notably, these conjugates display activity in both cisplatin sensitive- and resistant tumor cells capable of both markedly enhanced accumulation in tumor cells and acting in a dual threat manner, concurrently targeting histone deacetylase and genomic DNA.  These results demonstrate the dual targeting strategy to be a valuable route to pursue in the design of platinum agents which may be more effective in cancer types that are typically resistant to therapy by conventional cisplatin.  Moreover, platinum(IV) derivs. contg. VPA axial ligands seem to be promising dual-targeting candidates for addnl. preclin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUyC3cksfQ2rVg90H21EOLACvtfcHk0lhGHWBdel4XeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Khu7rL&md5=9bb753b45976997c1ab2b0416d1fd89a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2014.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2014.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DNovohradsky%26aufirst%3DV.%26aulast%3DZerzankova%26aufirst%3DL.%26aulast%3DStepankova%26aufirst%3DJ.%26aulast%3DVrana%26aufirst%3DO.%26aulast%3DRaveendran%26aufirst%3DR.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DKasparkova%26aufirst%3DJ.%26aulast%3DBrabec%26aufirst%3DV.%26atitle%3DAntitumor%2520platinum%2528IV%2529%2520derivatives%2520of%2520oxaliplatin%2520with%2520axial%2520valproato%2520ligands%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2014%26volume%3D140%26spage%3D72%26epage%3D79%26doi%3D10.1016%2Fj.jinorgbio.2014.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Zhang, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wexselblatt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, D.</span><span> </span><span class="NLM_article-title">Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">849</span><span class="refDoi"> DOI: 10.1039/C1CC16647F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1039%2FC1CC16647F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22124352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ersbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=847-849&author=J.+Z.+Zhangauthor=E.+Wexselblattauthor=T.+W.+Hambleyauthor=D.+Gibson&title=Pt%28IV%29+analogs+of+oxaliplatin+that+do+not+follow+the+expected+correlation+between+electrochemical+reduction+potential+and+rate+of+reduction+by+ascorbate&doi=10.1039%2FC1CC16647F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate</span></div><div class="casAuthors">Zhang, Jenny Z.; Wexselblatt, Ezequiel; Hambley, Trevor W.; Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">847-849</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">In contrast to the Pt(IV) derivs. of cisplatin, Pt(IV) derivs. of oxaliplatin do not show the expected correlation between the electrochem. redn. potentials and rates of redn. by ascorbate.  This is probably due to the lower ability of the amine and carboxylato ligands to form a bridge with the reducing agents to facilitate electron transfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ueBJeBlazLVg90H21EOLACvtfcHk0lgHF4aTi3qxaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ersbfE&md5=c28a1148f32a79389fe6b2509f014e26</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2FC1CC16647F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC1CC16647F%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%2BZ.%26aulast%3DWexselblatt%26aufirst%3DE.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DPt%2528IV%2529%2520analogs%2520of%2520oxaliplatin%2520that%2520do%2520not%2520follow%2520the%2520expected%2520correlation%2520between%2520electrochemical%2520reduction%2520potential%2520and%2520rate%2520of%2520reduction%2520by%2520ascorbate%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2012%26volume%3D48%26spage%3D847%26epage%3D849%26doi%3D10.1039%2FC1CC16647F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Khokhar, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">al-Baker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shamsuddin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddik, Z. H.</span><span> </span><span class="NLM_article-title">Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1021/jm960587l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960587l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=112-116&author=A.+R.+Khokharauthor=S.+al-Bakerauthor=S.+Shamsuddinauthor=Z.+H.+Siddik&title=Chemical+and+biological+studies+on+a+series+of+novel+%28trans-%281R%2C2R%29-%2C+trans-%281S%2C2S%29-%2C+and+cis-1%2C2-diaminocyclohexane%29platinum%28IV%29+carboxylate+complexes&doi=10.1021%2Fjm960587l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm960587l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960587l%26sid%3Dliteratum%253Aachs%26aulast%3DKhokhar%26aufirst%3DA.%2BR.%26aulast%3Dal-Baker%26aufirst%3DS.%26aulast%3DShamsuddin%26aufirst%3DS.%26aulast%3DSiddik%26aufirst%3DZ.%2BH.%26atitle%3DChemical%2520and%2520biological%2520studies%2520on%2520a%2520series%2520of%2520novel%2520%2528trans-%25281R%252C2R%2529-%252C%2520trans-%25281S%252C2S%2529-%252C%2520and%2520cis-1%252C2-diaminocyclohexane%2529platinum%2528IV%2529%2520carboxylate%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D112%26epage%3D116%26doi%3D10.1021%2Fjm960587l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murrer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giandomenico, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrap, K. R.</span><span> </span><span class="NLM_article-title">Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">822</span><span class="NLM_x">–</span> <span class="NLM_lpage">828</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1992&pages=822-828&author=L.+R.+Kellandauthor=B.+A.+Murrerauthor=G.+Abelauthor=C.+M.+Giandomenicoauthor=P.+Mistryauthor=K.+R.+Harrap&title=Ammine%2Famine+platinum%28IV%29+dicarboxylates%3A+a+novel+class+of+platinum+complex+exhibiting+selective+cytotoxicity+to+intrinsically+cisplatin-resistant+human+ovarian+carcinoma+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DMurrer%26aufirst%3DB.%2BA.%26aulast%3DAbel%26aufirst%3DG.%26aulast%3DGiandomenico%26aufirst%3DC.%2BM.%26aulast%3DMistry%26aufirst%3DP.%26aulast%3DHarrap%26aufirst%3DK.%2BR.%26atitle%3DAmmine%252Famine%2520platinum%2528IV%2529%2520dicarboxylates%253A%2520a%2520novel%2520class%2520of%2520platinum%2520complex%2520exhibiting%2520selective%2520cytotoxicity%2520to%2520intrinsically%2520cisplatin-resistant%2520human%2520ovarian%2520carcinoma%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1992%26volume%3D52%26spage%3D822%26epage%3D828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Ellis, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Er, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">The Influence of the axial ligands of a series of platinum(IV) anti-cancer complexes on their reduction to platinum(II) and reaction with DNA</span> <span class="citation_source-journal">Aust. J. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">806</span><span class="refDoi"> DOI: 10.1071/CH9950793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1071%2FCH9950793" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1995&pages=793-806&author=L.+T.+Ellisauthor=H.+M.+Erauthor=T.+W.+Hambley&title=The+Influence+of+the+axial+ligands+of+a+series+of+platinum%28IV%29+anti-cancer+complexes+on+their+reduction+to+platinum%28II%29+and+reaction+with+DNA&doi=10.1071%2FCH9950793"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1071%2FCH9950793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1071%252FCH9950793%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DL.%2BT.%26aulast%3DEr%26aufirst%3DH.%2BM.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DThe%2520Influence%2520of%2520the%2520axial%2520ligands%2520of%2520a%2520series%2520of%2520platinum%2528IV%2529%2520anti-cancer%2520complexes%2520on%2520their%2520reduction%2520to%2520platinum%2528II%2529%2520and%2520reaction%2520with%2520DNA%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D1995%26volume%3D48%26spage%3D793%26epage%3D806%26doi%3D10.1071%2FCH9950793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Cui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porschke, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamacher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassack, M. U.</span><span> </span><span class="NLM_article-title">Bispidine analogues of cisplatin, carboplatin, and oxaliplatin. synthesis, structures, and cytotoxicity</span> <span class="citation_source-journal">Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3371</span><span class="NLM_x">–</span> <span class="NLM_lpage">3384</span><span class="refDoi"> DOI: 10.1021/ic402737f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic402737f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3371-3384&author=H.+Cuiauthor=R.+Goddardauthor=K.+R.+Porschkeauthor=A.+Hamacherauthor=M.+U.+Kassack&title=Bispidine+analogues+of+cisplatin%2C+carboplatin%2C+and+oxaliplatin.+synthesis%2C+structures%2C+and+cytotoxicity&doi=10.1021%2Fic402737f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fic402737f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic402737f%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DH.%26aulast%3DGoddard%26aufirst%3DR.%26aulast%3DPorschke%26aufirst%3DK.%2BR.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26atitle%3DBispidine%2520analogues%2520of%2520cisplatin%252C%2520carboplatin%252C%2520and%2520oxaliplatin.%2520synthesis%252C%2520structures%252C%2520and%2520cytotoxicity%26jtitle%3DInorg.%2520Chem.%26date%3D2014%26volume%3D53%26spage%3D3371%26epage%3D3384%26doi%3D10.1021%2Fic402737f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Buss, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalayda, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reithofer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaehde, U.</span><span> </span><span class="NLM_article-title">Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues</span> <span class="citation_source-journal">JBIC, J. Biol. Inorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">–</span> <span class="NLM_lpage">708</span><span class="refDoi"> DOI: 10.1007/s00775-012-0889-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1007%2Fs00775-012-0889-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22456982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVWit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=699-708&author=I.+Bussauthor=G.+V.+Kalaydaauthor=A.+Lindauerauthor=M.+R.+Reithoferauthor=M.+Galanskiauthor=B.+K.+Kepplerauthor=U.+Jaehde&title=Effect+of+reactivity+on+cellular+accumulation+and+cytotoxicity+of+oxaliplatin+analogues&doi=10.1007%2Fs00775-012-0889-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues</span></div><div class="casAuthors">Buss, Irina; Kalayda, Ganna V.; Lindauer, Andreas; Reithofer, Michael R.; Galanski, Markus; Keppler, Bernhard K.; Jaehde, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">JBIC, Journal of Biological Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">699-708</span>CODEN:
                <span class="NLM_cas:coden">JJBCFA</span>;
        ISSN:<span class="NLM_cas:issn">0949-8257</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The purpose of this study was to systematically investigate the relationships between reactivity, cellular accumulation, and cytotoxicity of a panel of oxaliplatin analogs with different leaving groups in human carcinoma cells.  The reactivity of the complexes towards the nucleotides 2'-deoxyguanosine 5'-monophosphate and 2'-deoxyadenosine 5'-monophosphate was studied using capillary electrophoresis.  Cellular accumulation and cytotoxicity were measured in an oxaliplatin-sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cell line pair (HCT-8/HCT-8ox).  Platinum concns. were detd. by flameless at. absorption spectrometry.  The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was used to assess cytotoxicity.  Early cellular platinum accumulation was predominantly affected by lipophilicity.  A relation between reactivity and cellular accumulation was obsd. for three of four platinum complexes investigated, whereas the most lipophilic oxaliplatin analog was an exception.  Increased reactivity and reduced lipophilicity were assocd. with high cytotoxic activity.  Resistance was influenced by lipophilicity but not by reactivity.  The obsd. relationships may help in the design of analogs with high antitumoral activity in oxaliplatin-sensitive as well as oxaliplatin-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6wukIWqJE0bVg90H21EOLACvtfcHk0liolrAdmMzgFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVWit78%253D&md5=cfa35a41a798d1785e66eca2a2cac937</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs00775-012-0889-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00775-012-0889-9%26sid%3Dliteratum%253Aachs%26aulast%3DBuss%26aufirst%3DI.%26aulast%3DKalayda%26aufirst%3DG.%2BV.%26aulast%3DLindauer%26aufirst%3DA.%26aulast%3DReithofer%26aufirst%3DM.%2BR.%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26aulast%3DJaehde%26aufirst%3DU.%26atitle%3DEffect%2520of%2520reactivity%2520on%2520cellular%2520accumulation%2520and%2520cytotoxicity%2520of%2520oxaliplatin%2520analogues%26jtitle%3DJBIC%252C%2520J.%2520Biol.%2520Inorg.%2520Chem.%26date%3D2012%26volume%3D17%26spage%3D699%26epage%3D708%26doi%3D10.1007%2Fs00775-012-0889-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Kozubik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaculova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soucek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vondracek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turanek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmanova, J.</span><span> </span><span class="NLM_article-title">Novel anticancer platinum(IV) complexes with adamantylamine: their efficiency and innovative chemotherapy strategies modifying lipid metabolism</span> <span class="citation_source-journal">Met.-Based Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2008</span><span class="NLM_x">, </span> <span class="NLM_fpage">417897</span><span class="refDoi"> DOI: 10.1155/2008/417897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1155%2F2008%2F417897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=18414587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A280%3ADC%252BD1c3lsVSksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2008&publication_year=2008&pages=417897&author=A.+Kozubikauthor=A.+Vaculovaauthor=K.+Soucekauthor=J.+Vondracekauthor=J.+Turanekauthor=J.+Hofmanova&title=Novel+anticancer+platinum%28IV%29+complexes+with+adamantylamine%3A+their+efficiency+and+innovative+chemotherapy+strategies+modifying+lipid+metabolism&doi=10.1155%2F2008%2F417897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism</span></div><div class="casAuthors">Kozubik Alois; Vaculova Alena; Soucek Karel; Vondracek Jan; Turanek Jaroslav; Hofmanova Jirina</div><div class="citationInfo"><span class="NLM_cas:title">Metal-based drugs</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2008</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">417897</span>
        ISSN:<span class="NLM_cas:issn">0793-0291</span>.
    </div><div class="casAbstract">The impressive impact of cisplatin on cancer on one side and severe side effects, as well as the development of drug resistance during treatment on the other side, were the factors motivating scientists to design and synthesize new more potent analogues lacking disadvantages of cisplatin.  Platinum(IV) complexes represent one of the perspective groups of platinum-based drugs.  In this review, we summarize recent findings on both in vitro and in vivo effects of platinum(IV) complexes with adamantylamine.  Based on a literary overview of the mechanisms of activity of platinum-based cytostatics, we discuss opportunities for modulating the effects of novel platinum complexes through interactions with apoptotic signaling pathways and with cellular lipids, including modulations of the mitochondrial cell death pathway, oxidative stress, signaling of death ligands, lipid metabolism/signaling, or intercellular communication.  These approaches might significantly enhance the efficacy of both novel and established platinum-based cytostatics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwTaw6zIjXY-R_TJajKxJDfW6udTcc2eaS67ZpjhlFmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3lsVSksg%253D%253D&md5=bb26de47c209644aaec6efdcf53a5317</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1155%2F2008%2F417897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2008%252F417897%26sid%3Dliteratum%253Aachs%26aulast%3DKozubik%26aufirst%3DA.%26aulast%3DVaculova%26aufirst%3DA.%26aulast%3DSoucek%26aufirst%3DK.%26aulast%3DVondracek%26aufirst%3DJ.%26aulast%3DTuranek%26aufirst%3DJ.%26aulast%3DHofmanova%26aufirst%3DJ.%26atitle%3DNovel%2520anticancer%2520platinum%2528IV%2529%2520complexes%2520with%2520adamantylamine%253A%2520their%2520efficiency%2520and%2520innovative%2520chemotherapy%2520strategies%2520modifying%2520lipid%2520metabolism%26jtitle%3DMet.-Based%2520Drugs%26date%3D2008%26volume%3D2008%26spage%3D417897%26doi%3D10.1155%2F2008%2F417897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Karra, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benita, S.</span><span> </span><span class="NLM_article-title">The ligand nanoparticle conjugation approach for targeted cancer therapy</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.2174/138920012798356899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.2174%2F138920012798356899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=21892918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVehsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=22-41&author=N.+Karraauthor=S.+Benita&title=The+ligand+nanoparticle+conjugation+approach+for+targeted+cancer+therapy&doi=10.2174%2F138920012798356899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The ligand nanoparticle conjugation approach for targeted cancer therapy</span></div><div class="casAuthors">Karra, Nour; Benita, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-41</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer therapy often requires frequent and high drug dosing.  Yet, despite the significant progress in cancer research and the wide versatility of potent available drugs, treatment efficacy is still hurdled and often failed by the lack of pharmaco-selectivity to diseased cells, indiscriminate drug toxicities and poor patient compliance.  Thus, innovative pharmaceutical solns. are needed to effectively deliver the cytotoxic drugs specifically to the tumor site while minimizing systemic exposure to frequent and high drug doses.  Polymeric nanocarriers, particularly nanoparticles, were extensively studied for improved oncol. use.  Such nanocarriers hold great potential in cancer treatment as they can be biocompatible, adapted to specific needs, tolerated and deliver high drug payloads while targeting tumors.  Active targeting, as opposed to passive targeting, should add value to selective and site specific treatment.  Active targeting of nanosized drug delivery systems is firmly rooted in the Magic Bullet Concept as was envisioned by Paul Ehrlich over 100 years ago.  This targeting strategy is based on the mol. recognition of tumor biomarkers which are over-expressed on cancer cells, via specific vector mols. conjugated to the surface of the drug carrier.  These vector mols. dictate the carrier's biodistribution and its biol. affinity to the desired site of action.  Many recent publications have shown encouraging results suggesting that targeting nanocarriers represent a highly-promising strategy for improved cancer treatment.  This chapter will focus mainly on polymeric nanoparticles as the main drug carriers to be conjugated to various ligands able to deliver the drug to the specific desired pathol. tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM_XjavVzKgbVg90H21EOLACvtfcHk0lhEp9CYoBSDAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVehsrk%253D&md5=90cd0d48c6124311681eea7b909d5836</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2174%2F138920012798356899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012798356899%26sid%3Dliteratum%253Aachs%26aulast%3DKarra%26aufirst%3DN.%26aulast%3DBenita%26aufirst%3DS.%26atitle%3DThe%2520ligand%2520nanoparticle%2520conjugation%2520approach%2520for%2520targeted%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D22%26epage%3D41%26doi%3D10.2174%2F138920012798356899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Fatemeh, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebrahimi Shahmabadi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abedi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alavi, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Movahedi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koohi Moftakhari Esfahani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zadeh Mehrizi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akbarzadeh, A.</span><span> </span><span class="NLM_article-title">Polybutylcyanoacrylate nanoparticles and drugs of the platinum family: last status</span> <span class="citation_source-journal">Indian J. Clin. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span><span class="refDoi"> DOI: 10.1007/s12291-013-0364-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1007%2Fs12291-013-0364-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=24966482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaktrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=333-338&author=D.+R.+Fatemehauthor=H.+Ebrahimi+Shahmabadiauthor=A.+Abediauthor=S.+E.+Alaviauthor=F.+Movahediauthor=M.+Koohi+Moftakhari+Esfahaniauthor=T.+Zadeh+Mehriziauthor=A.+Akbarzadeh&title=Polybutylcyanoacrylate+nanoparticles+and+drugs+of+the+platinum+family%3A+last+status&doi=10.1007%2Fs12291-013-0364-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Polybutylcyanoacrylate Nanoparticles and Drugs of the Platinum Family: Last Status</span></div><div class="casAuthors">Fatemeh, Dashti Rahmat Abadi; Ebrahimi Shahmabadi, Hasan; Abedi, Anita; Alavi, Seyed Ebrahim; Movahedi, Fatemeh; Koohi Moftakhari Esfahani, Maedeh; Zadeh Mehrizi, Tahereh; Akbarzadeh, Azim</div><div class="citationInfo"><span class="NLM_cas:title">Indian Journal of Clinical Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-338</span>CODEN:
                <span class="NLM_cas:coden">IJCBEY</span>;
        ISSN:<span class="NLM_cas:issn">0974-0422</span>.
    
            (<span class="NLM_cas:orgname">Springer (India) Private Ltd.</span>)
        </div><div class="casAbstract">Cisplatinum and carboplatinum drugs from platinum-contg. family are anti-cancer drugs.  Using these drugs causes side effects.  Targeted and selective prescription decreases side effects of the drugs.  This can be achieved using nanotechnol.  In this study, cisplatinum and carboplatinum drugs were loaded on polybutylcyanoacrylate nanoparticles using emulsion polymn. method.  To det. amt. of loaded drug onto nanoparticle, spectrophotometry method was used.  Evaluation of cytotoxicity of such nanoparticles was performed on MCF-7 cell line using MTT assay.  Loading percentage of cisplatinum and carboplatinum drugs on nanoparticles were estd. 4 and 6 %, resp.  Cytotoxicity survival rate for cisplatinum and nanoparticle contg. cisplatinum at the lowest concn. (p < 0.01) (20 μM) were estd. 64 ± 1 and 67 ± 0.5 %, resp.  These values at the highest concn. (p < 0.01) (160 μM) were measured 28 ± 0.7 and 31 ± 0.4 %.  Addnl. for carboplatinum and nanoparticles contg. carboplatinum at the concn. (p < 0.01) (20 μM) amts. were estd. to be 80 ± 0.6 and 84 ± 0.6 %, while at the concn. (p < 0.01) (160 μM) were identified to be 44 ± 0.5 and 51 ± 0.2 %, resp.  Probably, due to low level of loading, cytotoxicity of both drugs at nano particle status was decreased in comparison with their std. form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc4LbZC9c82LVg90H21EOLACvtfcHk0lhEp9CYoBSDAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaktrrN&md5=ea93bdf8e99482747fb2a984ddfddef9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs12291-013-0364-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12291-013-0364-6%26sid%3Dliteratum%253Aachs%26aulast%3DFatemeh%26aufirst%3DD.%2BR.%26aulast%3DEbrahimi%2BShahmabadi%26aufirst%3DH.%26aulast%3DAbedi%26aufirst%3DA.%26aulast%3DAlavi%26aufirst%3DS.%2BE.%26aulast%3DMovahedi%26aufirst%3DF.%26aulast%3DKoohi%2BMoftakhari%2BEsfahani%26aufirst%3DM.%26aulast%3DZadeh%2BMehrizi%26aufirst%3DT.%26aulast%3DAkbarzadeh%26aufirst%3DA.%26atitle%3DPolybutylcyanoacrylate%2520nanoparticles%2520and%2520drugs%2520of%2520the%2520platinum%2520family%253A%2520last%2520status%26jtitle%3DIndian%2520J.%2520Clin.%2520Biochem.%26date%3D2014%26volume%3D29%26spage%3D333%26epage%3D338%26doi%3D10.1007%2Fs12291-013-0364-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Avgoustakis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beletsi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panagi, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klepetsanis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karydas, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ithakissios, D. S.</span><span> </span><span class="NLM_article-title">PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">135</span><span class="refDoi"> DOI: 10.1016/S0168-3659(01)00530-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2FS0168-3659%2801%2900530-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2002&pages=123-135&author=K.+Avgoustakisauthor=A.+Beletsiauthor=Z.+Panagiauthor=P.+Klepetsanisauthor=A.+G.+Karydasauthor=D.+S.+Ithakissios&title=PLGA-mPEG+nanoparticles+of+cisplatin%3A+in+vitro+nanoparticle+degradation%2C+in+vitro+drug+release+and+in+vivo+drug+residence+in+blood+properties&doi=10.1016%2FS0168-3659%2801%2900530-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0168-3659%2801%2900530-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-3659%252801%252900530-2%26sid%3Dliteratum%253Aachs%26aulast%3DAvgoustakis%26aufirst%3DK.%26aulast%3DBeletsi%26aufirst%3DA.%26aulast%3DPanagi%26aufirst%3DZ.%26aulast%3DKlepetsanis%26aufirst%3DP.%26aulast%3DKarydas%26aufirst%3DA.%2BG.%26aulast%3DIthakissios%26aufirst%3DD.%2BS.%26atitle%3DPLGA-mPEG%2520nanoparticles%2520of%2520cisplatin%253A%2520in%2520vitro%2520nanoparticle%2520degradation%252C%2520in%2520vitro%2520drug%2520release%2520and%2520in%2520vivo%2520drug%2520residence%2520in%2520blood%2520properties%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2002%26volume%3D79%26spage%3D123%26epage%3D135%26doi%3D10.1016%2FS0168-3659%2801%2900530-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Aryal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span> </span><span class="NLM_article-title">Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery</span> <span class="citation_source-journal">ACS Nano</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span><span class="refDoi"> DOI: 10.1021/nn9014032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn9014032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1alu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=251-258&author=S.+Aryalauthor=C.+M.+Huauthor=L.+Zhang&title=Polymer%2D%2Dcisplatin+conjugate+nanoparticles+for+acid-responsive+drug+delivery&doi=10.1021%2Fnn9014032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Polymer-Cisplatin Conjugate Nanoparticles for Acid-Responsive Drug Delivery</span></div><div class="casAuthors">Aryal, Santosh; Hu, Che-Ming Jack; Zhang, Liangfang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">251-258</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis of novel acid-responsive therapeutic nanoparticles (NPs) with sub-100 nm size consisting of polymer-cisplatin conjugates.  The uniqueness of these drug delivery polymeric NPs lies in the covalent conjugation of each cisplatin drug to the hydrophobic segment of two biocompatible diblock copolymer chains through a hydrazone bond, resulting in highly differential drug release profile at different environmental acidity.  We demonstrate that the synthesized polymer-cisplatin conjugates can readily ppt. to form sub-100 nm NPs in aq. soln. due to their very low crit. micelle concn. (CMC).  The resulting NPs show well-controlled cisplatin loading yield, excellent acid-responsive drug release kinetics, and enhanced in vitro cytotoxicity against ovarian cancer cells as compared to free cisplatin.  As an environmentally sensitive drug delivery vehicle, these NPs can potentially minimize the drug loss during NP circulation in the blood, where the pH value is neutral, and trigger rapid intracellular drug release after the NPs are endocytosed by the target cells.  This characteristic drug release profile holds the promise to suppress cancer cell chemoresistance by rapidly releasing a high dose of chemotherapy drugs inside the tumor cells, thereby improving the therapeutic efficacy of the drug payload.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV_42W2iyJk7Vg90H21EOLACvtfcHk0liphAAQqlp49g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1alu7%252FP&md5=c1de368e7df18df3f2b13e64f7be4963</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fnn9014032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn9014032%26sid%3Dliteratum%253Aachs%26aulast%3DAryal%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DC.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DPolymer--cisplatin%2520conjugate%2520nanoparticles%2520for%2520acid-responsive%2520drug%2520delivery%26jtitle%3DACS%2520Nano%26date%3D2010%26volume%3D4%26spage%3D251%26epage%3D258%26doi%3D10.1021%2Fnn9014032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Brown, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nativo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirling, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venugopal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flint, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plumb, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheate, N. J.</span><span> </span><span class="NLM_article-title">Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">4678</span><span class="NLM_x">–</span> <span class="NLM_lpage">4684</span><span class="refDoi"> DOI: 10.1021/ja908117a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja908117a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFOqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=4678-4684&author=S.+D.+Brownauthor=P.+Nativoauthor=J.+A.+Smithauthor=D.+Stirlingauthor=P.+R.+Edwardsauthor=B.+Venugopalauthor=D.+J.+Flintauthor=J.+A.+Plumbauthor=D.+Grahamauthor=N.+J.+Wheate&title=Gold+nanoparticles+for+the+improved+anticancer+drug+delivery+of+the+active+component+of+oxaliplatin&doi=10.1021%2Fja908117a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin</span></div><div class="casAuthors">Brown, Sarah D.; Nativo, Paola; Smith, Jo-Ann; Stirling, David; Edwards, Paul R.; Venugopal, Balaji; Flint, David J.; Plumb, Jane A.; Graham, Duncan; Wheate, Nial J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4678-4684</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platinum-based anticancer drugs cisplatin, carboplatin, and oxaliplatin are an important component of chemotherapy but are limited by severe dose-limiting side effects and the ability of tumors to develop resistance rapidly.  These drugs can be improved through the use of drug-delivery vehicles that are able to target cancers passively or actively.  In this study, we have tethered the active component of the anticancer drug oxaliplatin to a gold nanoparticle for improved drug delivery.  Naked gold nanoparticles were functionalized with a thiolated poly(ethylene glycol) (PEG) monolayer capped with a carboxylate group. [Pt(1R,2R-diaminocyclohexane)(H2O)2]2NO3 was added to the PEG surface to yield a supramol. complex with 280 (±20) drug mols. per nanoparticle.  The platinum-tethered nanoparticles were examd. for cytotoxicity, drug uptake, and localization in the A549 lung epithelial cancer cell line and the colon cancer cell lines HCT116, HCT15, HT29, and RKO.  The platinum-tethered nanoparticles demonstrated as good as, or significantly better, cytotoxicity than oxaliplatin alone in all of the cell lines and an unusual ability to penetrate the nucleus in the lung cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUk6dJnl0UHLVg90H21EOLACvtfcHk0liphAAQqlp49g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFOqsLY%253D&md5=43e99fc4fd527cc738b59adf226e00e9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fja908117a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja908117a%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BD.%26aulast%3DNativo%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DStirling%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DP.%2BR.%26aulast%3DVenugopal%26aufirst%3DB.%26aulast%3DFlint%26aufirst%3DD.%2BJ.%26aulast%3DPlumb%26aufirst%3DJ.%2BA.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26atitle%3DGold%2520nanoparticles%2520for%2520the%2520improved%2520anticancer%2520drug%2520delivery%2520of%2520the%2520active%2520component%2520of%2520oxaliplatin%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D4678%26epage%3D4684%26doi%3D10.1021%2Fja908117a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Paraskar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papa, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengupta, S.</span><span> </span><span class="NLM_article-title">Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy</span> <span class="citation_source-journal">Nanotechnology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">075103</span><span class="refDoi"> DOI: 10.1088/0957-4484/23/7/075103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1088%2F0957-4484%2F23%2F7%2F075103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=22275055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFOmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=075103&author=A.+Paraskarauthor=S.+Soniauthor=B.+Royauthor=A.+L.+Papaauthor=S.+Sengupta&title=Rationally+designed+oxaliplatin-nanoparticle+for+enhanced+antitumor+efficacy&doi=10.1088%2F0957-4484%2F23%2F7%2F075103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy</span></div><div class="casAuthors">Paraskar, Abhimanyu; Soni, Shivani; Roy, Bhaskar; Papa, Anne-Laure; Sengupta, Shiladitya</div><div class="citationInfo"><span class="NLM_cas:title">Nanotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">075103/1-075103/9</span>CODEN:
                <span class="NLM_cas:coden">NNOTER</span>;
        ISSN:<span class="NLM_cas:issn">1361-6528</span>.
    
            (<span class="NLM_cas:orgname">Institute of Physics Publishing</span>)
        </div><div class="casAbstract">Nanoscale drug delivery vehicles have been extensively studied as carriers for cancer chemotherapeutics.  However, the formulation of platinum chemotherapeutics in nanoparticles has been a challenge arising from their physicochem. properties.  There are only a few reports describing oxaliplatin nanoparticles.  In this study, we derivatized the monomeric units of a polyisobutylene maleic acid copolymer with glucosamine, which chelates trans-1,2-diaminocyclohexane (DACH) platinum (II) through a novel monocarboxylato and O → Pt coordination linkage.  At a specific polymer to platinum ratio, the complex self-assembled into a nanoparticle, where the polymeric units act as the leaving group, releasing DACH-platinum in a sustained pH-dependent manner.  Sizing was done using dynamic light scatter and electron microscopy.  The nanoparticles were evaluated for efficacy in vitro and in vivo.  Biodistribution was quantified using inductively coupled plasma at. absorption spectroscopy (ICP-AAS).  The PIMA-GA-DACH-platinum nanoparticle was found to be more active than free oxaliplatin in vitro.  In vivo, the nanoparticles resulted in greater tumor inhibition than oxaliplatin (equiv. to 5 mg kg-1 platinum dose) with minimal nephrotoxicity or body wt. loss.  ICP-AAS revealed significant preferential tumor accumulation of platinum with reduced biodistribution to the kidney or liver following PIMA-GA-DACH-platinum nanoparticle administration as compared with free oxaliplatin.  These results indicate that the rational engineering of a novel polymeric nanoparticle inspired by the bioactivation of oxaliplatin results in increased antitumor potency with reduced systemic toxicity compared with the parent cytotoxic.  Rational design can emerge as an exciting strategy in the synthesis of nanomedicines for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOVl2RPeRX-7Vg90H21EOLACvtfcHk0lhXL0LXZ7JAZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFOmu7w%253D&md5=bcf5dbd1d6de2e129d1e2bc9820d784e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1088%2F0957-4484%2F23%2F7%2F075103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F0957-4484%252F23%252F7%252F075103%26sid%3Dliteratum%253Aachs%26aulast%3DParaskar%26aufirst%3DA.%26aulast%3DSoni%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DB.%26aulast%3DPapa%26aufirst%3DA.%2BL.%26aulast%3DSengupta%26aufirst%3DS.%26atitle%3DRationally%2520designed%2520oxaliplatin-nanoparticle%2520for%2520enhanced%2520antitumor%2520efficacy%26jtitle%3DNanotechnology%26date%3D2012%26volume%3D23%26spage%3D075103%26doi%3D10.1088%2F0957-4484%2F23%2F7%2F075103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Owen, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doak, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wassam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span> </span><span class="NLM_article-title">Colloidal aggregation affects the efficacy of anticancer drugs in cell culture</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1429</span><span class="NLM_x">–</span> <span class="NLM_lpage">1435</span><span class="refDoi"> DOI: 10.1021/cb300189b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300189b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFOmsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1429-1435&author=S.+C.+Owenauthor=A.+K.+Doakauthor=P.+Wassamauthor=M.+S.+Shoichetauthor=B.+K.+Shoichet&title=Colloidal+aggregation+affects+the+efficacy+of+anticancer+drugs+in+cell+culture&doi=10.1021%2Fcb300189b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Colloidal Aggregation Affects the Efficacy of Anticancer Drugs in Cell Culture</span></div><div class="casAuthors">Owen, Shawn C.; Doak, Allison K.; Wassam, Pascal; Shoichet, Molly S.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1429-1435</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Many small mols., including bioactive mols. and approved drugs, spontaneously form colloidal aggregates in aq. soln. at micromolar concns.  Though it is widely accepted that aggregation leads to artifacts in screens for ligands of sol. proteins, the effects of colloid formation in cell-based assays have not been studied.  Here, seven anticancer drugs and one diagnostic reagent were found to form colloids in both biochem. buffer and in cell culture media.  In cell-based assays, the antiproliferative activities of three of the drugs were substantially reduced when in colloidal form as compared to monomeric form; a new formulation method ensured the presence of drug colloids vs. drug monomers in soln.  We also found that Evans Blue, a dye classically used to measure vascular permeability and to demonstrate the "enhanced permeability and retention (EPR) effect" in solid tumors, forms colloids that adsorb albumin, as opposed to older literature that suggested the reverse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN47RUN9WrPrVg90H21EOLACvtfcHk0lhXL0LXZ7JAZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFOmsrs%253D&md5=207a6f05e2ee718392562b28d2c52f89</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fcb300189b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300189b%26sid%3Dliteratum%253Aachs%26aulast%3DOwen%26aufirst%3DS.%2BC.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DWassam%26aufirst%3DP.%26aulast%3DShoichet%26aufirst%3DM.%2BS.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DColloidal%2520aggregation%2520affects%2520the%2520efficacy%2520of%2520anticancer%2520drugs%2520in%2520cell%2520culture%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1429%26epage%3D1435%26doi%3D10.1021%2Fcb300189b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Oh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. H.</span><span> </span><span class="NLM_article-title">Endocytosis and exocytosis of nanoparticles in mammalian cells</span> <span class="citation_source-journal">Int. J. Nanomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.2147/IJN.S26592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.2147%2FIJN.S26592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=24872703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ynt7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=51-63&issue=Suppl+1&author=N.+Ohauthor=J.+H.+Park&title=Endocytosis+and+exocytosis+of+nanoparticles+in+mammalian+cells&doi=10.2147%2FIJN.S26592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Endocytosis and exocytosis of nanoparticles in mammalian cells</span></div><div class="casAuthors">Oh, Nuri; Park, Ji-Ho</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">51-63, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Engineered nanoparticles that can be injected into the human body hold tremendous potential to detect and treat complex diseases.  Understanding of the endocytosis and exocytosis mechanisms of nanoparticles is essential for safe and efficient therapeutic application.  In particular, exocytosis is of significance in the removal of nanoparticles with drugs and contrast agents from the body, while endocytosis is of great importance for the targeting of nanoparticles in disease sites.  Here, we review the recent research on the endocytosis and exocytosis of functionalized nanoparticles based on various sizes, shapes, and surface chemistries.  We believe that this review contributes to the design of safe nanoparticles that can efficiently enter and leave human cells and tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSAt0ZKnAmz7Vg90H21EOLACvtfcHk0lhNP3qOLTL8_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ynt7rE&md5=10fcfd0a3107b852a052e51d8ac9a932</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.2147%2FIJN.S26592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S26592%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DN.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26atitle%3DEndocytosis%2520and%2520exocytosis%2520of%2520nanoparticles%2520in%2520mammalian%2520cells%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2014%26volume%3D9%26issue%3DSuppl%25201%26spage%3D51%26epage%3D63%26doi%3D10.2147%2FIJN.S26592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Sahay, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alakhova, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabanov, A. V.</span><span> </span><span class="NLM_article-title">Endocytosis of nanomedicines</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">182</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2010.01.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2Fj.jconrel.2010.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=20226220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosF2ntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2010&pages=182-195&author=G.+Sahayauthor=D.+Y.+Alakhovaauthor=A.+V.+Kabanov&title=Endocytosis+of+nanomedicines&doi=10.1016%2Fj.jconrel.2010.01.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Endocytosis of nanomedicines</span></div><div class="casAuthors">Sahay, Gaurav; Alakhova, Daria Y.; Kabanov, Alexander V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">182-195</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Novel nanomaterials are being developed to improve diagnosis and therapy of diseases through effective delivery of drugs, biopharmaceutical mols. and imaging agents to target cells in disease sites.  Such diagnostic and therapeutic nanomaterials, also termed "nanomedicines", often require site-specific cellular entry to deliver their payload to sub-cellular locations hidden beneath cell membranes.  Nanomedicines can employ multiple pathways for cellular entry, which are currently insufficiently understood.  This review, first, classifies various mechanisms of endocytosis available to nanomedicines including phagocytosis and pinocytosis through clathrin-dependent and clathrin-independent pathways.  Second, it describes the current exptl. tools to study endocytosis of nanomedicines.  Third, it provides specific examples from recent literature and the authors' own work on endocytosis of nanomedicines.  Finally, these examples are used to ascertain (1) the role of particle size, shape, material compn., surface chem. and/or charge for utilization of a selected pathway(s); (2) the effect of cell type on the processing of nanomedicines; and (3) the effect of nanomaterial-cell interactions on the processes of endocytosis, the fate of the nanomedicines and the resulting cellular responses.  This review will be useful to a diverse audience of students and scientists who are interested in understanding endocytosis of nanomedicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX2G8IickFdbVg90H21EOLACvtfcHk0lhNP3qOLTL8_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosF2ntbY%253D&md5=1423604a78852ba1fb912262a19058e1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2010.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2010.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DSahay%26aufirst%3DG.%26aulast%3DAlakhova%26aufirst%3DD.%2BY.%26aulast%3DKabanov%26aufirst%3DA.%2BV.%26atitle%3DEndocytosis%2520of%2520nanomedicines%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2010%26volume%3D145%26spage%3D182%26epage%3D195%26doi%3D10.1016%2Fj.jconrel.2010.01.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lykotrafitis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suresh, S.</span><span> </span><span class="NLM_article-title">Size-dependent endocytosis of nanoparticles</span> <span class="citation_source-journal">Adv. Mater.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1002/adma.200801393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1002%2Fadma.200801393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=19606281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVSiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=419-424&author=S.+Zhangauthor=J.+Liauthor=G.+Lykotrafitisauthor=G.+Baoauthor=S.+Suresh&title=Size-dependent+endocytosis+of+nanoparticles&doi=10.1002%2Fadma.200801393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Size-dependent endocytosis of nanoparticles</span></div><div class="casAuthors">Zhang, Sulin; Li, Ju; Lykotrafitis, George; Bao, Gang; Suresh, Subra</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Materials (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-424</span>CODEN:
                <span class="NLM_cas:coden">ADVMEW</span>;
        ISSN:<span class="NLM_cas:issn">0935-9648</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The cellular uptake of nanoparticles by living cells is predicted to be strongly size-dependent, according the thermodn. anal., and an optimal particle radius of ∼ 25-30 nm at which the cellular uptake reaches a max. of several thousand is shown to exist.  The theor. prediction provides valuable guidance for the rational design of nanoparticle-based drug-delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopRULIAIihu7Vg90H21EOLACvtfcHk0lhNP3qOLTL8_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVSiur4%253D&md5=242bf02e151f139ff830f37d401fadb5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fadma.200801393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadma.200801393%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLykotrafitis%26aufirst%3DG.%26aulast%3DBao%26aufirst%3DG.%26aulast%3DSuresh%26aufirst%3DS.%26atitle%3DSize-dependent%2520endocytosis%2520of%2520nanoparticles%26jtitle%3DAdv.%2520Mater.%26date%3D2009%26volume%3D21%26spage%3D419%26epage%3D424%26doi%3D10.1002%2Fadma.200801393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Karra, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nassar, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripin, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwob, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borlak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benita, S.</span><span> </span><span class="NLM_article-title">Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model</span> <span class="citation_source-journal">Small</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">4221</span><span class="NLM_x">–</span> <span class="NLM_lpage">4236</span><span class="refDoi"> DOI: 10.1002/smll.201301417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1002%2Fsmll.201301417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=23873835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFemur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=4221-4236&author=N.+Karraauthor=T.+Nassarauthor=A.+N.+Ripinauthor=O.+Schwobauthor=J.+Borlakauthor=S.+Benita&title=Antibody+conjugated+PLGA+nanoparticles+for+targeted+delivery+of+paclitaxel+palmitate%3A+efficacy+and+biofate+in+a+lung+cancer+mouse+model&doi=10.1002%2Fsmll.201301417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody Conjugated PLGA Nanoparticles for Targeted Delivery of Paclitaxel Palmitate: Efficacy and Biofate in a Lung Cancer Mouse Model</span></div><div class="casAuthors">Karra, Nour; Nassar, Taher; Ripin, Alina Nemirovski; Schwob, Ouri; Borlak, Juergen; Benita, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Small</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4221-4236</span>CODEN:
                <span class="NLM_cas:coden">SMALBC</span>;
        ISSN:<span class="NLM_cas:issn">1613-6810</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Aberrant signaling of the epidermal growth factor receptor (EGFR) is common to a variety of human cancers and is also found to be over-expressed in most cases of non-small cell lung cancer.  For the development of a molecularly targeted therapy, cetuximab-conjugated nanoparticles (immunonanoparticles, INPs) are designed and loaded with the lipophilic paclitaxel palmitate (pcpl) prodrug.  Oleyl cysteineamide (OCA) is synthesized whereby its amphiphilic nature enables interfacial anchoring and thiol surface functionalization of PLGA NPs, facilitating bioconjugation to cetuximab by thioether bonds.  It is demonstrated that the in vitro targeting efficiency and improved cellular internalization and cytotoxicity of this targeted delivery system in lung cancer cells over-expressing EGFR.  A quant. measure of the high binding affinity of INPs to EGFR is demonstrated using surface plasmon resonance.  In vivo tolerability and enhanced efficacy of cetuximab pcpl INPs in a metastatic lung cancer model are reported.  Its therapeutic efficacy in A549-luc-C8 lung tumors is shown using non-invasive bioluminescent imaging.  I.v. administration of cetuximab pcpl INPs to mice results in significantly higher inhibition of tumor growth and increased survival rates as compared to the non-targeted drug soln., drug-loaded nanoparticles or blank INPs.  Pharmacokinetics and organ biodistribution of the prodrug and parent drug are evaluated by LC-MS/MS in lung tumor bearing mice.  No enhanced total accumulation of nanoparticles or INPs is found at the tumor tissue.  However, persistent pcpl levels with sustained conversion and release of paclitaxel are obsd. for the encapsulated prodrug possibly suggesting the formation of a drug reservoir.  The overall results indicate the potential of this promising targeted platform for the improved treatment of lung cancer and other EGFR pos. tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBQ-RvTX7NK7Vg90H21EOLACvtfcHk0ljbOLhA3Hdtuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFemur%252FP&md5=d72f0727e44c88429bd05a96f36502c4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fsmll.201301417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsmll.201301417%26sid%3Dliteratum%253Aachs%26aulast%3DKarra%26aufirst%3DN.%26aulast%3DNassar%26aufirst%3DT.%26aulast%3DRipin%26aufirst%3DA.%2BN.%26aulast%3DSchwob%26aufirst%3DO.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DBenita%26aufirst%3DS.%26atitle%3DAntibody%2520conjugated%2520PLGA%2520nanoparticles%2520for%2520targeted%2520delivery%2520of%2520paclitaxel%2520palmitate%253A%2520efficacy%2520and%2520biofate%2520in%2520a%2520lung%2520cancer%2520mouse%2520model%26jtitle%3DSmall%26date%3D2013%26volume%3D9%26spage%3D4221%26epage%3D4236%26doi%3D10.1002%2Fsmll.201301417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Hall, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hambley, T. W.</span><span> </span><span class="NLM_article-title">Platinum(IV) antitumour compounds: their bioinorganic chemistry</span> <span class="citation_source-journal">Coord. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x"> (</span><span class="NLM_issue">1–2</span><span class="NLM_x">) </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1016/S0010-8545(02)00026-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1016%2FS0010-8545%2802%2900026-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD38XntF2ktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2002&pages=49-67&issue=1%E2%80%932&author=M.+D.+Hallauthor=T.+W.+Hambley&title=Platinum%28IV%29+antitumour+compounds%3A+their+bioinorganic+chemistry&doi=10.1016%2FS0010-8545%2802%2900026-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(IV) antitumour compounds: their bioinorganic chemistry</span></div><div class="casAuthors">Hall, Matthew D.; Hambley, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">49-67</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  This article reviews the studies undertaken into Pt(IV) antitumor compds. since Barnett Rosenberg 1st noted the activity of Pt(IV) complexes.  The chem. and pharmacol. properties of the drugs are discussed and both the reactions with individual biomols., which have received attention and the characterization of biotransformation products from animal and clin. trials are reviewed.  The bioinorg. chem. of Pt(IV) complexes has not previously been reviewed, and the purpose here is to provide insight into the requirements for the antitumor activity of Pt(IV) complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkHxf962L07rVg90H21EOLACvtfcHk0liN0NZV8Rpziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntF2ktbs%253D&md5=200992ab1e4313bea2f5c9b3f60ac26f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0010-8545%2802%2900026-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0010-8545%252802%252900026-7%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DHambley%26aufirst%3DT.%2BW.%26atitle%3DPlatinum%2528IV%2529%2520antitumour%2520compounds%253A%2520their%2520bioinorganic%2520chemistry%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2002%26volume%3D232%26issue%3D1%25E2%2580%25932%26spage%3D49%26epage%3D67%26doi%3D10.1016%2FS0010-8545%2802%2900026-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Johnstone, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulak, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pridgen, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farokhzad, O. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippard, S. J.</span><span> </span><span class="NLM_article-title">Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties</span> <span class="citation_source-journal">ACS Nano</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">–</span> <span class="NLM_lpage">5683</span><span class="refDoi"> DOI: 10.1021/nn401905g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn401905g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotV2ksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=5675-5683&author=T.+C.+Johnstoneauthor=N.+Kulakauthor=E.+M.+Pridgenauthor=O.+C.+Farokhzadauthor=R.+Langerauthor=S.+J.+Lippard&title=Nanoparticle+encapsulation+of+mitaplatin+and+the+effect+thereof+on+in+vivo+properties&doi=10.1021%2Fnn401905g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle Encapsulation of Mitaplatin and the Effect Thereof on In Vivo Properties</span></div><div class="casAuthors">Johnstone, Timothy C.; Kulak, Nora; Pridgen, Eric M.; Farokhzad, Omid C.; Langer, Robert; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5675-5683</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nanoparticle (NP) therapeutics have the potential to significantly alter the in vivo biol. properties of the pharmaceutically active agents that they carry.  Here we describe the development of a polymeric NP, termed M-NP, comprising poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-PEG), stabilized with poly(vinyl alc.) (PVA), and loaded with a water-sol. platinum(IV) [Pt(IV)] prodrug, mitaplatin.  Mitaplatin, c,c,t-[PtCl2(NH3)2(OOCCHCl2)2], is a compd. designed to release cisplatin, an anticancer drug in widespread clin. use, and the orphan drug dichloroacetate following chem. redn.  An optimized prepn. of M-NP by double emulsion and its phys. characterization are reported, and the influence of encapsulation on the properties of the platinum agent is evaluated in vivo.  Encapsulation increases the circulation time of Pt in the bloodstream of rats.  The biodistribution of Pt in mice is also affected by nanoparticle encapsulation, resulting in reduced accumulation in the kidneys.  Finally, the efficacy of both free mitaplatin and M-NP, measured by tumor growth inhibition in a mouse xenograft model of triple-neg. breast cancer, reveals that controlled release of mitaplatin over time from the nanoparticle treatment produces long-term efficacy comparable to that of free mitaplatin, which might limit toxic side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnDKITCPYSzrVg90H21EOLACvtfcHk0liN0NZV8Rpziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotV2ksbg%253D&md5=cfbe9f3c377ab22f494d9d145ff08615</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fnn401905g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn401905g%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DKulak%26aufirst%3DN.%26aulast%3DPridgen%26aufirst%3DE.%2BM.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DLanger%26aufirst%3DR.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DNanoparticle%2520encapsulation%2520of%2520mitaplatin%2520and%2520the%2520effect%2520thereof%2520on%2520in%2520vivo%2520properties%26jtitle%3DACS%2520Nano%26date%3D2013%26volume%3D7%26spage%3D5675%26epage%3D5683%26doi%3D10.1021%2Fnn401905g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Bast, R. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennessy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span> </span><span class="NLM_article-title">The biology of ovarian cancer: new opportunities for translation</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">428</span><span class="refDoi"> DOI: 10.1038/nrc2644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1038%2Fnrc2644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=19461667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmt1Skt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=415-428&author=R.+C.+Bastauthor=B.+Hennessyauthor=G.+B.+Mills&title=The+biology+of+ovarian+cancer%3A+new+opportunities+for+translation&doi=10.1038%2Fnrc2644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The biology of ovarian cancer: new opportunities for translation</span></div><div class="casAuthors">Bast, Robert C.; Hennessy, Bryan; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">415-428</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past two decades, the 5-yr survival for ovarian cancer patients has substantially improved owing to more effective surgery and treatment with empirically optimized combinations of cytotoxic drugs, but the overall cure rate remains approx. 30%.  Many investigators think that further empirical trials using combinations of conventional agents are likely to produce only modest incremental improvements in outcome.  Given the heterogeneity of this disease, increases in long-term survival might be achieved by translating recent insights at the mol. and cellular levels to personalize individual strategies for treatment and to optimize early detection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPoLW_Fq0TYrVg90H21EOLACvtfcHk0liN0NZV8Rpziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmt1Skt7g%253D&md5=42b5e0e351dbb9cfeb44df1d7ec7b3ee</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnrc2644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2644%26sid%3Dliteratum%253Aachs%26aulast%3DBast%26aufirst%3DR.%2BC.%26aulast%3DHennessy%26aufirst%3DB.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DThe%2520biology%2520of%2520ovarian%2520cancer%253A%2520new%2520opportunities%2520for%2520translation%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D415%26epage%3D428%26doi%3D10.1038%2Fnrc2644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Sankhala, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adinin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamagata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuno, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujisawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, A.</span><span> </span><span class="NLM_article-title">A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">15S</span><span class="NLM_x">) </span> <span class="NLM_fpage">2535</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=2535&issue=15S&author=K.+K.+Sankhalaauthor=A.+C.+Mitaauthor=R.+Adininauthor=L.+Woodauthor=M.+Beeramauthor=S.+Bullockauthor=N.+Yamagataauthor=K.+Matsunoauthor=T.+Fujisawaauthor=A.+Phan&title=A+phase+I+pharmacokinetic+%28PK%29+study+of+MBP-426%2C+a+novel+liposome+encapsulated+oxaliplatin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSankhala%26aufirst%3DK.%2BK.%26aulast%3DMita%26aufirst%3DA.%2BC.%26aulast%3DAdinin%26aufirst%3DR.%26aulast%3DWood%26aufirst%3DL.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DBullock%26aufirst%3DS.%26aulast%3DYamagata%26aufirst%3DN.%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DFujisawa%26aufirst%3DT.%26aulast%3DPhan%26aufirst%3DA.%26atitle%3DA%2520phase%2520I%2520pharmacokinetic%2520%2528PK%2529%2520study%2520of%2520MBP-426%252C%2520a%2520novel%2520liposome%2520encapsulated%2520oxaliplatin%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26issue%3D15S%26spage%3D2535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabral, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kano, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, K.</span><span> </span><span class="NLM_article-title">Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">64ra2</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3001385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1126%2Fscitranslmed.3001385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=21209412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=64ra2&author=M.+Murakamiauthor=H.+Cabralauthor=Y.+Matsumotoauthor=S.+Wuauthor=M.+R.+Kanoauthor=T.+Yamoriauthor=N.+Nishiyamaauthor=K.+Kataoka&title=Improving+drug+potency+and+efficacy+by+nanocarrier-mediated+subcellular+targeting&doi=10.1126%2Fscitranslmed.3001385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting</span></div><div class="casAuthors">Murakami, Mami; Cabral, Horacio; Matsumoto, Yu; Wu, Shourong; Kano, Mitsunobu R.; Yamori, Takao; Nishiyama, Nobuhiro; Kataoka, Kazunori</div><div class="citationInfo"><span class="NLM_cas:title">Science Translational Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">64</span>),
    <span class="NLM_cas:pages">64ra2</span>CODEN:
                <span class="NLM_cas:coden">STMCBQ</span>;
        ISSN:<span class="NLM_cas:issn">1946-6242</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Nanocarrier-mediated drug targeting is an emerging strategy for cancer therapy and is being used, for example, with chemotherapeutic agents for ovarian cancer.  Nanocarriers are selectively accumulated in tumors as a result of their enhanced permeability and retention of macromols., thereby enhancing the antitumor activity of the nanocarrier-assocd. drugs.  We investigated the real-time subcellular fate of polymeric micelles incorporating (1,2-diaminocyclohexane) platinum(II) (DACHPt/m), the parent complex of oxaliplatin, in tumor tissues by fluorescence-based assessment of their kinetic stability.  These observations revealed that DACHPt/m was extravasated from blood vessels to the tumor tissue and dissocd. inside each cell.  Furthermore, DACHPt/m selectively dissocd. within late endosomes, enhancing drug delivery to the nearby nucleus relative to free oxaliplatin, likely by circumvention of the cytoplasmic detoxification systems such as metallothionein and methionine synthase.  Thus, these drug-loaded micelles exhibited higher antitumor activity than did oxaliplatin alone, even against oxaliplatin-resistant tumors.  These findings suggest that nanocarriers targeting subcellular compartments may have considerable benefits in clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWKR-rRV0SYLVg90H21EOLACvtfcHk0liSOYFXkcW_qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWisb0%253D&md5=5231121539f9a5707a7976a12f16c127</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001385%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DCabral%26aufirst%3DH.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DKano%26aufirst%3DM.%2BR.%26aulast%3DYamori%26aufirst%3DT.%26aulast%3DNishiyama%26aufirst%3DN.%26aulast%3DKataoka%26aufirst%3DK.%26atitle%3DImproving%2520drug%2520potency%2520and%2520efficacy%2520by%2520nanocarrier-mediated%2520subcellular%2520targeting%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D64ra2%26doi%3D10.1126%2Fscitranslmed.3001385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Campone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rademaker-Lakhai, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howell, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowotnik, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span> </span><span class="NLM_article-title">Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1007/s00280-006-0397-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.1007%2Fs00280-006-0397-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=17308894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFKntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=523-533&author=M.+Camponeauthor=J.+M.+Rademaker-Lakhaiauthor=J.+Bennounaauthor=S.+B.+Howellauthor=D.+P.+Nowotnikauthor=J.+H.+Beijnenauthor=J.+H.+Schellens&title=Phase+I+and+pharmacokinetic+trial+of+AP5346%2C+a+DACH-platinum-polymer+conjugate%2C+administered+weekly+for+three+out+of+every+4+weeks+to+advanced+solid+tumor+patients&doi=10.1007%2Fs00280-006-0397-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients</span></div><div class="casAuthors">Campone, Mario; Rademaker-Lakhai, Jeany M.; Bennouna, Jaafar; Howell, Stephen B.; Nowotnik, David P.; Beijnen, Jos H.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-533</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To det. the max. tolerated dose (MTD) safety and pharmacokinetics of AP5346, a copolymer-linked 1,2-diaminocyclohexane(DACH)-platinum compd., in advanced solid tumor patients.  Exptl. design: AP5346 was administered as a 1-h IV infusion on days 1, 8, 15 of a 28-day cycle.  Seven dose levels (DL) were explored: DL1: 40 mg platinum (Pt)/m2 (1 patient); DL2: 80 (1); DL3: 160 (3); DL4: 320 (3); DL5: 640 (6); DL6: 850 (6); DL7: 1280 (6) mg Pt/m2.  Dose-limiting toxicity (DLT) included infusion omission and cycle delay >2 wk.  Results: Twenty-six patients received 41 cycles (median 1/patient, range 1-4).  No DLT occurred in DL 1-4; 1 DLT in DL5 (RD; renal insufficiency), two in DL6 (MTD; vomiting; fatigue) and 5 in DL7 (neutropenic infection with diarrhea; neutropenia with vomiting; vomiting with fatigue; renal insufficiency; and fatigue).  Two deaths occurred due to renal insufficiency (DL5); in both cases patients had disease in or surrounding genitourinary tract whose contribution could not be accurately discerned.  Grade 1-2 creatinine abnormalities occurred in seven patients.  Nausea/emesis was frequent (92%), reaching grade 3-4 (23%), but controlled by antiemetics.  Grade 2-4 allergic reactions occurred in 4 patients.  C max and AUC increased linearly with dose for total plasma platinum and ultrafiltrate platinum.  Antitumor activity included two partial responses in metastatic melanoma and ovarian cancer, and an addnl. CA-125 normalization (from 133 IU/l) in a suspected ovarian cancer.  Conclusions: AP5346 administered weekly for 3 wk out of every four is tolerated up to a dose of 640 mg Pt/m2 on the first cycle when given with antiemetic prophylaxis.  The pharmacokinetics of AP5346 indicates a prolonged half-life, and evidence of antitumor activity was obsd. at this dose level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTrOqvqg8AeLVg90H21EOLACvtfcHk0liSOYFXkcW_qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFKntrk%253D&md5=eda0f0004a1065f5fef5eb3385b71a18</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0397-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0397-0%26sid%3Dliteratum%253Aachs%26aulast%3DCampone%26aufirst%3DM.%26aulast%3DRademaker-Lakhai%26aufirst%3DJ.%2BM.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DHowell%26aufirst%3DS.%2BB.%26aulast%3DNowotnik%26aufirst%3DD.%2BP.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DPhase%2520I%2520and%2520pharmacokinetic%2520trial%2520of%2520AP5346%252C%2520a%2520DACH-platinum-polymer%2520conjugate%252C%2520administered%2520weekly%2520for%2520three%2520out%2520of%2520every%25204%2520weeks%2520to%2520advanced%2520solid%2520tumor%2520patients%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2007%26volume%3D60%26spage%3D523%26epage%3D533%26doi%3D10.1007%2Fs00280-006-0397-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Z. X.</span><span> </span><span class="NLM_article-title">PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma</span> <span class="citation_source-journal">Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1621</span><span class="NLM_x">–</span> <span class="NLM_lpage">1628</span><span class="refDoi"> DOI: 10.3892/or.2011.1238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=10.3892%2For.2011.1238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=21455585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVWht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1621-1628&author=C.+Yangauthor=H.+Z.+Liuauthor=W.+D.+Luauthor=Z.+X.+Fu&title=PEG-liposomal+oxaliplatin+potentialization+of+antitumor+efficiency+in+a+nude+mouse+tumor-xenograft+model+of+colorectal+carcinoma&doi=10.3892%2For.2011.1238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma</span></div><div class="casAuthors">Yang, Chuang; Liu, Hai-Zhong; Lu, Wei-Dong; Fu, Zhong-Xue</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1621-1628</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">The non-selectivity of chemotherapeutics between normal tissue and pathol. sites poses a challenge for the treatment strategy for advanced colorectal carcinoma.  To obtain sufficient antitumor activity, optimization of the therapeutic regimen is of great importance.  We investigated PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.  A tumor-bearing nude mouse model, i.v. injections of (Dio)-labeled PEG-liposomes via tail vein and fluorescence imaging with in vivo imaging system were employed.  Mice were treated with free L-oHP, PEG-liposomal L-oHP via the tail vein, followed by anal. of the accumulation of L-oHP in tumor tissues by high-performance liq. chromatog. (HPLC), observation of the tumor vol. and the survival rate.  Apoptosis and proliferation of tumors were detected by TUNEL assay and immunohistochem.  The mRNA and protein levels of Bcl-2, Bax, caspase-3 (P17) and Ki-67 were detd. by RT-PCR and Western blotting.  Fluorescence imaging with in vivo imaging showed PEG-liposome targeting in tumor tissues.  After i.v. injections of PEG-liposomal oxaliplatin, tumor tissue max. accumulation of L-oHP was 9.37±0.79 μg/g at 24 h; The tumor vol. was significantly suppressed, and mice showed longer survival, compared with the free oxaliplatin group.  Apoptosis increased, but proliferation decreased in tumor tissues.  The mRNA expression of Bcl-2 and Ki-67 was down-regulated, while Bax and caspase-3 expression was up-regulated.  Protein expression of Bcl-2 was down-regulated, while Bax and P17 expression was up-regulated.  The results indicate that PEG-liposomal oxaliplatin can improve antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-cLzsXaTfLLVg90H21EOLACvtfcHk0lizykbsqsMp-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVWht78%253D&md5=1dc0e7f4001d6b20807052362830712c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.3892%2For.2011.1238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2011.1238%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DH.%2BZ.%26aulast%3DLu%26aufirst%3DW.%2BD.%26aulast%3DFu%26aufirst%3DZ.%2BX.%26atitle%3DPEG-liposomal%2520oxaliplatin%2520potentialization%2520of%2520antitumor%2520efficiency%2520in%2520a%2520nude%2520mouse%2520tumor-xenograft%2520model%2520of%2520colorectal%2520carcinoma%26jtitle%3DOncol.%2520Rep.%26date%3D2011%26volume%3D25%26spage%3D1621%26epage%3D1628%26doi%3D10.3892%2For.2011.1238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i34"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00955">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_61613"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00955">10.1021/acs.jmedchem.6b00955</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">IC<sub>50</sub> (μM) and resistant factor values for OXA and <b>1</b> against A2780 and A2780-cisR cell lines,  IC<sub>50</sub> values of OXA, <b>1</b>, and <b>2</b> in cancer cell lines used in the efficacy animal studies, DLS particle size distribution of <b>1</b> NPs spontaneously formed following dilution of <b>1</b> solution in DMSO by DDW at the same concentration as used for the cell culture experiments, the freeze-drying parameters and characterization of lyophilized NPs after various time periods, and the <sup>1</sup>H and <sup>195</sup>Pt NMR spectra, HPLC chromatograms, and ESI-MS spectra of complex <b>1</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular strings for OXA, <b>1</b>, and <b>2</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_001.pdf">jm6b00955_si_001.pdf (1.34 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00955/suppl_file/jm6b00955_si_002.csv">jm6b00955_si_002.csv (0.23 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00955%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-19" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00955" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799838eaf4924f5","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
